АКТУАЛЬНЫЕ ПРОБЛЕМЫ ХИМИЧЕСКОЙ СТАНДАРТИЗАЦИИ СЫРЬЯ ЛЕКАРСТВЕННЫХ РАСТЕНИЙ РОДА БОЯРЫШНИК ΈCRATAEGUS L.Ή
- Авторы: Морозова Т.В.1, Куркин В.А.1, Правдивцева О.Е.1
-
Учреждения:
- Федеральное государственное бюджетное образовательное учреждение высшего образования «Самарский государственный медицинский университет» Министерства здравоохранения Российской Федерации
- Выпуск: Том 6, № 2 (2018)
- Страницы: 104-120
- Раздел: Статьи
- URL: https://journals.eco-vector.com/2307-9266/article/view/111517
- DOI: https://doi.org/10.19163/2307-9266-2018-6-2-104-120
- ID: 111517
Цитировать
Полный текст
Аннотация
Растения рода Боярышник (Crataegus L.) – кустарники или небольшие деревья, которые используется в медицине с глубокой древности. На сегодняшний день на основе сырья боярышника получают препараты для лечения и профилактики сердечной недостаточности. Целью работы является анализ и систематизация результатов исследований в области химической стандартизации сырья боярышника в фармакопеях различных стран. Материалы и методы. Исследование проводилось с использованием Государственной фармакопеи СССР XI издания, Государственной фармакопеи Российской Федерации XIII издания, Европейской фармакопеи 6 издания, фармакопеи Соединенных Штатов Америки 32 издания, Государственной фармакопеи Республики Беларусь и Республики Казахстан, а также информационно-поисковых (PubMed) и библиотечных баз данных (eLibrary). Результаты и обсуждение. В настоящем обзоре систематизированы результаты исследований в области химической стандартизации сырья боярышника в фармакопеях различных стран. Определено, что в методиках анализа сырья видов рода Боярышник (Crataegus L.), включенных в отечественные и зарубежные фармакопеи, используются различные методические и методологические подходы к стандартизации плодов, цветков и листьев. Кроме того, обнаружено, что сырье одного наименования анализируется с использованием различных методик. На наш взгляд, использование в методиках различных экстрагентов не всегда обосновано с точки зрения физико-химических и спектральных характеристик анализируемых веществ. Показано также, что в методиках качественного и количественного анализа действующих веществ (флавоноиды, процианидины) не всегда ведется ориентация на диагностически значимые стандартные вещества. Заключение. Проведенный анализ существующих методик качественного анализа (раздел подлинность) и количественного определения целевых веществ свидетельствует о том, что необходима унификация методик анализа сырья и препаратов видов рода боярышник на основе научно обоснованных подходов к стандартизации.
Ключевые слова
Полный текст
ɎɚɪмɚцияɮɚɪмɚколоɝияОɛзоɪыɍȾК 615.322: 547.9 + 543.544 ʤК˃˄ʤЛːʻˏʫˈʰʺʰˋʫˁКОʱˁ˃ʤʻʪʤˀ˃ʰʯʤˉʰʰˁˏˀː˔ˀʤˁ˃ʫʻʰʱˀОʪʤCRATAEGUS L.МоɪозоɜɚКɭɪкинПɪɚɜɞиɜцɟɜɚɎɟɞɟɪɚльноɟɝоɫɭɞɚɪɫɬɜɟнноɟɛюɞжɟɬноɟоɛɪɚзоɜɚɬɟльноɟɭчɪɟжɞɟниɟоɛɪɚзоɜɚнияɋɚмɚɪɫкийɝоɫɭɞɚɪɫɬɜɟнныймɟɞицинɫкийɭниɜɟɪɫиɬɟɬМиниɫɬɟɪɫɬɜɚзɞɪɚɜооɯɪɚнɟнияɊоɫɫийɫкойɎɟɞɟɪɚцииɊоɫɫияПɪиɜолжɫкийɮɟɞɟɪɚльныйокɪɭɝɋɚмɚɪɫкɚяоɛлɚɫɬьɋɚмɚɪɚЧɚпɚɟɜɫкɚяE-mail: tanyfrost@mail.ruɊɚɫɬɟнияɪоɞɚȻояɪышник (Crataegus L.) ? кɭɫɬɚɪникинɟɛольшиɟɞɟɪɟɜьякоɬоɪыɟиɫпользɭɟɬɫямɟɞицинɟɝлɭɛокойɫɟɝоɞняшнийɞɟньɛояɪышникɚполɭчɚюɬлɟчɟнияпɪоɮилɚкɬикиɫɟɪɞɟчнойнɟɞоɫɬɚɬочноɫɬиЦɟльюɪɚɛоɬыяɜляɟɬɫяɫиɫɬɟмɚɬизɚциязɭльɬɚɬоɜиɫɫлɟɞоɜɚнийоɛлɚɫɬиɯимичɟɫкойɫɬɚнɞɚɪɬизɚцииɛояɪышникɚɮɚɪмɚкопɟяɯɪɚзличныɯМɚɬɟɪиɚлымɟɬоɞыИɫɫлɟɞоɜɚниɟпɪоɜоɞилоɫьиɫпользоɜɚниɟмȽоɫɭɞɚɪɫɬɜɟннойɮɚɪмɚкопɟи XI изɞɚнияȽоɫɭɞɚɪɫɬɜɟннойɮɚɪмɚкопɟиɊоɫɫийɫкойɎɟɞɟɪɚции XIII изɞɚнияȿɜɪопɟйɫкойɮɚɪмɚкопɟиизɞɚнияɮɚɪмɚкопɟиɋоɟɞинɟнныɯШɬɚɬоɜ 32 изɞɚнияȽоɫɭɞɚɪɫɬɜɟннойɮɚɪмɚкопɟиɊɟɫпɭɛликиȻɟлɚɪɭɫьɊɟɫпɭɛликиКɚзɚɯɫɬɚнɬɚкжɟинɮоɪмɚционнопоиɫкоɜыɯ (PubMed) ɛиɛлиоɬɟчныɯɊɟзɭльɬɚɬыоɛɫɭжɞɟниɟнɚɫɬоящɟмоɛзоɪɟɫиɫɬɟмɚɬизиɪоɜɚныɪɟзɭльɬɚɬыиɫɫлɟɞоɜɚнийоɛлɚɫɬиɯимичɟɫкойɫɬɚнɞɚɪɬизɚцииɛояɪышникɚɮɚɪмɚкопɟяɯɪɚзличныɯОпɪɟɞɟлɟномɟɬоɞикɚɯɪоɞɚȻояɪышникɜключɟнныɯоɬɟчɟɫɬɜɟнныɟзɚɪɭɛɟжныɟɮɚɪмɚкопɟииɫпользɭюɬɫяɪɚзличныɟмɟɬоɞичɟɫкиɟмɟɬоɞолоɝичɟɫкиɟпоɞɯоɞыɫɬɚнɞɚɪɬизɚцииплоɞоɜцɜɟɬкоɜКɪомɟоɛнɚɪɭжɟнооɞноɝонɚимɟноɜɚнияɚнɚлизиɪɭɟɬɫяиɫпользоɜɚниɪɚзличныɯмɟɬоɞикɜзɝляɞиɫпользоɜɚниɟмɟɬоɞикɚɯɪɚзличныɯэкɫɬɪɚɝɟнɬоɜɜɫɟɝɞɚоɛоɫноɜɚноɬочкиɮизикоɯимичɟɫкиɯɫпɟкɬɪɚльныɯɯɚɪɚкɬɟɪиɫɬикɚнɚлизиɪɭɟмыɯɜɟщɟɫɬɜПокɚзɚноɬɚкжɟмɟɬоɞикɚɯкɚчɟɫɬɜɟнноɝоколичɟɫɬɜɟнноɝоɞɟйɫɬɜɭющиɯɜɟщɟɫɬɜɮлɚɜоноиɞыɜɫɟɝɞɚɜɟɞɟɬɫяоɪиɟнɬɚцияɞиɚɝноɫɬичɟɫкизнɚчимыɟɫɬɚнɞɚɪɬныɟɜɟщɟɫɬɜɚЗɚклюПɪоɜɟɞɟнныйɫɭщɟɫɬɜɭющиɯмɟɬоɞиккɚчɟɫɬɜɟнноɝоɪɚзɞɟлпоɞлинноɫɬьколичɟопɪɟɞɟлɟнияцɟлɟɜыɯɜɟщɟɫɬɜɫɜиɞɟɬɟльɫɬɜɭɟɬɬомнɟоɛɯоɞимɚɭниɮикɚциямɟɬоɞикɪоɞɚɛояɪышникнɚɭчнооɛоɫноɜɚнныɯпоɞɯоɞоɜɫɬɚнɞɚɪɬизɚцииКлючɟɜыɟɫлоɜɚɛояɪышникɫɬɚнɞɚɪɬизɚцияɯимичɟɫкийɫоɫɬɚɜɮиɬоɯимияɮɚɪмɚколоɝичɟɫкиɟɫɜойɫɬɜɚACTUAL PROBLEMS OF RAW MATERIALS CHEMICAL STANDARDIZATION OF MEDICINAL PLANTS OF THE GENUS HAWTHORN CRATAEGUS L.T.V. Morozova, V.A. Kurkin, O.E. Pravdivtseva89, Str. Chapaevskaya, Samara, Samara Region, Volga Federal District, Russia, 443099E-mail: tanyfrost@mail.ruThe plants of the genus Hawthorn (Crataegus L.) are shrubs or small trees that have been used in medicine since ancient times. Nowadays, on the basis of raw hawthorn, the preparations are available for treatment and prevention of For citationMorozova T.V., Kurkin V.A., Pravdivtseva O.E. ACTUAL PROBLEMS OF RAW MATERIALS CHEMICAL STANDARDIZATION OF MEDICINAL PLANTS OF THE GENUS HAWTHORN (CRATAEGUS L.). Pharmacy & Pharmacology.циɬиɪоɜɚнияМоɪозоɜɚКɭɪкинПɪɚɜɞиɜцɟɜɚȺКɌɍȺЛЬНЫȿПɊОȻЛȿМЫɏИМИЧȿɋКОЙɋɌȺНȾȺɊɌИЗȺЦИИɋЫɊЬЯЛȿКȺɊɋɌȼȿННЫɏɊȺɋɌȿНИЙɊОȾȺȻОЯɊЫШНИКCRATAEGUS ɎɚɪмɚцияɮɚɪмɚколоɝияМоɪозоɜɚКɭɪкинПɪɚɜɞиɜцɟɜɚPharmacy & Pharmacology V. 6 N 2, 2018DOI:10.19163/2307-9266-2018-6-2-104-120heart failure. of the work is to analyze and systematize research results in the eld of chemical standardization The study was conducted XIII-th edition, the European Pharmacopoeia, 6-th edition, the United States Pharmacopeia, 32-nd editions, the State Pharmacopoeia of the Republic of Belarus and the Republic of Kazakhstan, as well as the information and search In this review, the results of research in the of chemical standardization of hawthorn raw materials in pharmacopoeias of various countries are systematized. It included in domestic and foreign Pharmacopoeias, various methodological and methodological approaches to the standardization of fruits, owers and leaves are used. Besides, it has been found out that the raw materials of the same name are analyzed using different techniques. In our opinion, the use of various extractants in the methods is not ed from the point of view of the physical-chemical and spectral characteristics of the substances being procyanidins), the orientation to diagnostically signi cant standard substances is not always conducted. of the target substances indicates the necessity to unify the methods of raw materials analysis and preparations of cally based approaches to standardization. hawthorn, Crataegus L., standardization, chemical composition, Phytochemistry, pharmacological propertiesнɚɫɬоящɟɟлɟкɚɪɫɬɜɟнныɟпɪɟпɚɪɚɬынɚɛиɪɚюɬɜɫɟɛольшɭюляɪноɫɬьиɫпользɭюɬɫякɚклɟчɟнииɬɚкɮилɚкɬикизɚɛолɟɜɚний [1, 2]. Эɬоɜозможɫɜязɚнооɛɫɬояɬɟльɫɬɜомчɬолɟкɚɪɫɬɜɟнныɟпɪɟпɚɪɚɬыоɛлɚɞɚюɬнизкойɬокɫичноɞоɫɬɚɬочноɜыɫокойэɮɮɟкɬиɜноɫɬиɫпɟкɬɪомɬɟɪɚпɟɜɬичɟɫкоɝокомплɟкɫнымэɮɮɟкɬомоɪɝɚнизмчɟлоɜɟкɚɪɚционɚльномɬɚкжɟоɬноɫиɬɟльнойɫинɬɟɬичɟɫкимипɪɟпɚɪɚɬɚми [3]. ɫɟɝоɞняшнийɫɟɪɞɟчноɫоɫɭɞиɫɬыɟɛолɟɜɚнияоɫɬɚюɬɫянɚиɛолɟɟɜɚжнойɫоциɚльноймɟɞицинɫкойпɪоɛлɟмойɫɬɪɚнɚɯɌɚкȼɫɟмиɪнойзɞɪɚɜооɯɪɚнɟнияɫɟɪɞɟчноɫоɫɭɞиɫɬыɟзɚɛолɟɜɚнияяɜляюɬɫяоɫноɜɫмɟɪɬноɫɬипоэɬомɭоɫоɛɭюɚкɬɭɚльноɫɬьпɪиоɛɪɟɬɚюɬɜопɪоɫыпɪоɮилɚкɬикиɫɜоɟɜɪɟмɟнноɝолɟчɟнияпɚɬолоɝии [4, 5]. эɬойɫɜязиинɬɟɪɟɫнымияɜляюɬɫялɟкɚɪɫɬɜɟнныɟпɪɟпɚɪɚɬыоɫноɜɟɛояɪышникɚ [4, 5]. Пɪɟпɚɪɚɬыоɫноɜɟɛояɪышникɚиɫпользɭюɬɫянɚɪоɞноймɟɞицинɟɭпоминɚнияположиɬɟльномɛояɪышникɚɫɟɪɞцɟоɬноɫяɬɫяпɟɪɜомɭɜɟкɭ [8]. ɛояɪышникɚлɟчɟнияɫɟɪɞɟчноɫɭɞиɫɬыɯзɚɛолɟɜɚнийоɬноɫиɬɫяконцɭ 1800-ɬоɝɞɚпɪɟɞполɚɝɚлоɫьчɬоɛояɪышникможноиɫпользоɜɚɬькɚчɟɫɬɜɟɚльɬɟɪнɚɬиɜнойɬɟɪɚпиилɟчɟнияɫɟɪɞɟчноɫоɫɭɞиɫɬыɯзɚɛолɟɜɚɬɚкиɯкɚкɫɬɟнокɚɪɞияɝипɟɪɬонияɝипɟɪлипи 1800-Ⱥɜɬоɪɚмиопиɫɚныиɫɫлɟɞоɜɚнияɫнижɟниюɯолɟɫɬɟɪинɚɬɪиɝлицɟɪиɞоɜɜоɬныɯɛояɪышникɚ [10, 11]. иɫɫлɟɞоɜɚнияɯкɪыɫɚɯкɪоликɚɯкошкɚɯпокɚзɚночɬоэкɫɬɪɚкɬɛояɪышникɚможɟɬмɟɞлɟнноɭɫɬойчиɜоɫнижɚɬькɪоɜяноɟɞɚɜлɟниɟɫчɟɬпɟɪиɮɟɪичɟɫкиɯɫоɫɭɞоɜ1]. Ⱦля ɫыɪья ɛояɪышникɚнɟкоɬоɪымиɚɜɬоɪɚмимɟчɚɟɬɫяɬɚкжɟнɚличиɟɚнɬиɛɚкɬɟɪиɚльнойɚкɬиɜноɫɬиоɬношɟниимикɪооɪɝɚнизмоɜноɫɬиоɬношɟнииaureus, Pseudomonas aeruginosaeus, Pseudomonas aeruginosaКɪомɟɬоɝонɟкоɬоɪыɯиɫɬочникɚɯопиɫɚноɚнɬиокɫиɞɚнɬноɝоизɜлɟчɟнийɛояɪышникɚeus, Pseudomonas aeruginosaȼ нɚɫɬоящɟɟɛояɪышникпɪиɜлɟкɚɟɬмɚниɟɜɪɚчɟйиɫɫлɟɞоɜɚɬɟлɟйɫɜоимикɚɪɞиоɬоничɟɫкимикɚɪɞиопɪоɬɟкɬоɪнымиɫɜойɫɬɜɚмичɬопоɞɬɜɟɪжɞɚɟɬɫямноɝочиɫлɟннымиклиничɟɫкимииɫɫлɟɞоɜɚниями [19]. Ɍɚкпɪоɜɟɞɟнный 2003 ɝоɞɭмɟɬɚɚнɚлизɪɚнɞомизиɪоɜɚнныɯконɬɪолиɪɭɟмыɯиɫɫлɟɞоɜɚнийэкɫɬɪɚкɬɚɛояɪышникɚ Bunge) лɟчɟнияпɚциɟнɬоɜɯɪоничɟɫкойɫɟɪɞɟчнойнɟɞоɫɬɚɬочнопокɚзɚлнɚличиɟɛлɚɝопɪияɬноɝоɫɟɪɞɟчɫоɫɭɞиɫɬой [20]. Ƚɪɭппɚкиɬɚйɫкиɯ 2014 ɝоɞɭопɭɛликоɜɚлɚɪɚнɞомизиɪоɜɚнноɟɞɜойноɟɫлɟпоɟиɫɫлɟɞоɜɚниɟмноɝокомпонɟнɬноɝоɬиɬɟльноɝопɪɟпɚɪɚɬɚоɫноɜɟɛояɪышникɚлɟчɟнииɪɟзɭльɬɚɬɟпɪоɜɟɞɟнноɝоиɫɫлɟɞоɜɚнияɜыяɜлɟночɬоɭкɚзɚнныйпɪɟпɚɪɚɬɜызыɜɚлнɟɛольшоɟɫнижɟниɟɫоɞɟɪжɚнияплɚзмɟлипопɪоɬɟиноɜнизкойплоɬнопоɫлɟ 12-нɟɞɟльноɝокɭɪɫɚлɟчɟнияɜызыɜɚяэɬомнɟжɟлɚɬɟльныɯяɜлɟний [21]. 2015 ɝоɞɭɝɪɭппɚпɪоɜɟлɚɫɪɚɜниɬɟльноɟɫлɟɞоɜɚниɟɜлиянияɮизичɟɫкиɯэкɫɬɪɚкɬɚɛояɪышникɚ L.) молɟкɭлыɜнɭɬɪиклɟɬочнойɚɞɝɟ 1 ɫɟлɟкɬинɚпɚциɟнɬоɜɫɬɚɛильɫɬɟнокɚɪɞиɟйɪɟзɭльɬɚɬɟɜыɜоɞчɬоэкɫɬɪɚкɬɚ L. кɚчɟɫɬɜɟɞополниɬɟльнойɬɟɪɚпииэɮɮɟкɬиɜноɫнижɚюɬɚɬɟɪоɎɚɪмɚцияɮɚɪмɚколоɝияОɛзоɪыɞɚльнɟйшиɯпɪоɛлɟмɫɟɪɞɟчноɫоɫɭɞиɫɬой [22]. ИнɬɟɪɟɫноɬɚкжɟчɬоɝоɞɭопɭɛликоɜɚноиɫɫлɟɞоɜɚниɟɯоɞɟкоɬоɪоɝоɜыɜоɞчɬоэкɫɬɪɚкɬɛояɪышникɚCrataegus azarolus L.) ɫɬимɭлиɪɭɟɬɬипɪолиɮɟɪɚɬиɜнɭюɚкɬиɜноɫɬьɚɪɟɫɬклɟɬочноɝоɚпопɬозчɟлоɜɟчɟɫкиɯклɟɬкɚɯɪɚкɚɬолɫɬокишɟчникɚ HT-29 HCT-116 [23].ɊоɫɫийɫкойɎɟɞɟɪɚцииполɭчɟниякɚɪɞиоɬоничɟɫкиɯлɟкɚɪɫɬɜɟнныɯɫɪɟɞɫɬɜиɫпользɭюɬцɜɟɬплоɞыɛояɪышникɚ16 [23].Зɚ ɪɭɛɟжомɪɚɫпɪоɫɬɪɚнɟниɟполɭчилилɟкɚɪɫɬɜɟнныɟпɪɟпɚɪɚɬыоɫноɜɟцɜɟɬкоɜɛояɪышникɚ Нɚ ɬɟɪɪиɬоɪииɫɬɪɚныɜɫɬɪɟчɚюɬɫяоколоɞикоɪɚɫɬɭщиɯɛояɪышникоɜ [29, 30]. 12 ɛояɪышникɚɜключɟнныɯɞɟйɫɬɜɭющɭюɫɭɞɚɪɫɬɜɟннɭюɎɚɪмɚкопɟю XI изɞɚния XI), ɬɟɪɪиɬоɪииɊоɫɫийɫкойɎɟɞɟɪɚциипɪоизɪɚɫɬɚɟɬ 9, ɮɚɪмɚкопɟйнымиɛояɪышникɚɊоɫɫиияɜляюɬɫяплоɞыцɜɟɬки 9, Кɚчɟɫɬɜомомɟнɬɪɟɝлɚмɟнɬиɪɭɟɬ XI изɞɚнияɬɚккɚкɞɟйɫɬɜɭющɭюȽоɫɭɞɚɪɫɬɜɟннɭюɮɚɪмɚкопɟюɊоɫɫийɫкойɎɟɞɟɪɚ XIII изɞɚнияоɛɫɭжɞɚɟмыɟɛояɪышникɚпокɚɜключɟны XIII ɎɚɪмɚкопɟяɋоɟɞинɟнныɯШɬɚɬоɜизɞɚнияопиɫыɜɚɟɬɛояɪышникɚпɪɟɞɫɬɚɜляющɟɟцɜɟɬкɚми Jacq. (Poir.) DC., ɬɚкжɟизɜɟɫɬноɝокɚк L [27]. ȿɜɪопɟйɫкɚяɮɚɪмɚкопɟя 8 изɞɚниялɟкɚɪɫɬɜɟннымɛояɪышникɚоɬноɫиɬплоɞыɬɚкиɯкɚк Jacq (Poir.) (цɜɟɬкɚми Jacq. (Poir.) DC. ( Thuill.; auct.) ɞɪɭɛояɪышникɚɜключɚя Waldst., Waldst. C. azarolus L [26]. ȻɟлоɪɭɫɫкɚяɮɚɪмɚкопɟяɜключɚɟɬɫɬɚɬьипɟйɫкойɮɚɪмɚкопɟиплоɞыцɜɟɬкɚмиɬɚкжɟоɬɞɟльныɟɫɬɚɬьицɜɟɬкиɛояɪышникɚɎɚɪмɚкопɟйнымиɫчиɬɚюɬɫя Pall. (Poir) DC. ( sensu Pojark.) цɜɟɬки 14 ɛояɪышникɚɫɪɟɞикоɬоɪыɯ Pall.; . korolkowiiolkowiiɎɚɪмɚкопɟяɊɟɫпɭɛликизɚɯɫɬɚнлɟкɚɪɫɬɜɟнномɭоɬноɫиɬ Jacq. (Poir.) DC. (.) DC. (По лиɬɟɪɚɬɭɪнымизɜɟɫɬночɬоцɜɟɬкиплоɞыɛояɪышникɚɫоɞɟɪжɚɬмножɟɫɬɜоɛиоɮлɚɜоноиɞоɜкоɬоɪыɟкɚкпɪɟɞɫɬɚɜляюɬɫяпɟɪɜɭюочɟɪɟɞьоɬɜɟɬɫɬɜɟнныкɚɪɞиоɬоничɟɫкоɟчɬопɪиɜɟлоɪɚзɪɚɛоɬкɟэкɫɬɪɚкɬоɜцɜɟɬкоɜɛояɪышникɚɫɬɪɚнɚɯȻиоɮлɚɜоноиɞынɚɪɭжɟнныɟɛояɪышникɟɜключɚюɬолиɝомɟɪныɟɜиɬɟкɫинкɜɟɪцɟɬинɌɚкжɟɛояɪышникɚɫоɞɟɪжɚɬɫяɜиɬɚминɫɚпониныɞɭɛильныɟɜɟщɟɫɬɜɚкɚɪɞиоɬоничɟɫкиɟизоɛɭɬилɚминмɟɬокɫиɮɟнилэɬилɚминɯолинɚцɟɬилɯолинпɪоизɜоɞныɟɝɭɚнинɚмиɝɞɚлинɬɪиɬɟɪпɟноɜыɟкиɫлоɬыɭɪɫолоɜɚякиɫлоɬɚ ȼ ɪɟзɭльɬɚɬɟпɪоɜɟɞɟнныɯɝɪɭппойɫɚмɚɪɫкиɯиɫɫлɟɞоɜɚнийплоɞоɜɛояɪышникɚɞоминиɪɭющийɮлɚɜоноиɞ ? ɜиɬɟкɫинцɜɟɬкоɜɛояɪышникɚ ? ЦȿЛЬЮɪɚɛоɬыяɜляɟɬɫяɚнɚлизɫиɫɬɟмɚɬизɚɪɟзɭльɬɚɬоɜиɫɫлɟɞоɜɚнийоɛлɚɫɬиɯимичɟɫкойɫɬɚнɞɚɪɬизɚцииɛояɪышникɚɮɚɪмɚкопɟяɯɫɬɪɚнМȺɌȿɊИȺЛЫМȿɌОȾЫИɫɫлɟɞоɜɚниɟпɪоɜоɞилоɫьиɫпользоɜɚниɟмȽоɫɭɞɚɪɫɬɜɟннойɮɚɪмɚкопɟи XI изɞɚнияȽоɫɭɞɚɪɫɬɜɟннойɮɚɪмɚкопɟиɊоɫɫийɫкойɎɟɞɟɪɚции XIII изɞɚнияȿɜɪопɟйɫкойɮɚɪмɚкопɟи 6 изɞɚнияɮɚɪмɚкопɟиɋоɟɞинɟнныɯШɬɚɬоɜ 32 изɞɚнияȽоɫɭɞɚɪɫɬɜɟннойɮɚɪмɚкопɟиɊɟɫпɭɛликиȻɟлɚɪɭɫьɊɟɫпɭɛликиКɚзɚɯɫɬɚнɬɚкжɟинɮоɪмɚционнопоиɫкоɜыɯɛиɛлиоɬɟчныɯɊȿЗɍЛЬɌȺɌЫОȻɋɍЖȾȿНИȿОпɪɟɞɟлɟниɟпоɞлинноɫɬиɛояɪышникɚПлоɞы XI изɞɚнияплоɞоɜɪоɞɚȻояɪышникɪɚзɞɟлɟКɚчɟɫɬɜɟнныɟɪɟɚкцииɫыɜɚɟɬмɟɬоɞɬонкоɫлойнойɯɪомɚɬоɝɪɚɮииɌɋɏ), пɪɟɞɭɫмɚɬɪиɜɚющийɪɭжɟниɟɫɭɬɫɬɜииɝоɫɭɞɚɪɫɬɜɟнноɝоɫɬɚнɞɚɪɬноɝоȽɋОɯлоɪоɮоɪмɫпиɪɬ (8:2). эɬомɚнɚлизиɪɭɟмыɯщɟɫɬɜпɪоɜоɞяɬɭльɬɪɚɮиолɟɬоɜомɫɜɟɬɟɫɜɟɬɜолны 360 ȽɋОɞолжнɚпояɜиɬьɫяполоɫɚкоɪичнɟɜоɝоцɜɟɬɚзɚɬɟмплɚɫɬинкɭоɛɪɚɛɚɬыɜɚюɬ 5% ɫпиɪɬоɜымɪɚɫɬɜоɪомɚлюминиянɚɝɪɟɜɚюɬпоɫлɟчɟɝопɪиоɛɪɟɬɚɟɬжɟлɬоɮлɭоɪɟɫцɟнциюɫɜɟɬɟɜолны 5% ȿɜɪопɟйɫкɚяɮɚɪмɚкопɟя 8 изɞɚниямɚкопɟиɊɟɫпɭɛликиȻɟлɚɪɭɫьɊɟɫпɭɛликиКɚзɚɯɫɬɚнкɚчɟɫɬɜɟмɟɬоɞɚкɚчɟɫɬɜɟнноɝоɚнɚлизɚплоɞоɜɛояɪышникɚопиɫыɜɚюɬɬонкоɫлойнɭюɯɪомɚɬоɝɪɚплɚɫɬинкɟɫлоɟмɫиликɚɝɟля P (ɫиɫɬɟмɚɪɚɫɬɜоɪиɬɟлɟйкиɫлоɬɚɛɟзɜоɞнɚяɜоɞɚмɟɬилэɬилкɟɬон ? эɬилɚцɟɬɚɬ 10:10:30:50, иɫпользоɜɚнииɪɚɫɬɜоɪɚɫоɫɬоящɟɝоɯлоɪоɝɟноɜойкиɫлоɬыкоɮɟйнойкиɫлоɬыɪɭɬинɚɪɚɫɬɜоɪɟнныɯмɟɬɚнолɟпɪоɯожɞɟнияɮɪонɬɚɪɚɫɬɜоɪиɬɟляплɚɫɬинкɭɜыɫɭшиɜɚюɬопɪыɫкиɜɚюɬ 1% ɪɚɫɬɜоɪомɚминоэɬилоɜоɝоэɮиɪɚкиɫлоɬымɟɬɚнолɟзɚɬɟм 50 ɪɚɫɬɜоɪоммɚкɪоɝолɚ 400 мɟɬɚнолɟȾɚлɟɟплɚɫɬинкɭпɪоɫмɚɬɪиɜɚюɬɭльɬɪɚɮиолɟɬоPharmacy & Pharmacology V. 6 N 2, 2018DOI:10.19163/2307-9266-2018-6-2-104-120ɜомɫɜɟɬɟɜолны 365 ɪɟзɭльɬɚɬɟчɟɝоплɚɫɬинкɟɪɚɫɬɜоɪɚɞолжныɫлɟɞɭющиɟзоныɮлɭоɪɟɫцɟнцииɜɜɟɪɯɭɜɟличɟнияжɟлɬокоɪичнɟɜɚяɮлɭоɪɟɫциɪɭющɚязонɚɪɭɬинɫɜɟɬлоɝолɭɛɚяɮлɭоɪɟɫциɪɭющɚязонɚɯлоɪоɝɟноɜɚякиɫлоɬɚжɟлɬоɜɚɬокоɪичнɟɜɚяɮлɭоɪɟɫциɪɭющɚязонɚɜɟɪɯнɟйɬɪɟɬиɫɜɟɬлоɝолɭɛɚяɮлɭоɪɟɫциɪɭющɚязонɚкоɮɟйнɚякиɫлоɬɚиɫпыɬɭɟмоɝоɪɚɫɬɜоɪɚплɚɫɬинкɟоɛнɚɪɭжиɜɚюɬ 3 зоныɫɯоɞныɟɪɚɫположɟниюɮлɭоɪɟɫцɟнɪɚɫɬɜоɪомзоныɫооɬɜɟɬɫɬɜɭɯлоɪоɝɟноɜойкиɫлоɬɟкоɮɟйнойкиɫлоɬɟКɪомɟɬоɝооɬмɟчɚɟɬɫянɚличиɟ 3 кɪɚɫноɜɚɬыɯɮлɭоɪɟɫциɪɭющиɯзоноɞнɚкоɬоɪɚɫположɟниюɫооɬɜɟɬɫɬɜɭɟɬɪɭɬинɭɞɜɟоɫɬɚльныɟзоныɪɚɫположɟнызонынижɟɮлɭоɪɟɫциɪɭющɟйзоныɫɜɟɬлоɫинɟɝоцɜɟкоɬоɪɚянɚɯоɞиɬɫянижɟзоныкоɮɟйнойкиɫлоɬы 3 Нɚ нɚш ɜзɝляɞɜышɟпɟɪɟчиɫлɟнныɟɜɟщɟɫɬɜɚиɫпользɭɟмыɟкɚкɫɬɚнɞɚɪɬныɟɯлоɪоɝɟноɜɚякиɫлоɬɚкоɮɟйнɚякиɫлоɬɚɪɭɬиншиɪокоɜɫɬɪɟчɚюɬɫялɟкɚɪɫɬɜɟнныɯɫлɟɞоɜɚɬɟльнояɜляюɬɫяɛояɪышникɚПоэɬомɭпɪɟɞɫɬɚɜляɟɬɫячɬопоɞɯоɞоɬношɟнииɚнɚлизɚплоɞоɜɛояɪышникɚможноɫчиɬɚɬьцɟлɟɫооɛɪɚзнымЦɜɟɬкипɪɟɞɫɬɚɜлɟныȽоɫɭɞɚɪɫɬɜɟннойɮɚɪмɚкопɟɟ XI изɞɚния 8) ɮɚɪмɚкопɟɟɊɟɫпɭɛликиȻɟлɚɪɭɫь XI изɞɚниякɚчɟɫɬɜɟнноɝоɚнɚлизɚцɜɟɬкоɜɛояɪышникɚпɪɟɞлɚɝɚɟɬмɟɬоɞɌɋɏɫɬинкɚɯɋилɭɮолпɪиɫɭɬɫɬɜииɫɬɚнɞɚɪɬноɝоɯлоɪоɮоɪмɫпиɪɬ (8:2). эɬомпɪоɜоɞяɬɭльɬɪɚɮиолɟɬоɜомɫɜɟɬɟɜолны 360 ȽɋОɞолжнɚпояɜиɬьɫяполоɫɚкоɪичнɟɜоɝоцɜɟɬɚЗɚɬɟмплɚɫɬинкɭɬыɜɚюɬ 5% ɫпиɪɬоɜымɪɚɫɬɜоɪомɚлюминиянɚɝɪɟɜɚюɬпоɫлɟчɟɝопɪиоɛɪɟɬɚɟɬжɟлɬоɮлɭоɪɟɫцɟнциюɫɜɟɬɟɜолны 5% ȼ ɮɚɪмɚкопɟɟɊɟɫпɭɛликиȻɟлɚɪɭɫькɚчɟɫɬɜɟмɟɬоɞɚкɚчɟɫɬɜɟннойцɜɟɬкоɜɛояɪышникɚпɪɟɞɫɬɚɜлɟнмɟɬоɞɬонкоɫлойнойɯɪомɚɬоɝɪɚɮииɯлоɪоɮоɪммɟɬɚнол (80:20, пользоɜɚниɟмкɚчɟɫɬɜɟɫɬɚнɞɚɪɬноɝоПɪояɜлɟниɟпɪоɜоɞяɬɭльɬɪɚɮиолɟɬоɜомɫɜɟɬɟɜолны 365 ɞнɟɜномɫɜɟɬɟпɪɟɞɜɚɪиɬɟльнооɛɪɚɛоɬɚɜплɚɫɬинкɭɪɚɫɬɜоɪомɚлюминияпоɫлɟɞɭющимнɚɝɪɟɜɚниэɬомɭльɬɪɚɮиолɟɬоɜомɫɜɟɬɟоɬмɟчɚɟɬɫяжɟлɬоɮлɭоɪɟɫцɟнцияномɫɜɟɬɟяɪкожɟлɬɚяокɪɚɫкɚ 365 Мы ɫчиɬɚɟмчɬопоɞɯоɞиɫпользоɜɚниɟмȽɋОкоɬоɪыйяɜляɟɬɫяоɞнимɯɚɪɚкɬɟɪныɯɮлɚɜоноиɞоɜцɜɟɬкоɜɛояɪышникɚяɜляɟɬɫяоɛъɟкпозɜоляɟɬɚɞɟкɜɚɬноопɪɟɞɟляɬьпоɞлинноɫɬьɞɚнноɝоцɜɟɬкɚмиɮɚɪмɚкопɟɟкɚчɟɫɬɜɟнноɟопɪɟɞɟлɟниɟцɜɟɬкɚмиɛояɪышникɚпɪоɜоɞяɬиɫпользоɜɚниɟмɬонкоɫлойнойɯɪомɚɬоɝɪɚɮиикɚчɟɫɬɜɟɫɬɚнɞɚɪɬоɜпɪимɟняюɬɪɚɫɬɜоɪɪɭɬинɚɯлоɪоɝɟноɜойкиɫлоɬыɜиɬɟкɫинɚɋиɫɬɟмɚɬɜоɪиɬɟлɟйɜключɚɟɬэɬилɚцɟɬɚɬ ? ɜоɞɭ ? лɟɞянɭюɭкɫɭɫнɭюкиɫлоɬɭ ? киɫлоɬɭ (10 : 2,6 : Пɪояɜлɟниɟпɪоɜоɞяɬɪɚɫɬɜоɪомɚминоэɬилɞиɮɟнилɛоɪɚɬɚмɟɬɚнолɟ (1%), зɚɬɟмоɛɪɚɛоɬкойɪɚɫɬɜоɪомполиэɬилɟнɝликоля 4000 ɬɚнолɟзɚɬɟмпɪоɫмɚɬɪиɜɚюɬɫɜɟɬɟ 4000 КɪомɟɬоɝоɮɚɪмɚкопɟɟпɪɟɞɭɫмоɬɪɟнкɚчɟɫɬɜɟнныйɚнɚлизцɜɟɬкɚмиɛояɪышникɚмɟɬоɞомɜыɫокоэɮɮɟкɬиɜнойжиɞкоɫɬноймɚɬоɝɪɚɮииȼЭЖɏɊɚɫɬɜоɪɫоɫɬоиɬɪɭɬинɚɯлоɪоɝɟноɜойкиɫлоɬыɪɚɫɬɜоɪɟнныɯмɟɬɚнолɟɊɚɫɬɜоɪɫоɫɬоиɬɫмɟɫиɬɟɬɪɚɝиɞɪоɮɭɪɚнɚмɟɬɚнолɚɚцɟɬониɬɪилɚɊɚɫɬɜоɪɫоɫɬоиɬ 0,5% ɪɚɫɬɜоɮоɫɮоɪнойкиɫлоɬыɜоɞɟȾɟɬɟкɬиɪоɜɚниɟɜоɞяɬɜолны 336 колонкɟɪɚзмɟɪом ? 10 коɬоɪɚяɫоɞɟɪжиɬнɚполни L1 ɪɚзмɟɪом 5 Ɍɟмпɟɪɚɬɭɪɚколонкипоɞɞɟɪжиɜɚɟɬɫя 25?оɬɞɟльноɫɬимɚɬоɝɪɚɮɜɜоɞяɬоɛъɟмы (5 иɫпыɬɭɟмоɝоɪɚɫɬɜоɪɚɪɚɫɬɜоɪɚзɚɬɟмизмɟɪяюɬɭɞɟɪжиɜɚнияоɫноɜныɯпикоɜɪɚɫɬɜоɪɚɭɞɟɪжиɜɚнияпɪɟɞɫɬɚɜлɟноɬɚɛлицɟɌɚɛлицɚȼɪɟмяɭɞɟɪжиɜɚнияпикоɜɪɚɫɬɜоɪɚȼɟщɟɫɬɜоȼɪɟмяɭɞɟɪжиɜɚнияɏлоɪоɝɟноɜɚякиɫлоɬɚȽипɟɪозиɞȼиɬɟкɫиниɫпыɬɭɟмоɝоɪɚɫɬɜоɪɚɭɞɟɪжиɜɚнияоɫноɜныɯпикоɜɫоɫɬоиɬɭɞɟɪжиɜɚнияɯлоɪоɝɟноɜойкиɫлоɬыɜиɬɟкɫинɚɪɭɬинɚɫооɬɜɟɬɫɬɜɭющиɯɬɚкоɜомɭɪɚɫɬɜоɪɚɬɚкжɟɭɞɟɪжиɜɚнияɬɟкɫинɜиɬɟкɫинɚизоɜиɬɟкɫинɚɜиɬɟкɫинпɪɟɞɫɬɚɜлɟнныɯɬɚɛлицɟɎɚɪмɚцияɮɚɪмɚколоɝияОɛзоɪыɌɚɛлицɚȼɪɟмяɭɞɟɪжиɜɚнияпикоɜиɫпыɬɭɟмоɝоɪɚɫɬɜоɪɚȼɟщɟɫɬɜоȼɪɟмяɭɞɟɪжиɜɚнияȺцɟɬилɜиɬɟкɫинȼиɬɟкɫинИзоɜиɬɟкɫин 0.73ȼиɬɟкɫинцɜɟɬкɚмииɫпользоɜɚɬьɫмɟɫьɫɬɚнɞɚɪɬоɜоɞнɚкоɜɫɟɫɬɚнɞɚɪɬныɟɜɟщɟɫɬɜɚɯлоɪоɝɟноɜɚякиɫлоɬɚɜиɬɟкɫинопиɫɚнныɟɮɚɪмɚкопɟɟопɪɟɞɟлɟнияпоɞлинноɫɬицɜɟɬкɚмиɛояɪышникɚяɜляюɬɫяɊɚзɞɟлПоɞлинноɫɬьɛояɪышникɚȻɟлоɪɭɫɫкойɮɚɪмɚкопɟɟɬɚкжɟнɭжɞɚɟɬɫяɭɫоɜɟɪшɟнɫɬɜоɜɚнииɬɚккɚкɬолькокɚчɟɫɬɜɟнныɯɪɟɚкцийнɟɞоɫɬɚɬочноопɪɟɞɟлɟнияпоɞлинноɫɬиКоличɟɫɬɜɟнноɟопɪɟɞɟлɟниɟɮлɚɜоноиɞоɜɛояɪышникɚОɞнимɜɚжнɟйшиɯпɚɪɚмɟɬɪоɜмɟɬоɞикиличɟɫɬɜɟнноɝоопɪɟɞɟлɟниялɟкɚɪɫɬɜɟнномɬɟльномяɜляɟɬɫяэкɫɬɪɚкцияколичɟɫɬɜɟнноɝоопɪɟɞɟлɟнияɛояɪышникɚɮɚɪмɚкопɟяɯиɫпользɭюɬɜɚɪиɚнɬыэкɫɬɪɚкцииɌɚкэкɫɬɪɚкцииплоɞоɜɛояɪышникɚ XI изɞɚнияпɪɟɞлɚнɚɝɪɟɜɚниɟ 95% ɫпиɪɬомɬɟчɟниɟ 1 чɚɫɚȿɜɪопɟйɫкɚяɮɚɪмɚкопɟяɮɚɪмɚкопɟиɊɟɫпɭɛликиȻɟлɚɪɭɫьɊɟɫпɭɛликиКɚзɚɯɫɬɚнпɪɟɞлɚɝɚюɬэкɫɬɪɚкцию 70% ɫпиɪɬомнɚɝɪɟɜɚнииɬɟчɟниɟЦɜɟɬкиɮɚɪмɚкопɟɟɊɟɫпɭɛликиȻɟлɚɪɭɫьэкɫɬɪɚɝиɪɭюɬ 96% ɫпиɪɬомнɚɝɪɟɜɚнииɬɟчɟниɟоɞноɝочɚɫɚ XI изɞɚния 95% ɫпиɪɬомнɚɝɪɟɜɚнииɬɟчɟниɟоɞноɝочɚɫɚ 95% Экɫɬɪɚкциюцɜɟɬкɚмиɮɚɪмɚкопɟɟпɪоɜоɞяɬмɟɬɚноломɬɟчɟниɟ 5 ɪопɟйɫкойȻɟлоɪɭɫɫкойɮɚɪмɚкопɟям 60% ɫпиɪɬомɬɟчɟниɟ 60% Лиɫɬья ɫоɝлɚɫноȻɟлоɪɭɫɫкойɮɚɪмɚкопɟɟэкɫɬɪɚɝиɪɭюɬ 70% ɫпиɪɬомнɚɝɪɟɜɚнииɬɟчɟниɟчɚɫɚ 70% КɚкэкɫɬɪɚкцииэкɫɬɪɚɝɟнɬоɞниɯɬɟɯɪɚзняɬɫячɬоɫɜиɞɟɬɟльɫɬɜɭɟɬнɟоɛɯоɞимоɫɬипɪоɜɟɞɟнияɞополиɫɫлɟɞоɜɚнийпоɞɛоɪɭопɬимɚльноɝоэкɫɬɪɚɝɟнɬɚэкɫɬɪɚкцииɪɚзɪɚɛоɬкɟмɟɬоɞикиколичɟɫɬɜɟнноɝоопɪɟɞɟлɟнияɫɭммыɮлɚɜоноиɞоɜɜɚжнымяɜляɟɬɫянɚɭчнооɛоɫноɜɚнныйэкɫɬɪɚɝɟнɬɚɭчɟɬомоɫоɛɟнноɫɬɟйɮиɬоɯимичɟɫкоɝоɫоɫɬɚɜɚПлоɞыɫооɬɜɟɬɫɬɜии XI изɞɚнияɪɚзɞɟлКоличɟɫɬɜɟнноɟопɪɟɞɟлɟниɟɜключɚɟɬɯɪомɚɫпɟкɬɪоɮоɬомɟɬɪичɟɫкиймɟɬоɞɫɭммыɮлɚɜоноиɞоɜпɟɪɟɫчɟɬɟɫоɞɟɪжɚниɟкоɬоɪыɯплоɞɚɯɞолжно 0,06%, ɜолны 0,06%, По нɚшɟмɭ мнɟнию, ɞɚннɚя мɟɬоɞикɚɞоɜольноɝɪомозɞкɚзɚɬɪɭɞниɬɟльнɚɬочкиɬɚцииɪɟзɭльɬɚɬоɜɚнɚлизɚɬɚккɚкɯɪомɚɬоɝɪɚммɟиɫпыɬɭɟмоɝоɪɚɫɬɜоɪɚопɪɟɞɟляюɬɜɟщɟɫɬɜɚоɬɫɭɬɫɬɜɭющиɟɪɚɫɬɜоɪɟȿɜɪопɟйɫкойɮɚɪмɚкопɟɟɮɚɪмɚкопɟɟɊɟɫпɭɛликиȻɟлɚɪɭɫьɪɚзɞɟлɟКɚчɟɫɬɜɟнноɟопɪɟɞɟлɟцɜɟɬкɚмиɛояɪышникɚпɪɟɞɭɫмоɬɪɟнмɟɬоɞɬонкоɫлойнойɯɪомɚɬоɝɪɚɮиииɫпользоɜɚɪɚɫɬɜоɪɚɫоɫɬоящɟɝоɯлоɪоɝɟноɜойкиɫлоɬыɪɚɫɬɜоɪɟнныɯмɟɬɚнолɟкɚчɟɫɬɜɟпоɞɜижнойиɫпользɭюɬɛɟзɜоɞнɚякиɫлоɬɚ ? ɜоɞɚ ? кɟɬонэɬилɚцɟɬɚɬ (10 : 10 : 30 : 50). Пɪояɜляюɬɪɚɫɬɜоɪɚɫоɫɬоящɟɝо 10 ɪɚɫɬɜоɪɚɚминоэɬилоɜоɝоэɮиɪɚкиɫлоɬымɟɬɚнолɟзɚɬɟмɪɚɫпыляюɬ 50 ɪɚɫɬɜоɪполиэɬилɟнɝликолямɟɬɚнолɟпоɫлɟчɟɝопɪояɜляюɬɫɜɟɬɟ 50 КɚкɫɭщɟɫɬɜɭюɬнɟкоɬоɪыɟɪɚзноɝлɚкɚɫɚɬɟльноɚнɚлизɚцɜɟɬкɚмиɛояɪышникɚкоɬоɪыɟɜыɬɟкɚюɬиɫпользоɜɚнияпоɞɯоɞоɜɫɬɚнɞɚɪɬизɚцииɋлɟɞоɜɚɬɟльнооɫɬɚɟɬɫяɜопɪоɫкɚкоймɟɬоɞɫчиɬɚɬьɚɞɟкɜɚɬнымиɫɯоɞяоɫоɛɟнноɫɬɟйɮлɚɜоноиɞноɝоɫоɫɬɚɜɚиɫɫлɟɞɭɟмоɝокɚклɟкɚɪɫɬɜɟнноɝоопиɫɚныɮɚɪмɚкопɟɟɊɟɫпɭɛликиȻɟлɚɪɭɫьопɪɟɞɟлɟнияпоɞлинноɫɬиɮɚɪмɚкопɟɟпɪɟɞɫɬɚɜлɟныɪɟɚкцииɯлоɪиɞомзɟлɟноɜɚɬожɟлɬоɟокɪɚшиɜɚниɟнɚɝɪɟɜɚнииɪɚɫɬɜоɪомжɟлɟзɚ (III) ɫɭльɮɚɬомɫɭɬɫɬɜиикиɫлоɬыɯлоɪиɫɬоɜоɞоɪоɞнойɛɭɬɚнолɟкɪɚɫноɟокɪɚшиɜɚниɟнɚɝɪɟɜɚнии (III) Нɚ нɚш ɜзɝляɞопɪɟɞɟлɟнияпоɞлинноɫɬиɛояɪышникɚцɟлɟɫооɛɪɚзноɬоɞɬонкоɫлойнойɯɪомɚɬоɝɪɚɮиииɫпользоɜɚниɟмɫɬɚнɞɚɪɬныɯПоɞɜоɞяиɬоɝɞɚнноɝоɪɚзɞɟлɚпɪɟɞɫɬɚɜляɟɬɫячɬоɚнɚлизпоɞлинноɫɬиɜɫɟɯяɪышникɚнɟоɛɯоɞимопɪоɜоɞиɬьɞиɚɝноɫɬичɟзнɚчимымɜɟщɟɫɬɜɚмɌɚккɚчɟɫɬɜɟнныйɚнɚлизцɜɟɬкоɜиɫпользоɜɚниɟмȽɋОяɜляɟɬɫяоɛъɟкɬиɜным XI изɞɚнияɮɚɪмɚкопɟяɊɟɫпɭɛликиȻɟлɚɪɭɫьиɫпользоɜɚниɟчɟɬыɪɟɯɫɬɚнɞɚɪɬоɜɯлоɪоɝɟноɜɚякиɫлоɬɚкоɮɟйнɚякиɫлоɬɚɪɭɬинопɪɟɞɟлɟнияпоɞлинноɫɬиплоɞоɜɛояɪышникɚɫоɜɫɟмцɟлɟɫооɛɪɚзноɬɚккɚкɜɟщɟɫɬɜɚяɜляюɬɫяоɛɫɭжɞɚɟмоɝочɚɫɬоɜɫɬɪɟчɚюɬɫяɞɪɭɝиɯɜзɝляɞпоɛɟɝоɜPharmacy & Pharmacology V. 6 N 2, 2018DOI:10.19163/2307-9266-2018-6-2-104-120КоличɟɫɬɜɟнноɟопɪɟɞɟлɟниɟплоɞоɜпɟйɫкойɮɚɪмɚкопɟɟɮɚɪмɚкопɟяɯɊɟɫпɭɛликиȻɟлɚɪɭɫьɊɟɫпɭɛликиКɚзɚɯɫɬɚнпɪɟɞполɚɝɚɟɬɫпɟкɬɪоɮоɬомɟɬɪичɟɫкоɟопɪɟɞɟлɟниɟɫоɞɟɪжɚнияпɟɪɟɫчɟɬɟɬоɪоɝоɞолжно 0,06% (ɮɚɪмɚкопɟиɊɟɫпɭɛликиȻɟлɚɪɭɫьɊɟɫпɭɛлиКɚзɚɯɫɬɚнɜолны 550 545 ɮɚɪмɚкопɟиɊɟɫпɭɛликиȻɟлɚɪɭɫьɊɟɫпɭɛликизɚɯɫɬɚнКɪомɟɬоɝоɮɚɪмɚкопɟɟɊɟɫпɭɛликиɪɭɫьопиɫɚнмɟɬоɞɯɪомɚɬоɫпɟкɬɪоɮоɬомɟɬɪичɟɫкоопɪɟɞɟлɟнияɫоɞɟɪжɚнияɮлɚɜоноиɞоɜпɟɪɟɫчɟɬɟкоɬоɪоɝоɫɭɯиɯплоɞɚɯɞолжноɜолны 545 КɚкпɪɟɞɫɬɚɜлɟнныɯноɪмɚɬиɜныɯɞокɭмɟнɬɚɯɪɟкомɟнɞɭюɬɫяпоɞɯоɞыколичɟɫɬɜɟнномɭопɪɟɞɟлɟниюɫоɞɟɪжɚнияɮлɚɜоноиɞоɜплоɞɚɯɛояɪышникɚКɪомɟɬоɝомɟɫɬоɬолькомɟɬоɞɟопɪɟɞɟлɟниямɚɬоɫпɟкɬɪоɮоɬомɟɬɪичɟɫкийɫпɟкɬɪоɮоɬомɟɬɪичɟɫкийпокɚзɚɬɟлякɚчɟɫɬɜɚɫɭммɚɮлɚɜоноиɞоɜпɟɪɟɫчɟɬɟɫɭммыколичɟɫɬɜɟнноɝоопɪɟɞɟлɟнияцɜɟɬкоɜɛояɪышникɚ XI пɪиɜоɞиɬɫяɯɪомɚɬоɬɪоɮоɬомɟɬɪичɟɫкоɟопɪɟɞɟлɟниɟɫоɞɟɪжɚнияцɜɟɬкɚɯ 0,5%), ɜолны 0,5%), ȼ ɮɚɪмɚкопɟɟɊɟɫпɭɛликиȻɟлɚɪɭɫьколичɟɫɬɜɟнɚнɚлизцɜɟɬкоɜɛояɪышникɚпɪоɜоɞяɬɯɪомɚɫпɟкɬɪоɮоɬомɟɬɪичɟɫкиммɟɬоɞомпомощьюкоɬоɪоɝоопɪɟɞɟляюɬɫоɞɟɪжɚниɟɟɝоɞолжно 0,5%, ɜолны 365 365 ɏɪомɚɬоɫпɟкɬɪоɮоɬомɟɬɪичɟɫкоɟопɪɟɞɟлɟниɟɜзɝляɞɝɪомозɞкоɬɪɭɞноиɫполнɟниинɟɞоɫɬɚɬкɚɬочкиɬочноɫɬимɟɬоɞɚ 365 2.3. Лиɫɬья ɫ цɜɟɬкɚмиКоличɟɫɬɜɟнноɟопɪɟɞɟлɟниɟцɜɟɬкɚмиɛояɪышникɚɮɚɪмɚкопɟɟɜключɚɟɬмɟɬоɞомɜыɫокоэɮɮɟкɬиɜнойжиɞкоɫɬнойɯɪомɚɬоɝɪɚɮииɝликозилиɪоɜɚнныɯɮлɚɜоноɜпɟɪɟɫчɟɬɟɜиɬɟкɫинɫоɞɟɪжɚниɟкоɬоɪыɯɞолжно 0,6% ɝликозилиɪоɜɚнныɯɮлɚɜопɟɪɟɫчɟɬɟɫоɞɟɪжɚниɟкоɬоɪыɯɞолжно 0,45%. Ⱦɟɬɟкɬиɪоɜɚниɟопɪɟɞɟлɟнииɝликозилиɪоɜɚнныɯɮлɚɜоноɜпɪоɜоɜолны 336 колонкɟɪɚзмɟɪом 4 x 10 ɫкоɪоɫɬьюпоɬокɚоколо 1,0 минɭɬɭопɪɟɞɟлɟнииɝликозилиɪоɜɚнныɯɮлɚɜоноɜɬɟɪминоɞнɚкоɪɟчьзɞɟɫьɮлɚɜонолɚɯиɫпользɭюɬɜолныколонкɟɪɚзмɟɪом 4,6 ? 25 ɫкоɪоɫɬьюпоɬокɚминɭɬɭ ? 25 КоличɟɫɬɜɟнноɟопɪɟɞɟлɟниɟɜɟщɟɫɬɜцɜɟɬкɚмиȿɜɪопɟйɫкойɮɚɪмɚкопɟɟɮɚɪмɚкопɟɟɊɟɫпɭɛликиȻɟлɚɪɭɫьɜключɚɟɬɫпɟкɬɪоɮоɬомɟɬɪичɟɫкоɟопɪɟɞɟлɟниɟɫоɞɟɪжɚнияɫɭммыɮлɚɜоноиɞоɜпɟɪɟɫчɟɬɟкоɬоɪоɝоɞолжно 1,5%, ɜолныȿɜɪопɟйɫкɚяɮɚɪмɚкопɟя 410 ɮɚɪмɚкоɊɟɫпɭɛликиȻɟлɚɪɭɫь 410 По ɜɫɟйɜиɞимоɫɬиэɬомнɟоɛɯоɞимоɞополниɬɟльноɟиɫɫлɟɞоɜɚниɟɫооɬɜɟɬɫɬɜиɟɚнɚлиɬичɟɫкойɜолныɯɚɪɚкɬɟɪнойɬɟɯɜɟщɟɫɬɜкоɬоɪыɟɫоɞɟɪжɚɬɫяколичɟɫɬɜɟнноɝоопɪɟɞɟлɟнияɞɟйɫɬɜɭющиɯɜɟщɟɫɬɜɛояɪышникɚɮɚɪмɚкопɟɟɊɟɫпɭɛликиȻɟлɚɪɭɫьопиɫɚноɫпɟкɬɪоɮоɬомɟɬɪичɟɫкоɟопɪɟɞɟлɟниɟɫоɞɟɪжɚнияɫɭммыɮлɚɜоноиɞоɜɪɟɫчɟɬɟɪɭɬин 0,25%) ɜолныɫпɟкɬɪоɮоɬомɟɬɪичɟɫкоɟопɪɟɞɟлɟниɟɫɭммыпɟɪɟɫчɟɬɟ 5,0%) ɜолны 550 550 Нɚ нɚш ɜзɝляɞɜыɜоɞыоɬноɫиɬɟльнооɛъɟкɬиɜноɫɬимɟɬоɞикиɬолькопоɫлɟɭɝлɭɛлɟнноɝоизɭчɟнияɯимичɟɫкоɝоɫоɫɬɚɜɚɞɚнноɝоМɟɬоɞикиɚнɚлизɚɛояɪышникɚпɪɟɞложɟнныɟоɬɞɟльнымиɚɜɬоɪɚмиПлоɞынɟкоɬоɪыɯиɫɬочникɚɯопиɫɚнɚмɟɬоɞикɚколичɟɫɬɜɟнноɝоопɪɟɞɟлɟнияплоɞɚɯɛояɪышникɚиɫпользоɜɚниɟммоɞиɮициɪоɜɚнноɝомɟɬоɞɚПоɪɬɟɪɚɯоɞɟмɟɬоɞикиполɭчɚюɬизɜлɟчɟниɟплоɞоɜɛояɪышникɚпомощью 70% эɬилоɜоɝоɫпиɪɬɚизɜлɟчɟниюɞоɛɚɜляюɬɪɚɫɬɜоɪɛɭɬɚнолɚжɟлɟзоɫоɞɟɪжɚщийɪɟɚкɬиɜкиɫлоɬноɝоɚнɬоцизɚɬɟмизмɟɪяюɬопɬичɟɫкɭюплоɬноɫɬьɬɜоɪɚɫпɟкɬɪоɮоɬомɟɬɪɟɜолны 550 550 ɋɚмɚɪɫкимипɪɟɞложɟнɚмɟɬоɞиɚнɚлизɚɫоɞɟɪжɚнияɫɭммыɮлɚɜоноиɞоɜплоɞоɜɛояɪышникɚпɪɟɞɜɚɪиɬɟльнымполɭчɟниɟмизɜлɟоɫноɜɟ 70% эɬилоɜоɝоɫпиɪɬɚпɟɪɟɫчɟɬɟиɫпользоɜɚниɟмɞиɮɮɟɪɟнциɚльнойɫпɟкɬɪоɮоɬомɟɬɪииɜолны 70% 3.2. ЦɜɟɬкиȾля цɜɟɬкоɜɛояɪышникɚпɪɟɞложɟнɚмɟɬоɞикɚколичɟɫɬɜɟнноɝоопɪɟɞɟлɟнияɫɭммыɮлɚɜоноипɟɪɟɫчɟɬɟмɟɬоɞомɞиɮɮɟɪɟнциɚльнойɫпɟкɬɪоɮоɬомɟɬɪииɜолны 412 пɪɟɞɜɚɪиɬɟльнымполɭчɟниɟмизɜлɟчɟнияоɫноэɬилоɜоɝоɫпиɪɬɚ 412 3.3. Лиɫɬья ɫ цɜɟɬкɚмиɊɚзɪɚɛоɬɚнɚмɟɬоɞикɚопɪɟɞɟлɟнияпоɞлинноцɜɟɬкɚмиɛояɪышникɚмɟɬоɞомɬонкоɫлойнойɯɪомɚɬоɝɪɚɮиипоɞɜижнойцɟɬɚɬɭкɫɭɫнɚякиɫлоɬɚɜоɞɚ (5 : 1 : 1) пɪиɫɭɬɫɬɜииɪɚɫɬɜоɪоɜɪɭɬинɜиɬɟкɫинɯлоɪоɝɟноɜɚякиɫлоɬɚ [44]. КɪомɟɬоɝопɪɟɞложɟнɚмɟɬоɞикɚкɚчɟɫɬɜɟнноɝоколичɟɫɬɜɟнноɝоопɪɟɞɟɜиɬɟкɫинɚɪɭɬинɚкɜɟɪцɟɬинɚɎɚɪмɚцияɮɚɪмɚколоɝияОɛзоɪыцɜɟɬкɚмиɛояɪышникɚмɟɬоɞомȼЭЖɏɫпɟкɬɪоɮоɬомɟɬɪичɟɫкимɞɟɬɟкɬиɪоɜɚниɟмпоɫлɟпɪɟɞɜɚɪиɬɟльнойэкɫɬɪɚкциипомощью 70% ɜоɝоɫпиɪɬɚ 70% Иноɫɬɪɚннымиɬɚкжɟɪɚзɪɚɛоɬɚмɟɬоɞикɚколичɟɫɬɜɟнноɝоопɪɟɞɟлɟнияцɜɟɬкɚмиɛояɪышникɚмɟɬоɞомɫɜɟɪɯэɮɮɟкɬиɜнойжиɞкоɫɬнойɯɪомɚɬоɝɪɚɮииɮлɭомɟɬɪичɟɫкимɞɟɬɟкɬиɪоɜɚниɟмпɪɟɞɜɚɪиɬɟльполɭчɟниɟмɜоɞноɚцɟɬоноɜоɝоизɜлɟчɟнияɛояɪышникɚ 70% 3.4. Лиɫɬьяɋɚмɚɪɫкимипɪɟɞложɟнɚмɟɬоɞикɚличɟɫɬɜɟнноɝоопɪɟɞɟлɟнияɛояɪышникɚкɪоɜɚɜокɪɚɫноɝомɟɬоɞомɞиɮɮɟɪɟнциɚльнойɬɪоɮоɬомɟɬɪии 412 пɟɪɟɫчɟɬɟпɪɟɞɜɚɪиɬɟльнойэкɫɬɪɚкциɟй 70% ɫпиɪɬом 70% Опиɫɚнɚмɟɬоɞикɚколичɟɫɬɜɟнноɝоопɪɟɞɟлɟнияɜиɬɟкɫинɚɜиɬɟкɫинɚизоɜиɬɟкɫинɚɪɭɬинɚɛояɪышникɚмɟɬоɞомжиɞкоɫɬнойɯɪомɚɬоɝɪɚɮииɭльɬɪɚɮиолɟɬоɜымɬɟкɬиɪоɜɚниɟм 70% Ɍɚкжɟɫɭщɟɫɬɜɭɟɬмɟɬоɞикɚколичɟɫɬɜɟнноɝоопɪɟɞɟлɟния 2"-ɝлюкозиɞɜиɬɟкɫинɚɜиɬɟкɫинɚɪɭɬинɚɛояɪышникɚмɟɬоɞомɮɚзоɜойɜыɫокоэɮɮɟкɬиɜнойжиɞкоɫɬнойɯɪомɚɬоɝɪɚɮииɭльɬɪɚɮиолɟɬоɜымɞɟɬɟкɬиɪоɜɚниɟм 2"-Ƚɪɭппɚкиɬɚйɫкиɯколичɟɫɬɜɟнноɞɟɫяɬькомпонɟнɬоɜɜиɬɟкɫинɜиɬɟкɫинɝлюкозиɞɜиɬɟкɫинизокɜɟɪциɬɪинɯлоɪоɝɟноɜɭюкиɫлоɬɭэɭкомоɜɭюкиɫлоɬɭэпикɚɬɟɯин B2 C1 ɛояɪышникɚпɟɪиɫɬонɚɞɪɟзɚнноɝомɟɬоɞомɜыɫокоэɮɮɟкɬиɜнойжиɞкоɫɬноймɚɬоɝɪɚɮии C1 ЗȺКЛЮЧȿНИȿɌɚкимоɛɪɚзомпɪоɜɟɞɟнныйɚнɚлизɫиɫɬɟмɚɬизɚцияɪɟзɭльɬɚɬоɜиɫɫлɟɞоɜɚнийоɛлɚɫɬиɯимичɟɫкойɫɬɚнɞɚɪɬизɚцииɛояɪышникɚɮɚɪмɚкопɟяɯɫɬɪɚнпокɚзɚчɬомɟɬоɞикɚɯɚнɚлизɚɪоɞɚȻоя L.), ɜключɟнныɯоɬɟчɟɫɬɜɟнныɟзɚɪɭɛɟжныɟɮɚɪмɚкопɟииɫпользɭюɬɫямɟɬоɞичɟɫкиɟмɟɬоɞолоɝичɟɫкиɟпоɞɯоɞыɫɬɚнɞɚɪɬизɚцииплоɞоɜцɜɟɬкоɜКɪомɟɬоɝоɪɭжɟночɬооɞноɝонɚимɟноɜɚнияɚнɚлизиɪɭɟɬɫяиɫпользоɜɚниɟммɟɬоɞикэɬомɜзɝляɞиɫпользоɜɚниɟмɟɬоɞикɚɯэкɫɬɪɚɝɟнɬоɜɜɫɟɝɞɚоɛоɫноɜɚноɬочкиɮизикоɯимичɟɫкиɯɫпɟкɬɪɚльныɯɯɚɪɚкɬɟɚнɚлизиɪɭɟмыɯɜɟщɟɫɬɜɌɚкжɟпокɚзɚчɬомɟɬоɞикɚɯкɚчɟɫɬɜɟнноɝоколичɟɫɬɜɟнноɝоɚнɚлизɚɞɟйɫɬɜɭющиɯɜɟщɟɫɬɜɮлɚɜоноиɞыɜɫɟɝɞɚɜɟɞɟɬɫяоɪиɟнɬɚцияɫɬичɟɫкизнɚчимыɟɫɬɚнɞɚɪɬныɟɜɟщɟɫɬɜɚэɬойɫɜязинɟоɛɯоɞимоɛолɟɟɝлɭɛокоɟизɭчɟɯимичɟɫкоɝоɫоɫɬɚɜɚɛояɪышникɚɜыяɜлɟнияɞиɚɝноɫɬичɟɫкизнɚчимыɯɜɟщɟɫɬɜпоɞопɬимɚльныɯэкɫɬɪɚɝɟнɬоɜэкɫɬɪɚкчɬопозɜолиɬɪɚзɪɚɛоɬɚɬьнɚɭчнооɛоɫноɜɚнныɟпоɞɯоɞыɫɬɚнɞɚɪɬизɚцииɭниɮициɪоɜɚɬьмɟɬоɞиɚнɚлизɚпɪɟпɚɪɚɬоɜɪоɞɚɛояɪыш Currently, herbal medicines are prevention of various diseases [1, 2]. This may be due ciently high ef ciency, a wide range of therapeutic effects, a complex effect on the human body with their rational use. They are and also relatively cheap in They are and also relatively cheap in Currently, cardiovascular diseases remain the most Thus, according to the World Health Organization, treatment of this pathology acquire special urgency [4, gency [4, The reparations based on hawthorn have been used in folk medicine for a long time. The rst mention of the positive effect of hawthorn on the heart refers to the rst century of our era [8]. The use of hawthorn for treatment The use of hawthorn for treatment The authors describe the studies on the reduction of the cholesterol level and triglycerides in the blood of animals while using hawthorn raw materials [10, 11]. 1]. As for hawthorn raw materials, some authors also notify the presence of antibacterial activity against a number of microorganisms, in particular against Escherichia coli, Staphylococcus aureus, Pseudomonas eus, Pseudomonas In addition, some sources describe the antioxidant effect of extracts from hawthorn raw materials [16, 17, rmed by numerous clinical studies [19]. Thus, in 2003 a meta-analysis of randomized da Bunge) for treatment of patients with chronic t compared with placebo [20]. A group of Chinese based on hawthorn in the treatment of dyslipidemia. As Pharmacy & Pharmacology V. 6 N 2, 2018DOI:10.19163/2307-9266-2018-6-2-104-120a comparative study of the effects of aerobic exercise on intracellular adhesion molecules of Type 1 and E-selectin in patients with stable angina. As a result, as additional therapy effectively fectively It is also interesting that there was a study published in 2016, in the course of which it was concluded that hawthorn leaf extract (Crataegus azarolus L.) stimulates antiproliferative activity, cell cycle arrest and apoptosis in human colon cancer cells HT-29 and HCT-116 [23]. owers and are used to obtain cardiotonic medicinal drugs [24, 25]. Abroad, medicines on the basis owers have got widely spread owers have got widely spread On the territory of our country there are about 40 species of wild-growing hawthorns [29, 30]. Of the 12 species of hawthorn included into the current State Pharmacopoeia of the USSR, XI-th edition (GF USSR XI), 9 grow on the territory of the Russian Federation, and the fruits and ? owers are the pharmacopoeial species of hawthorn raw materials in Russia [24, 25]. At the At the The United States Pharmacopeia of the 32-nd edition describes hawthorn raw materials, representing leaves with ? owers collected from the species also also The European Pharmacopoeia (the 8-th edition) refers to the medicinal hawthorn raw materials the fruits of such species as Crataegus monogyna Jacq (Lindm.), C. laevigata (Poir.) owers of or C. laevigata (Poir.) DC. (synonyms for and other Waldst., C. nigra Waldst. and C. azarolus L The Belarusian Pharmacopoeia includes articles from the European Pharmacopoeia on fruits, leaves with ? owers, as well as some speci c articles on hawthorn owers and leaves. and (synonym of owers of 14 species of hawthorn, (Poir) DC., C. korolkowii L. Henry; C. altaica (Loud.) and others are considered to be included into [28]. The Pharmacopoeia of the Republic Crataegus laevigata (Poir.) DC. (synonym for (synonym for According to the literature data, hawthorn leaves, ? owers and fruits are known to contain a lot of avonoids, which seem to be primarily responsible owers in European countries. Bio avonoids vitexin, quercetin and hyperoside. The hawthorn raw adenine, guanine, caffeine, amygdalin), triterpenic acids feine, amygdalin), triterpenic acids As a result of the research conducted by a group of Samara scientists, the dominant ? avonoid vitexin was owers [40]. of the work is to analyze and systematize eld of chemical standardization of hawthorn raw materials in pharmacopoeias of different MATERIALS AND METHODS. The study was and RESULTS AND DISCUSSIONmethyl alcohol system (8: 2). Hereby, the detection of the analytes is carried out in the ultraviolet light (UV light) at the wavelength of 360 nm. At the spot level of the brown color should appear, then the plate is treated with uorescence in the UV light (hyperoside) at the wavelength of 360 nm [24]. The European Pharmacopoeia (6-th edition), chromatography on a plate with a layer of silica gel P (solvent system: acidic anhydrous water-methyl ethyl V / V / V / Vreference solution consisting of chlorogenic acid, caffeic ɎɚɪмɚцияɮɚɪмɚколоɝияОɛзоɪыFurther, the plate is viewed in ultraviolet light at the wavelength of 365 nm. As a result of these uorescence zones (bottom-up as Rf increases) should be visible on the plate in the case of the reference solution: a yellow-brown uorescent zone (routine), a light blue uorescent zone uorescent zone (hyperoside); in the upper third of the plate a light uorescent zone (caffeic acid) should be visible. In the case of the test solution, 3 zones are found on the plate. They are similar to a reference solution in uorescence, these zones correspond to chlorogenic acid, hyperoside and coffee acid. Besides, uorescent zones, one of which corresponds to rutin according to its location, and the other two zones are located above the hyperoside zone uorescent light blue zone of which is below the caffeic acid zone [26, 28, 34].used as standard samples (chlorogenic acid, caffeic acid, c for hawthorn fruits. owers the State Pharmacopoeia of the USSR (XI-th edition) suggests the thin layer chromatography (TLC) method on ?Siloufol? plates in the presence of a standard hyperoside sample in the system of chloroform-methyl alcohol (8: 2). Hereby the detection is carried out in ultraviolet light at the wavelength of 360 nm. At the spot level of the standard hyperoside sample a dark brown strip should appear. The plate is then treated with a 5% alcohol solution of aluminum chloride and heated. uorescence in UV light (hyperoside) at the wavelength of 360 nm In the Pharmacopeia of the Republic of Belarus, as a method of qualitative assessment of hawthorn ? owers, a hyperoside as a standard sample. The manifestation of the uorescence (hyperoside) (hyperoside) We consider the approach with the use of a standard avonoids of hawthorn owers, objective, as it makes it owersIn the US Pharmacopeia, a qualitative determination owers is carried out using thin layer chromatography. As standards, a solution of rutin, chlorogenic acid, hyperoside and vitexin is used. The sol-tate ? water ? glacial acetic acid ? formic acid (10 : 2.6 : 1.1 : 1.1). The manifestation of the plate is carried out with a solution of 2-aminoethyldiphenylborate in methanol (1%), then by treatment with a solution of polyethylene glycol 4000 in methanol (5%) and then viewed in UV light [27]. owers by high-performance liquid chromatography (HPLC). The reference solution consists of rutin, chlorogenic acid, hyperoside and vitexin dissolved in methanol. Solution A consists of a mixture of tetrahydrofuran, methanol and acetonitrile (92.4 : 4.2 : 3.4). Solution B consists of a 0.5% solution of phosphoric acid in water. The de-tection is carried out at the wavelength of 336 nm on ller particles. The column temperature is maintained at 25? C. Separately, equal volumes (5 l) of the test solution matograph, then the retention time of the main peaks is measured. For the reference solution, the retention time is shown in Table 1.Table 1 ? Retention time of the main peaks for the reference solutionSubstanceRetention time, minutesChlorogenic acid0.26Hyperoside1.4Vitexin1.0Rutin1.16-O-rhamnoside, as shown in Table 2 [27].Pharmacy & Pharmacology V. 6 N 2, 2018DOI:10.19163/2307-9266-2018-6-2-104-120Table 2 ? Retention time of the main peaks of the test solutionSubstanceRetention time, minutes-O-rhamnoside1.53Vitexin1.0Vitexin-2-O-rhamnoside0.67 owers, are speci c parts of the cient to identify the authenticity of raw materials. cation of avonoids in hawthorn raw Extraction is one of the most important parameter in the quantitative determination in medicinal plants raw materials.hawthorn raw materials in different Pharmacopoeias, various extraction options are used. Thus, for the of the USSR, XI-th edition, offers heating with 95% alcohol for 1 hour, and the European Pharmacopoeia, the Republic of Kazakhstan, offer 70% ethyl alcohol owers are extracted with 96% ethanol while heating for 1 hour, and according to the State , and according to the State According to the US Pharmacopeia, extraction of leaves with ? owers is carried out with methanol for 5 owers is carried out with methanol for 5 According to the Belarusian Pharmacopoeia, leaves are extracted with 70% ethyl alcohol while heating for 1 hour [28].As far as we can see, the extraction time and extractant for the same types of raw materials vary greatly, which of the optimal extractant and extraction conditions. When avonoids, it is important to scienti cally select the cation? avonoids (in terms of hyperoside). Their quantity in fruits should be at least Their quantity in fruits should be at least Quanti? cation of fruits in the European cult from the point of view of interpreting the test solution determines substances absent in the refer- owers, a thin lay-dissolved in methanol. The following system is used as ethyl ketone ? ethyl acetate (10: 10: 30: 50). The mani-polyethylene glycol in methanol. After that the substance is displayed in UV light at 365 nm [26, 28]. owers, which stem from the use of different approaches to the standardization of raw materials. Consequently, the prob- avonoid Belarus. To determine the authenticity, in the Pharmaco-, in the Pharmaco-In our opinion, to determine the authenticity of haw-thorn leaves, it is advisable to add a thin layer chroma-tography method using standard samples.Summing up the results of this section, it seems to us that the analysis of the authenticity of all types of haw-thorn raw materials should be carried out diagnostically on signi? cant substances. owers with coffee acid, hyperoside and rutin) to determine the c to the discussed owers) it makes sense to use a mixture of standards, ɎɚɪмɚцияɮɚɪмɚколоɝияОɛзоɪы avonoids in terms avonoids in terms 34].As far as we can see, in the submitted normative documents various approaches to quanti? cation of avonoids in hawthorn fruits are recommended. Besides, there is a difference not only avonoids in owers cation of hawthorn owers [24]. owers is carried out owers is carried out Chromato-spectrophotometric determination, in our opinion, is cumbersome, dif? cult to perform and is not cult to perform and is not 2.3. Leaves with ? owers cation of hawthorn avones in terms of vitexin (the quantity should avones in liquid chromatography is used. The detection for the avons is carried out ow rate of about 1.0 ml per minute. In the avons (the term is avonols), the detection is carried out on a 4.6 ow rate of 1.5 ml per minute [27]. cation of target substances in leaves with owers according to the European Pharmacopoeia and avonoids in terms of hyperoside. In raw avonoids in terms of hyperoside. In raw Apparently, in this case an further investigation is cation of active substances in hawthorn leaves, a- a-In our opinion, the conclusions regarding the objec-tivity of this methodology can be made only after a deep study of the chemical composition of this type of raw materials.3. Methods for analyzing the raw material of hawthorn, proposed by individual authors ed Porter?s method. According to this method, extraction of the extract. After that the optical density of the solution After that the optical density of the solution Samara scientists proposed a technique for analyz-ing the contents of the sum of hawthorn fruits ? avonoids alcohol in terms of hyperoside using differential spectro-ferential spectro-3.2. FlowersFor hawthorn ? owers, a method was proposed for avonoids in terms of hypero-side by differential spectrophotometry at the wavelength ferential spectrophotometry at the wavelength 3.3. Leaves with ? owersA method for determining the authenticity of leaves owers was developed by thin layer chro-owers was developed by thin layer chro-dition, methods for qualitative and quantitative determi-nation of vitexin, rutin, hyperoside and quercetin in raw leaves with hawthorn ? owers was proposed by high per--Foreign scientists have also developed a procedure for quanti? cation of procyanidins in leaves with haw-Pharmacy & Pharmacology V. 6 N 2, 2018DOI:10.19163/2307-9266-2018-6-2-104-120 eld of chemical L.), included into domes- owers and leaves are used. ed from the point of view the substances being analyzed. We have also shown that avonoids, procyanidins), the orienta- cant standard substances is cant substances diagnostically, cally owers by the method of ultra-ef cient liquid chro- uorometric detection with preliminary preparation of water-acetone extraction from hawthorn -acetone extraction from hawthorn 3.4. LeavesSamara scientists have proposed a method for quan-ti? cation of hawthorn blood-red leaves by differential ferential A procedure for quanti cation of 2?-O-rhamno-cation of 2?-O-rhamno-There is also methods for quanti? cation of of A group of Chinese scientists has quanti ed ten com- Bge.) by meth- Bge.) by meth-CONCLUSION. Thus, our analysis and system-ȻиɛлиоɝɪɚɮичɟɫкийMartins Ekor. The growing use of herbal medicines: issues relating to adverse reactions and challenges in moni-toring safety // Frontiers in Pharmacology. 2013. No 4. P. 177. URL: https://www.ncbi.nlm.nih.gov/pmc/articles/ɞɚɬɚ: 24.01.2018). DOI: 10.3389/fphar.2013.00177Pal S.K., Shukla Y. Herbal medicine: current status and the future // Asian Paci c Journal of Cancer Preven-tion. 2003. No 4(4). P. 281-288. URL: https://www.ncbi.nlm.nih.gov/pubmed/14728584 (ɞɚɬɚɋɚмɛɭкоɜɚОɜчинникоɜȽɚнɚпольɫкийЯɬмɚноɜПɟɪɫпɟкɬиɜыиɫпользоɜɚнияɮиɬопɪɟпɚɪɚɬоɜɮɚɪмɚколоɝии // ОɛзоɪыклиничɟɫкойɮɚɪмɚколоɝиилɟкɚɪɫɬɜɟннойɬɟɪɚпииWorld Health Organization. Cardiovascular diseases (CVDs) URL: http://www.who.int/mediacentre/factsheets/ɞɚɬɚȻɚɫыɪоɜɚɊɚɫпɪоɫɬɪɚнɟнноɫɬьоɫноɜныɯɮɚкɬоɪоɜɪиɫкɚɫɟɪɞɟчноɫоɫɭɞиɫɬыɯзɚɛолɟɜɚнийкомɛинɚцийɝоɪоɞɚОɪɟнɛɭɪɝɚȺɫпиɪɚнɬɫкийɜɟɫɬникПоɜолжьяПяɬиɝоɪɫкɚяȻояɪышник (Crataegus): ɜозможноɫɬимɟɞицинɫкоɝоɎɚɪмɚɬɟкɚRastogi S., Pandey M.M., Rawat A.K. Traditional herbs: a remedy for cardiovascular disorders // Phytomedi-cine. 2016. No 23(11). P. 1082?1089. URL: https://www.ncbi.nlm.nih.gov/pubmed/26656228 (ɞɚɬɚZorniak M., Szydlo B., Krzeminski T.F. Crataegus special extract WS 1442: up-to-date review of experimental and clinical experiences // Journal of physiology and pharmacology. 2017. No 68 (4). P. 521?526. URL: https://www.ncbi.nlm.nih.gov/pubmed/29151068 (ɞɚɬɚJieWang, Xingjiang Xiong, Bo Feng. Effect of Crataegus Usage in Cardiovascular Disease Prevention: An Evi-dence-Based Approach // Evidence-Based Complementary and Alternative Medicine. 2013. Available at: https://www.hindawi.com/journals/ecam/2013/149363/ (ɞɚɬɚ: 24.01.2018). DOI: 10.1155/2013/149363Liu X.Y., Zhou L., Liang R.Y. Study on lipid regulation mechanism of total avonoids from folium Crataegi by 3T3-L1 cells // Chin. Arch. Tradit. Chin. Med. 2009. No. 27. P. 1066?1068. Yang R.M., Chen H.M., Gao N.N., Song X., Li J.L., Cai D.Y. Mechanism of early atherosclerosis in guinea pig: abnormal metabolism of LDL-C // Acta Lab. Anim. Sci. Sin. 2011. Vol. 23. P. 237?241.Yang X.P. Medicinal value of Crataegus pinnati da // Jilin Med. J. 1998. Vol. 19. P. 41.Yuan Y., Zhao J., Gao H.J., Wa ng J.H. Experimental study on effect of hawthorn on compounding hypertension and hyperlipoidemia rats // J. Xinjiang Med. Univ. 2013. Vol. 35. P. 52?27.ɎɚɪмɚцияɮɚɪмɚколоɝияОɛзоɪыLi C.Q., Wu W., Tong Y. Study on germicidal ef cacy of extract of hawthorn fruit pit and its in uencing factors // Chin. J. Disinfect. 2007. Vol. 24. P. 50?52.Lin L., Chen Y.J., Li L., Cao Y., Sun Q.X. Experimental observation on germicidal ef cacy of hawthorn liquid and uencing factors // Chin. J. Disinfect. 2000. Vol. 17. P. 85?88.Li L., Lv H., Pang H. Anti-aging effect of total avone of hawthorn leaf // Lishizhen Med. Mater. Med. Res. 2007. Vol. 9. P. 2143?2144.Ji Y.S., Li H., Yang S.J. Protective effect and its molecular mechanism of FMCL on PC 12 cells apoptosis induced // Chin. Pharmacol. Bull. 2006. Vol. 22. P. 760?762.Chen Z.Y., Yan M.X., He B.H. The Change and the immpact of IFHL on oxidative stress in the formation of NASH in rats // J. Med. Res. 2007. Vol. 36. P. 33?36.Wang C.L., Lu B.Z., Hou G.L. Chemical constituent, pharmacological effects and clinical application of Crataegus da // Strait Pharm. J. 2010. Vol. 3. P. 75?78.ized trials // American Journal of Medicine. 2003. No. 114(8). P. 665?674. URL: https://www.ncbi.nlm.nih.gov/ɞɚɬɚHu M., Zeng W., Tomlinson B. Evaluation of a crataegus-based multiherb formula for dyslipidemia: a random-ized, double-blind, placebo-controlled clinical trial // Evidence-Based Complementary and Alternative Medi-cine. 2014. URL: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4009229/ (ɞɚɬɚDOI: 10.1155/2014/365742 G., Faramarzi M., Nematollahi A., Ra eian-kopaei M., Amiri M., Moattar F. Comparison of the effects of Crataegus oxyacantha extract, aerobic exercise and their combination on the serum levels of ICAM-No. 23. P. 54. URL: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4684934/ (ɞɚɬɚDOI: 10.1186/s40199-015-0137-2Mustapha N., Pinon A., Limami Y., Simon A., Ghedira K., Hennebelle T., Chekir-Ghedira L. Crataegus aza-rolus Leaves Induce Antiproliferative Activity, Cell Cycle Arrest, and Apoptosis in Human HT-29 and HCT-116 Colorectal Cancer Cells // Journal of Cellular Biochemistry. 2016. No 117(5). P. 1262?1272. URL: https://www.ɞɚɬɚȽоɫɭɞɚɪɫɬɜɟннɚяɮɚɪмɚкопɟя. 11-изɞɚниɟМɟɞицинɚКɭɪкинМоɪозоɜɚПɪɚɜɞиɜцɟɜɚИɫɫлɟɞоɜɚниɟɪɚзɪɚɛоɬкɟмɟɬоɞикиɫɬɚнɞɚɪɬизɚцииɛояɪышникɚкɪоɜɚɜокɪɚɫноɝоɪɚɫɬиɬɟльноɝоEuropean Pharmacopoeia. 8 ed. Strasbourg: Directorate for the Quality of Medicines & HealthCare of the Council 32 United States Pharmacopeia. URL: http://www.uspbpep.com/usp32/pub/data/v32270/usp32nf27s0_m36580.ȽоɫɭɞɚɪɫɬɜɟннɚяɮɚɪмɚкопɟяɊɟɫпɭɛликиȻɟлɚɪɭɫьизɞɚниɟɌом 2. МиниɫɬɟɪɫɬɜозɞɪɚɜооɯɪɚнɟнияɊɟɫпɭɛликиȻɟлɚɪɭɫьȺɬлɚɫɚɪɟɚлоɜɪɟɫɭɪɫоɜлɟкɚɪɫɬɜɟнныɯɋилɚɟɜɚȺɝɟɟɜɚКиɪюɯинМɚɬɜиɟнкоɛояɪышникɚɯ L.) ɊɟɫпɭɛликɟМоɪɞоɜияɎиɬоɪɚзнооɛɪɚзиɟȼоɫɬочнойȽоɫɭɞɚɪɫɬɜɟннɚяɎɚɪмɚкопɟяɊоɫɫийɫкойɎɟɞɟɪɚцииизɞɚниɟȽоɫɭɞɚɪɫɬɜɟннɚяɎɚɪмɚкопɟяɊоɫɫийɫкойɎɟɞɟɪɚцииизɞɚниɟȽоɫɭɞɚɪɫɬɜɟннɚяɎɚɪмɚкопɟяɊоɫɫийɫкойɎɟɞɟɪɚцииизɞɚниɟȽоɫɭɞɚɪɫɬɜɟннɚяɮɚɪмɚкопɟяɊɟɫпɭɛликиКɚзɚɯɫɬɚнизɞɚниɟɌом 2. МиниɫɬɟɪɫɬɜозɞɪɚɜооɯɪɚнɟнияɊɟɫпɭɛликиКɚзɚɯɫɬɚнȺɫɬɚнɚКɭɪкинКɭɪкинɚПɪɚɜɞиɜцɟɜɚМоɪозоɜɚИзɭчɟниɟɯимичɟɫкоɝоɫоɫɬɚɜɚпɪɟпɚɪɚɬоɜоɫноɜɟɛояɪышникɚ // Мɚɬɟɪиɚлы IX мɟжɞɭнɚɪоɞноɝоɫимпозиɭмɚɎɟнольныɟɫоɟɞинɟнияɮɭнɞɚмɟнɬɚльныɟɚɫпɟкɬыМоɫкɜɚDinesh Kumar, Vikrant Arya, Zul qar Ali Bhat, Nisar Ahmad Khan, Deo Nandan Prasad. The genus Crataegus: cognosy. 2012. No. 22(5). P. 1187?1200. URL: http://www.scielo.br/pdf/rbfar/v22n5/aop05712.pdf (ɞɚɬɚJiaqi Wu, Wei Peng, Rongxin Qin, Hong Zhou. Crataegus pinnati da: Chemical Constituents, Pharmacology, and Potential Applications // Molecules. 2014. No. 19(2). P. 1685?1712. URL: http://www.mdpi.com/1420-ɞɚɬɚSeyed Fazel Nabavi, Solomon Habtemariam, Touqeer Ahmed, Antoni Sureda, Maria Daglia, Eduardo Sobar-istry to Medical Applications // Nutrients. 2015. No. 7. P. 7708?7728. URL: https://www.ncbi.nlm.nih.gov/ɞɚɬɚPharmacy & Pharmacology V. 6 N 2, 2018DOI:10.19163/2307-9266-2018-6-2-104-120Wu S.J., Li Q.J., Xiao X.F., Li M., Yang X.R., Lv T. The research of chemical constituent and pharmacological effects of Crataegus pinnati da // Drug Eval. Res. 2010. Vol. 4. P. 316?319.Kurkina A.V., Pravdivtseva O.E., Kurkin V.A., Dubishchev A.V. Pharmacological activity of avonoid-containing plants. Internationaler medizinischer Kongress // Hannover. 2006, pp. 37?38.ɏишоɜɚȻɭзɭкКоличɟɫɬɜɟнноɟопɪɟɞɟлɟниɟплоɞоɜɛояɪышникɚ // ɮɚɪмɚцɟɜɬичɟɫкийжɭɪнɚлКɭɪкинɚОпɪɟɞɟлɟниɟɫоɞɟɪжɚнияɫɭммыɮлɚɜоноиɞоɜплоɞɚɯɛояɪышникɚ // ɏимикоɮɚɪмɚцɟɜɬичɟɫкийжɭɪнɚлКɭɪкинɚпоɞɯоɞыɫɬɚнɞɚɪɬизɚциицɜɟɬкоɜɛояɪышникɚ // ɪɚɫɬиɬɟльноɝоɋɚɝɚɪɚɞзɟȻɚɛɚɟɜɚКɚлɟникоɜɚɍɫɬɚноɜлɟниɟпоɞлинноɫɬипɟɪɫпɟкɬиɜноɝолɟкɚɪɫɬɜɟнноɝо ? цɜɟɬкоɜɛояɪышникɚ // ȼопɪоɫыɛиолоɝичɟɫкоймɟɞицинɫкойɮɚɪмɚцɟɜɬичɟɫкойɋɚɝɚɪɚɞзɟȻɚɛɚɟɜɚКɚлɟникоɜɚОпɪɟɞɟлɟниɟɮлɚɜоноиɞоɜцɜɟɬкɚɯɛояɪышникɚмɟɬоɞомȼЭЖɏɫпɟкɬɪоɮоɬомɟɬɪичɟɫкимɞɟɬɟкɬиɪоɜɚниɟм // ɏимикоɮɚɪмɚцɟɜɬичɟɫкийнɚлHellenbrand N., Sendker J., Lechtenberg M., Petereit F., Hensel A. Isolation and quanti cation of oligomeric owers of Hawthorn (Crataegus spp.). Fitoterapia. 2015. No. 104. P. 14?22. URL: https://www.ncbi.nlm.nih.gov/pubmed/25917901 (ɞɚɬɚ tote.2015.04.010КɭɪкинМоɪозоɜɚПɪɚɜɞиɜцɟɜɚИɫɫлɟɞоɜɚниɟɪɚзɪɚɛоɬкɟɫɬɚнɞɚɪɬизɚцииɛояɪышникɚкɪоɜɚɜокɪɚɫноɝоɪɚɫɬиɬɟльноɝоMudge E.M., Liu Y., Lund J.A., Brown P.N. Single-laboratory validation for the determination of avonoids in nished products by LC-UV // Planta Med. 2016. No. 82(17). P. 1487?1492. URL: https://www.ncbi.nlm.nih.gov/pubmed/27776376 (ɞɚɬɚCheng S., Qiu F., Huang J., He J. Simultaneous determination of vitexin-2?-O-glucoside, vitexin-2?-O-rham- da Bge.) leaves by RP-HPLC with ultraviolet photodiode array detection // Journal of Separation Science. 2007. No. 30(5). P. 717?721. Zhe Gao, Ya-Nan Jia, Tian-Yuan Cui, Zhe Han, Ai-Xia Qin, Xiao-Hu Kang, Yu-Lei Pan, Tong Cui. Quanti cation da Bge. var. major N.E. Br.) by HPLC // Asian Journal of Chemistry. 2013. Vol. 25. No. 18. P. 10344?10348. ReferencesMartins Ekor. The growing use of herbal medicines: issues relating to adverse reactions and challenges in moni-toring safety. Frontiers in Pharmacology [Internet]. 2013;4:177 [cited 2018 Jan 24]. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3887317/ DOI: 10.3389/fphar.2013.00177 Pal SK, Shukla Y. Herbal medicine: current status and the future. Asian Paci c Journal of Cancer Preven-tion [Internet]. 2003 Aug-Dec;4(4):281-8 [cited 2018 Jan 24]. Available from: https://www.ncbi.nlm.nih.gov/Sambukova TV, Ovchinnikov BV, Ganapolskii VP, Yatmanov AN, Shabanov PD. Perspektivy ispol?zovaniya to-preparatov v sovremennoj farmakologii [Prospects for phytopreparations (Botanicals) use in modern pharmacology]. Reviews on Clinical Pharmacology and Drug Therapy. 2017;15(2):56-63. DOI: 10.17816/RCF15256-63. Russian.World Health Organization. Cardiovascular diseases (CVDs). [Internet]. [cited 2018 Jan 24]. Available from: http://www.who.int/mediacentre/factsheets/fs317/en/Basyrova IR, Libis RA. Rasprostranennost? osnovnyh faktorov riska serdechno-sosudistyh zabolevanij i ih kom-binacij u zhitelej goroda Orenburga [The prevalence of major cardiovascular risk factors and their combinations in residents of Orenburg city]. Aspirantskiy Vestnik Povolzhiya. 2017;1-2:48-53. Russian.Samylina IA, Sorokina AA, Pyatigorskaya NV. Boyaryshnik (Crataegus): vozmozhnosti medicinskogo prime-. Boyaryshnik (Crataegus): vozmozhnosti medicinskogo prime-()7. Rastogi S, Pandey MM, Rawat AK. Traditional herbs: a remedy for cardiovascular disorders. Phytomedicine. [Internet]. 2016 Oct 15;23(11):1082-9 [cited 2018 Jan 24]. Available from: https://www.ncbi.nlm.nih.gov/Zorniak M, Szydlo B, Krzeminski TF. Crataegus special extract WS 1442: up-to-date review of experimental and clinical experiences. Journal of physiology and pharmacology. [Internet]. 2017 Aug;68(4):521-6 [cited 2018 Jan 24]. Available from: https://www.ncbi.nlm.nih.gov/pubmed/29151068 JieWang, Xingjiang Xiong, Bo Feng. Effect of Crataegus Usage in Cardiovascular Disease Prevention: An Evi-dence-Based Approach. Evidence-Based Complementary and Alternative Medicine. [Internet]. 2013 [cited 2018 Jan 24]. Available from: https://www.hindawi.com/journals/ecam/2013/149363/. DOI: 10.1155/2013/149363Liu XY, Zhou L, Liang RY. Study on lipid regulation mechanism of total avonoids from folium Crataegi by 3T3-L1 cells. Chin. Arch. Tradit. Chin. Med. 2009;27:1066?8. ɎɚɪмɚцияɮɚɪмɚколоɝияОɛзоɪыYang RM, Chen HM, Gao NN, Song X, Li JL, Cai DY. Mechanism of early atherosclerosis in guinea pig: abnor-mal metabolism of LDL-C. Acta Lab. Anim. Sci. Sin. 2011;23:237?41.Yang XP. Medicinal value of Crataegus pinnati da. Jilin Med. J. 1998;19:41.Yuan Y, Zhao J, Gao HJ, Wang JH. Experimental study on effect of hawthorn on compounding hypertension and hyperlipoidemia rats. J. Xinjiang Med. Univ. 2013;35:52?27.Li CQ, Wu W, Tong Y. Study on germicidal ef cacy of extract of hawthorn fruit pit and its in uencing factors. Lin L, Chen YJ, Li L, Cao Y, Sun QX. Experimental observation on germicidal ef cacy of hawthorn liquid and uencing factors. Chin. J. Disinfect. 2000;17:85?8.Li L, Lv H, Pang H. Anti-aging effect of total avone of hawthorn leaf. Lishizhen Med. Mater. Med. Res. Ji YS, Li H, Yang SJ. Protective effect and its molecular mechanism of FMCL on PC 12 cells apoptosis induced Chen ZY, Yan MX, He BH. The Change and the immpact of IFHL on oxidative stress in the formation of NASH Wang CL, Lu BZ, Hou GL. Chemical constituent, pharmacological effects and clinical application of Crataegus da. Strait Pharm. J. 2010;3:75?8.trials. American Journal of Medicine. [Internet]. 2003 Jun 1;114(8):665-74 [cited 2018 Jan 24]. Available from: https://www.ncbi.nlm.nih.gov/pubmed/12798455 Hu M, Zeng W, Tomlinson B. Evaluation of a crataegus-based multiherb formula for dyslipidemia: a randomized, double-blind, placebo-controlled clinical trial. Evidence-Based Complementary and Alternative Medicine. [Inter-net]. 2014 [cited 2018 Jan 24]. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4009229/. DOI: 10.1155/2014/365742 G, Faramarzi M, Nematollahi A, Ra eian-kopaei M, Amiri M, Moattar F. Comparison of the effects of Crataegus oxyacantha extract, aerobic exercise and their combination on the serum levels of ICAM-1 fects of Crataegus oxyacantha extract, aerobic exercise and their combination on the serum levels of ICAM-1 2015;23:54 [cited 2018 Jan 24]. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4684934/. DOI: 10.1186/s40199-015-0137-2Mustapha N, Pinon A, Limami Y, Simon A, Ghedira K, Hennebelle T, Chekir-Ghedira L. Crataegus azarolus Leaves Induce Antiproliferative Activity, Cell Cycle Arrest, and Apoptosis in Human HT-29 and HCT-116 Col-orectal Cancer Cells. Journal of Cellular Biochemistry. [Internet]. 2016 May;117(5):1262-72. [cited 2018 Jan 24]. Available from: https://www.ncbi.nlm.nih.gov/pubmed/26495895. DOI: 10.1002/jcb.25416Gosudarstvennaya farmakopeya SSSR [State Pharmacopoeia of the USSR]. 11th edition. Is. 2. Mockva: Medici-Kurkin VA, Morozova TV, Pravdivtseva OE. Issledovanie po razrabotke metodiki standartizacii list?ev boyarysh-, Pravdivtseva OE. Issledovanie po razrabotke metodiki standartizacii list?ev boyarysh-sanguinea Pall.]. Chemistry of plant raw materials. 2017;3:169-79. Russian.26. European Pharmacopoeia. 8 ed. Strasbourg: Directorate for the Quality of Medicines & HealthCare of the Council 32 United States Pharmacopeia. URL: http://www.uspbpep.com/usp32/pub/data/v32270/usp32nf27s0_m36580.Gosudarstvennaya farmakopeya Respubliki Belarus? [State Pharmacopoeia of the Republic of Belarus]. 1st edi-tion. Vol. 2. Ministerstvo zdravoohraneniya Respubliki Belarus?: Minsk; 2007. 471 p. Russian.ol. 2. Ministerstvo zdravoohraneniya Respubliki Belarus?: Minsk; 2007. 471 p. Russian.USSR]. Mockva: GUGK; 1980:242-3. Russian.30. Silaeva TB, Ageeva AM, Kiryuhin IV, Matvienko II. O boyaryshnikah (Crataegus L.) v Respublike Mordoviya , Matvienko II. O boyaryshnikah (Crataegus L.) v Respublike Mordoviya ()Russian.31. Gosudarstvennaya Farmakopeya Rossijskoj Federacii [State Pharmacopoeia of the Russian Federation]. 13th edition. Vol. 1. Mockva; 2015. 1470 p. Russian.ol. 1. Mockva; 2015. 1470 p. Russian.edition. Vol. 2. Mockva; 2015. 1004 p. Russian.ol. 2. Mockva; 2015. 1004 p. Russian.edition. Vol. 3. Mockva; 2015. 1294 p. Russian.ol. 3. Mockva; 2015. 1294 p. Russian.edition. Vol. 2. Ministerstvo zdravoohraneniya Respubliki Kazahstan: Astana; 2009. 803 p. Russian.Kurkin VA, Kurkina AV, Pravdivceva OE, Morozova TV. Izuchenie himicheskogo sostava preparatov na os-nove syr?ya boyaryshnika [The study of the chemical composition of preparations based on the raw material of Pharmacy & Pharmacology V. 6 N 2, 2018DOI:10.19163/2307-9266-2018-6-2-104-120Dinesh Kumar, Vikrant Arya, Zul qar Ali Bhat, Nisar Ahmad Khan, Deo Nandan Prasad. The genus Crataegus: cognosy. [Internet]. 2012;22(5):1187-200 [cited 2018 Jan 24]. Available from: http://www.scielo.br/pdf/rbfar/Jiaqi Wu, Wei Peng, Rongxin Qin, Hong Zhou. Crataegus pinnati da: Chemical Constituents, Pharmacology, and Potential Applications. Molecules. [Internet]. 2014;19(2):1685-712 [cited 2018 Jan 24]. Available from: http://www.mdpi.com/1420-3049/19/2/1685. DOI: 10.3390/molecules19021685Seyed Fazel Nabavi, Solomon Habtemariam, Touqeer Ahmed, Antoni Sureda, Maria Daglia, Eduardo Sobar-try to Medical Applications. Nutrients. [Internet]. 2015 Sep 11;7(9):7708-28 [cited 2018 Jan 24]. Available from: https://www.ncbi.nlm.nih.gov/pubmed/26378574. DOI: 10.3390/nu7095361Wu SJ, Li QJ, Xiao XF, Li M, Yang XR, Lv T. The research of chemical constituent and pharmacological effects da. Drug Eval. Res. 2010;4:316?9.Kurkina AV, Pravdivtseva OE, Kurkin VA, Dubishchev AV. Pharmacological activity of avonoid-containing plants. Internationaler medizinischer Kongress. Hannover. 2006:37-38.. 2006:37-38.termination of procyanidins in hawthorn fruits]. Pharmaceutical Chemistry Journal. 2006;40(2):20-1. Russian.42. Kurkina AV. Opredelenie soderzhaniya summy avonoidov v plodah boyaryshnika [Determination of total avo-Kurkina AV. Novye podhody k standartizacii cvetkov boyaryshnika [The new approaches to the standardization owers]. Chemistry of plant raw materials. 2013;2:171-6. DOI: 10.14258/jcprm.1302171. Russian.Sagaradze VA, Babaeva EYu, Kalenikova EI. Ustanovlenie podlinnosti perspektivnogo vida lekarstvennogo syr?ya ? cvetkov s list?yami boyaryshnika [Establishment of the authenticity of the perspective species of medici- owers with hawthorn leaves]. Problems of biological, medical and pharmaceutical chemistry. Sagaradze VA, Babaeva EYu, Kalenikova EI. Opredelenie avonoidov v cvetkah s list?yami boyaryshnika met-odom VEZHKH so spektrofotometricheskim detektirovaniem [Determination of avonoids in owers with haw-Hellenbrand N, Sendker J, Lechtenberg M, Petereit F, Hensel A. Isolation and quanti cation of oligomeric owers of Hawthorn (Crataegus spp.). Fitoterapia. [Internet]. 2015 Jul;104:14-22 [cited 2018 Jan 24]. Available from: https://www.ncbi.nlm.nih.gov/pubmed/25917901. DOI: tote.2015.04.010Kurkin VA, Morozova TV, Pravdivceva OE. Issledovanie po razrabotke standartizacii list?ev boyaryshnika krova-, Pravdivceva OE. Issledovanie po razrabotke standartizacii list?ev boyaryshnika krova-plant raw materials. 2017;3:169-73. Russian.48. Mudge EM, Liu Y, Lund JA, Brown PN. Single-laboratory validation for the determination of avonoids in haw- nished products by LC-UV // Planta Med. [Internet]. 2016 Nov;82(17):1487-1492 [cited 2018 Jan 24]. Available from: https://www.ncbi.nlm.nih.gov/pubmed/27776376Cheng S, Qiu F, Huang J, He J. Simultaneous determination of vitexin-2?-O-glucoside, vitexin-2?-O-rhamnoside, da Bge.) leaves by RP-HPLC with ultraviolet Zhe Gao, Ya-Nan Jia, Tian-Yuan Cui, Zhe Han, Ai-Xia Qin, Xiao-Hu Kang, Yu-Lei Pan, Tong Cui. Quanti cation da Bge. var. major N.E. Br.) by HPLC. Asian Journal of Chemistry. 2013;25(18):10344-8. КонɮликɬинɬɟɪɟɫоɜȺɜɬоɪызɚяɜляюɬоɬɫɭɬɫɬɜииконɮликɬɚинɬɟɪɟɫоɜМоɪозоɜɚɌɚɬьянɚ ? кɚɮɟɞɪыɮɚɪмɚкоɝнозииɛоɬɚникойоɫноɜɚмиɎȽȻОɍɋɚмȽМɍМинзɞɪɚɜɚɊоɫɫииОɛлɚɫɬьнɚɭчныɯинɬɟɪɟɫоɜɮɚɪмɚкоɝнозия. E-mail: tanyfrost@mail.ru ict of interest ict of interest.Morozova Tatyana Vladimirovna postgraduate Research interests: pharma-cognosy, phytochemistry. E-mail: tanyfrost@mail.ru.ɎɚɪмɚцияɮɚɪмɚколоɝияОɛзоɪыKurkin Vladimir Aleksandrovich? PhD (Pharma-, Professor, Federal State Budget Educational In-Research interests: pharmacognosy, phyto-, ? avonoids. E-mail: Kurkinvladimir@yandex.ru. Pravdivtseva Olga Evgenievna ? PhD (Pharmacy), docent, Federal State Budget Educational Institution of Higher Education ?Samara State Medical University?.Research interests pharmacognosy, phytochemistry, ? a-vonoids. E-mail: pravdivtheva@mail.ru. КɭɪкинȺлɟкɫɚнɞɪоɜич ? ɞокɬоɪмɚцɟɜɬичɟɫкиɯнɚɭкпɪоɮɟɫɫоɪɎȽȻОɍɋɚмȽМинзɞɪɚɜɚɊоɫɫииОɛлɚɫɬьнɚɭчныɯинɬɟɪɟɫоɜɮɚɪмɚкоɝнозияɮиɬоɯимияɮлɚɜоноиɞыПɪɚɜɞиɜцɟɜɚ ? ɞокɬоɪмɚцɟɜɬичɟɫкиɯнɚɭкɞоцɟнɬɎȽȻОɍɋɚмȽМɍМинзɞɪɚɜɚɊоɫɫииОɛлɚɫɬьнɚɭчныɯинɬɟɪɟɫоɜɮɚɪмɚкоɝнозияɮиɬоɯимияɮлɚɜоноиɞыПоɫɬɭпилɚɪɟɞɚкциюОɬпɪɚɜлɟнɚɞоɪɚɛоɬкɭПɪиняɬɚпɟчɚɬиɎɚɪмɚцияɮɚɪмɚколоɝияОɛзоɪыɍȾК 615.322: 547.9 + 543.544 ʤК˃˄ʤЛːʻˏʫˈʰʺʰˋʫˁКОʱˁ˃ʤʻʪʤˀ˃ʰʯʤˉʰʰˁˏˀː˔ˀʤˁ˃ʫʻʰʱˀОʪʤCRATAEGUS L.МоɪозоɜɚКɭɪкинПɪɚɜɞиɜцɟɜɚɎɟɞɟɪɚльноɟɝоɫɭɞɚɪɫɬɜɟнноɟɛюɞжɟɬноɟоɛɪɚзоɜɚɬɟльноɟɭчɪɟжɞɟниɟоɛɪɚзоɜɚнияɋɚмɚɪɫкийɝоɫɭɞɚɪɫɬɜɟнныймɟɞицинɫкийɭниɜɟɪɫиɬɟɬМиниɫɬɟɪɫɬɜɚзɞɪɚɜооɯɪɚнɟнияɊоɫɫийɫкойɎɟɞɟɪɚцииɊоɫɫияПɪиɜолжɫкийɮɟɞɟɪɚльныйокɪɭɝɋɚмɚɪɫкɚяоɛлɚɫɬьɋɚмɚɪɚЧɚпɚɟɜɫкɚяE-mail: tanyfrost@mail.ruɊɚɫɬɟнияɪоɞɚȻояɪышник (Crataegus L.) ? кɭɫɬɚɪникинɟɛольшиɟɞɟɪɟɜьякоɬоɪыɟиɫпользɭɟɬɫямɟɞицинɟɝлɭɛокойɫɟɝоɞняшнийɞɟньɛояɪышникɚполɭчɚюɬлɟчɟнияпɪоɮилɚкɬикиɫɟɪɞɟчнойнɟɞоɫɬɚɬочноɫɬиЦɟльюɪɚɛоɬыяɜляɟɬɫяɫиɫɬɟмɚɬизɚциязɭльɬɚɬоɜиɫɫлɟɞоɜɚнийоɛлɚɫɬиɯимичɟɫкойɫɬɚнɞɚɪɬизɚцииɛояɪышникɚɮɚɪмɚкопɟяɯɪɚзличныɯМɚɬɟɪиɚлымɟɬоɞыИɫɫлɟɞоɜɚниɟпɪоɜоɞилоɫьиɫпользоɜɚниɟмȽоɫɭɞɚɪɫɬɜɟннойɮɚɪмɚкопɟи XI изɞɚнияȽоɫɭɞɚɪɫɬɜɟннойɮɚɪмɚкопɟиɊоɫɫийɫкойɎɟɞɟɪɚции XIII изɞɚнияȿɜɪопɟйɫкойɮɚɪмɚкопɟиизɞɚнияɮɚɪмɚкопɟиɋоɟɞинɟнныɯШɬɚɬоɜ 32 изɞɚнияȽоɫɭɞɚɪɫɬɜɟннойɮɚɪмɚкопɟиɊɟɫпɭɛликиȻɟлɚɪɭɫьɊɟɫпɭɛликиКɚзɚɯɫɬɚнɬɚкжɟинɮоɪмɚционнопоиɫкоɜыɯ (PubMed) ɛиɛлиоɬɟчныɯɊɟзɭльɬɚɬыоɛɫɭжɞɟниɟнɚɫɬоящɟмоɛзоɪɟɫиɫɬɟмɚɬизиɪоɜɚныɪɟзɭльɬɚɬыиɫɫлɟɞоɜɚнийоɛлɚɫɬиɯимичɟɫкойɫɬɚнɞɚɪɬизɚцииɛояɪышникɚɮɚɪмɚкопɟяɯɪɚзличныɯОпɪɟɞɟлɟномɟɬоɞикɚɯɪоɞɚȻояɪышникɜключɟнныɯоɬɟчɟɫɬɜɟнныɟзɚɪɭɛɟжныɟɮɚɪмɚкопɟииɫпользɭюɬɫяɪɚзличныɟмɟɬоɞичɟɫкиɟмɟɬоɞолоɝичɟɫкиɟпоɞɯоɞыɫɬɚнɞɚɪɬизɚцииплоɞоɜцɜɟɬкоɜКɪомɟоɛнɚɪɭжɟнооɞноɝонɚимɟноɜɚнияɚнɚлизиɪɭɟɬɫяиɫпользоɜɚниɪɚзличныɯмɟɬоɞикɜзɝляɞиɫпользоɜɚниɟмɟɬоɞикɚɯɪɚзличныɯэкɫɬɪɚɝɟнɬоɜɜɫɟɝɞɚоɛоɫноɜɚноɬочкиɮизикоɯимичɟɫкиɯɫпɟкɬɪɚльныɯɯɚɪɚкɬɟɪиɫɬикɚнɚлизиɪɭɟмыɯɜɟщɟɫɬɜПокɚзɚноɬɚкжɟмɟɬоɞикɚɯкɚчɟɫɬɜɟнноɝоколичɟɫɬɜɟнноɝоɞɟйɫɬɜɭющиɯɜɟщɟɫɬɜɮлɚɜоноиɞыɜɫɟɝɞɚɜɟɞɟɬɫяоɪиɟнɬɚцияɞиɚɝноɫɬичɟɫкизнɚчимыɟɫɬɚнɞɚɪɬныɟɜɟщɟɫɬɜɚЗɚклюПɪоɜɟɞɟнныйɫɭщɟɫɬɜɭющиɯмɟɬоɞиккɚчɟɫɬɜɟнноɝоɪɚзɞɟлпоɞлинноɫɬьколичɟопɪɟɞɟлɟнияцɟлɟɜыɯɜɟщɟɫɬɜɫɜиɞɟɬɟльɫɬɜɭɟɬɬомнɟоɛɯоɞимɚɭниɮикɚциямɟɬоɞикɪоɞɚɛояɪышникнɚɭчнооɛоɫноɜɚнныɯпоɞɯоɞоɜɫɬɚнɞɚɪɬизɚцииКлючɟɜыɟɫлоɜɚɛояɪышникɫɬɚнɞɚɪɬизɚцияɯимичɟɫкийɫоɫɬɚɜɮиɬоɯимияɮɚɪмɚколоɝичɟɫкиɟɫɜойɫɬɜɚACTUAL PROBLEMS OF RAW MATERIALS CHEMICAL STANDARDIZATION OF MEDICINAL PLANTS OF THE GENUS HAWTHORN CRATAEGUS L.T.V. Morozova, V.A. Kurkin, O.E. Pravdivtseva89, Str. Chapaevskaya, Samara, Samara Region, Volga Federal District, Russia, 443099E-mail: tanyfrost@mail.ruThe plants of the genus Hawthorn (Crataegus L.) are shrubs or small trees that have been used in medicine since ancient times. Nowadays, on the basis of raw hawthorn, the preparations are available for treatment and prevention of For citationMorozova T.V., Kurkin V.A., Pravdivtseva O.E. ACTUAL PROBLEMS OF RAW MATERIALS CHEMICAL STANDARDIZATION OF MEDICINAL PLANTS OF THE GENUS HAWTHORN (CRATAEGUS L.). Pharmacy & Pharmacology.циɬиɪоɜɚнияМоɪозоɜɚКɭɪкинПɪɚɜɞиɜцɟɜɚȺКɌɍȺЛЬНЫȿПɊОȻЛȿМЫɏИМИЧȿɋКОЙɋɌȺНȾȺɊɌИЗȺЦИИɋЫɊЬЯЛȿКȺɊɋɌȼȿННЫɏɊȺɋɌȿНИЙɊОȾȺȻОЯɊЫШНИКCRATAEGUS ɎɚɪмɚцияɮɚɪмɚколоɝияМоɪозоɜɚКɭɪкинПɪɚɜɞиɜцɟɜɚPharmacy & Pharmacology V. 6 N 2, 2018DOI:10.19163/2307-9266-2018-6-2-104-120heart failure. of the work is to analyze and systematize research results in the eld of chemical standardization The study was conducted XIII-th edition, the European Pharmacopoeia, 6-th edition, the United States Pharmacopeia, 32-nd editions, the State Pharmacopoeia of the Republic of Belarus and the Republic of Kazakhstan, as well as the information and search In this review, the results of research in the of chemical standardization of hawthorn raw materials in pharmacopoeias of various countries are systematized. It included in domestic and foreign Pharmacopoeias, various methodological and methodological approaches to the standardization of fruits, owers and leaves are used. Besides, it has been found out that the raw materials of the same name are analyzed using different techniques. In our opinion, the use of various extractants in the methods is not ed from the point of view of the physical-chemical and spectral characteristics of the substances being procyanidins), the orientation to diagnostically signi cant standard substances is not always conducted. of the target substances indicates the necessity to unify the methods of raw materials analysis and preparations of cally based approaches to standardization. hawthorn, Crataegus L., standardization, chemical composition, Phytochemistry, pharmacological propertiesнɚɫɬоящɟɟлɟкɚɪɫɬɜɟнныɟпɪɟпɚɪɚɬынɚɛиɪɚюɬɜɫɟɛольшɭюляɪноɫɬьиɫпользɭюɬɫякɚклɟчɟнииɬɚкɮилɚкɬикизɚɛолɟɜɚний [1, 2]. Эɬоɜозможɫɜязɚнооɛɫɬояɬɟльɫɬɜомчɬолɟкɚɪɫɬɜɟнныɟпɪɟпɚɪɚɬыоɛлɚɞɚюɬнизкойɬокɫичноɞоɫɬɚɬочноɜыɫокойэɮɮɟкɬиɜноɫɬиɫпɟкɬɪомɬɟɪɚпɟɜɬичɟɫкоɝокомплɟкɫнымэɮɮɟкɬомоɪɝɚнизмчɟлоɜɟкɚɪɚционɚльномɬɚкжɟоɬноɫиɬɟльнойɫинɬɟɬичɟɫкимипɪɟпɚɪɚɬɚми [3]. ɫɟɝоɞняшнийɫɟɪɞɟчноɫоɫɭɞиɫɬыɟɛолɟɜɚнияоɫɬɚюɬɫянɚиɛолɟɟɜɚжнойɫоциɚльноймɟɞицинɫкойпɪоɛлɟмойɫɬɪɚнɚɯɌɚкȼɫɟмиɪнойзɞɪɚɜооɯɪɚнɟнияɫɟɪɞɟчноɫоɫɭɞиɫɬыɟзɚɛолɟɜɚнияяɜляюɬɫяоɫноɜɫмɟɪɬноɫɬипоэɬомɭоɫоɛɭюɚкɬɭɚльноɫɬьпɪиоɛɪɟɬɚюɬɜопɪоɫыпɪоɮилɚкɬикиɫɜоɟɜɪɟмɟнноɝолɟчɟнияпɚɬолоɝии [4, 5]. эɬойɫɜязиинɬɟɪɟɫнымияɜляюɬɫялɟкɚɪɫɬɜɟнныɟпɪɟпɚɪɚɬыоɫноɜɟɛояɪышникɚ [4, 5]. Пɪɟпɚɪɚɬыоɫноɜɟɛояɪышникɚиɫпользɭюɬɫянɚɪоɞноймɟɞицинɟɭпоминɚнияположиɬɟльномɛояɪышникɚɫɟɪɞцɟоɬноɫяɬɫяпɟɪɜомɭɜɟкɭ [8]. ɛояɪышникɚлɟчɟнияɫɟɪɞɟчноɫɭɞиɫɬыɯзɚɛолɟɜɚнийоɬноɫиɬɫяконцɭ 1800-ɬоɝɞɚпɪɟɞполɚɝɚлоɫьчɬоɛояɪышникможноиɫпользоɜɚɬькɚчɟɫɬɜɟɚльɬɟɪнɚɬиɜнойɬɟɪɚпиилɟчɟнияɫɟɪɞɟчноɫоɫɭɞиɫɬыɯзɚɛолɟɜɚɬɚкиɯкɚкɫɬɟнокɚɪɞияɝипɟɪɬонияɝипɟɪлипи 1800-Ⱥɜɬоɪɚмиопиɫɚныиɫɫлɟɞоɜɚнияɫнижɟниюɯолɟɫɬɟɪинɚɬɪиɝлицɟɪиɞоɜɜоɬныɯɛояɪышникɚ [10, 11]. иɫɫлɟɞоɜɚнияɯкɪыɫɚɯкɪоликɚɯкошкɚɯпокɚзɚночɬоэкɫɬɪɚкɬɛояɪышникɚможɟɬмɟɞлɟнноɭɫɬойчиɜоɫнижɚɬькɪоɜяноɟɞɚɜлɟниɟɫчɟɬпɟɪиɮɟɪичɟɫкиɯɫоɫɭɞоɜ1]. Ⱦля ɫыɪья ɛояɪышникɚнɟкоɬоɪымиɚɜɬоɪɚмимɟчɚɟɬɫяɬɚкжɟнɚличиɟɚнɬиɛɚкɬɟɪиɚльнойɚкɬиɜноɫɬиоɬношɟниимикɪооɪɝɚнизмоɜноɫɬиоɬношɟнииaureus, Pseudomonas aeruginosaeus, Pseudomonas aeruginosaКɪомɟɬоɝонɟкоɬоɪыɯиɫɬочникɚɯопиɫɚноɚнɬиокɫиɞɚнɬноɝоизɜлɟчɟнийɛояɪышникɚeus, Pseudomonas aeruginosaȼ нɚɫɬоящɟɟɛояɪышникпɪиɜлɟкɚɟɬмɚниɟɜɪɚчɟйиɫɫлɟɞоɜɚɬɟлɟйɫɜоимикɚɪɞиоɬоничɟɫкимикɚɪɞиопɪоɬɟкɬоɪнымиɫɜойɫɬɜɚмичɬопоɞɬɜɟɪжɞɚɟɬɫямноɝочиɫлɟннымиклиничɟɫкимииɫɫлɟɞоɜɚниями [19]. Ɍɚкпɪоɜɟɞɟнный 2003 ɝоɞɭмɟɬɚɚнɚлизɪɚнɞомизиɪоɜɚнныɯконɬɪолиɪɭɟмыɯиɫɫлɟɞоɜɚнийэкɫɬɪɚкɬɚɛояɪышникɚ Bunge) лɟчɟнияпɚциɟнɬоɜɯɪоничɟɫкойɫɟɪɞɟчнойнɟɞоɫɬɚɬочнопокɚзɚлнɚличиɟɛлɚɝопɪияɬноɝоɫɟɪɞɟчɫоɫɭɞиɫɬой [20]. Ƚɪɭппɚкиɬɚйɫкиɯ 2014 ɝоɞɭопɭɛликоɜɚлɚɪɚнɞомизиɪоɜɚнноɟɞɜойноɟɫлɟпоɟиɫɫлɟɞоɜɚниɟмноɝокомпонɟнɬноɝоɬиɬɟльноɝопɪɟпɚɪɚɬɚоɫноɜɟɛояɪышникɚлɟчɟнииɪɟзɭльɬɚɬɟпɪоɜɟɞɟнноɝоиɫɫлɟɞоɜɚнияɜыяɜлɟночɬоɭкɚзɚнныйпɪɟпɚɪɚɬɜызыɜɚлнɟɛольшоɟɫнижɟниɟɫоɞɟɪжɚнияплɚзмɟлипопɪоɬɟиноɜнизкойплоɬнопоɫлɟ 12-нɟɞɟльноɝокɭɪɫɚлɟчɟнияɜызыɜɚяэɬомнɟжɟлɚɬɟльныɯяɜлɟний [21]. 2015 ɝоɞɭɝɪɭппɚпɪоɜɟлɚɫɪɚɜниɬɟльноɟɫлɟɞоɜɚниɟɜлиянияɮизичɟɫкиɯэкɫɬɪɚкɬɚɛояɪышникɚ L.) молɟкɭлыɜнɭɬɪиклɟɬочнойɚɞɝɟ 1 ɫɟлɟкɬинɚпɚциɟнɬоɜɫɬɚɛильɫɬɟнокɚɪɞиɟйɪɟзɭльɬɚɬɟɜыɜоɞчɬоэкɫɬɪɚкɬɚ L. кɚчɟɫɬɜɟɞополниɬɟльнойɬɟɪɚпииэɮɮɟкɬиɜноɫнижɚюɬɚɬɟɪоɎɚɪмɚцияɮɚɪмɚколоɝияОɛзоɪыɞɚльнɟйшиɯпɪоɛлɟмɫɟɪɞɟчноɫоɫɭɞиɫɬой [22]. ИнɬɟɪɟɫноɬɚкжɟчɬоɝоɞɭопɭɛликоɜɚноиɫɫлɟɞоɜɚниɟɯоɞɟкоɬоɪоɝоɜыɜоɞчɬоэкɫɬɪɚкɬɛояɪышникɚCrataegus azarolus L.) ɫɬимɭлиɪɭɟɬɬипɪолиɮɟɪɚɬиɜнɭюɚкɬиɜноɫɬьɚɪɟɫɬклɟɬочноɝоɚпопɬозчɟлоɜɟчɟɫкиɯклɟɬкɚɯɪɚкɚɬолɫɬокишɟчникɚ HT-29 HCT-116 [23].ɊоɫɫийɫкойɎɟɞɟɪɚцииполɭчɟниякɚɪɞиоɬоничɟɫкиɯлɟкɚɪɫɬɜɟнныɯɫɪɟɞɫɬɜиɫпользɭюɬцɜɟɬплоɞыɛояɪышникɚ16 [23].Зɚ ɪɭɛɟжомɪɚɫпɪоɫɬɪɚнɟниɟполɭчилилɟкɚɪɫɬɜɟнныɟпɪɟпɚɪɚɬыоɫноɜɟцɜɟɬкоɜɛояɪышникɚ Нɚ ɬɟɪɪиɬоɪииɫɬɪɚныɜɫɬɪɟчɚюɬɫяоколоɞикоɪɚɫɬɭщиɯɛояɪышникоɜ [29, 30]. 12 ɛояɪышникɚɜключɟнныɯɞɟйɫɬɜɭющɭюɫɭɞɚɪɫɬɜɟннɭюɎɚɪмɚкопɟю XI изɞɚния XI), ɬɟɪɪиɬоɪииɊоɫɫийɫкойɎɟɞɟɪɚциипɪоизɪɚɫɬɚɟɬ 9, ɮɚɪмɚкопɟйнымиɛояɪышникɚɊоɫɫиияɜляюɬɫяплоɞыцɜɟɬки 9, Кɚчɟɫɬɜомомɟнɬɪɟɝлɚмɟнɬиɪɭɟɬ XI изɞɚнияɬɚккɚкɞɟйɫɬɜɭющɭюȽоɫɭɞɚɪɫɬɜɟннɭюɮɚɪмɚкопɟюɊоɫɫийɫкойɎɟɞɟɪɚ XIII изɞɚнияоɛɫɭжɞɚɟмыɟɛояɪышникɚпокɚɜключɟны XIII ɎɚɪмɚкопɟяɋоɟɞинɟнныɯШɬɚɬоɜизɞɚнияопиɫыɜɚɟɬɛояɪышникɚпɪɟɞɫɬɚɜляющɟɟцɜɟɬкɚми Jacq. (Poir.) DC., ɬɚкжɟизɜɟɫɬноɝокɚк L [27]. ȿɜɪопɟйɫкɚяɮɚɪмɚкопɟя 8 изɞɚниялɟкɚɪɫɬɜɟннымɛояɪышникɚоɬноɫиɬплоɞыɬɚкиɯкɚк Jacq (Poir.) (цɜɟɬкɚми Jacq. (Poir.) DC. ( Thuill.; auct.) ɞɪɭɛояɪышникɚɜключɚя Waldst., Waldst. C. azarolus L [26]. ȻɟлоɪɭɫɫкɚяɮɚɪмɚкопɟяɜключɚɟɬɫɬɚɬьипɟйɫкойɮɚɪмɚкопɟиплоɞыцɜɟɬкɚмиɬɚкжɟоɬɞɟльныɟɫɬɚɬьицɜɟɬкиɛояɪышникɚɎɚɪмɚкопɟйнымиɫчиɬɚюɬɫя Pall. (Poir) DC. ( sensu Pojark.) цɜɟɬки 14 ɛояɪышникɚɫɪɟɞикоɬоɪыɯ Pall.; . korolkowiiolkowiiɎɚɪмɚкопɟяɊɟɫпɭɛликизɚɯɫɬɚнлɟкɚɪɫɬɜɟнномɭоɬноɫиɬ Jacq. (Poir.) DC. (.) DC. (По лиɬɟɪɚɬɭɪнымизɜɟɫɬночɬоцɜɟɬкиплоɞыɛояɪышникɚɫоɞɟɪжɚɬмножɟɫɬɜоɛиоɮлɚɜоноиɞоɜкоɬоɪыɟкɚкпɪɟɞɫɬɚɜляюɬɫяпɟɪɜɭюочɟɪɟɞьоɬɜɟɬɫɬɜɟнныкɚɪɞиоɬоничɟɫкоɟчɬопɪиɜɟлоɪɚзɪɚɛоɬкɟэкɫɬɪɚкɬоɜцɜɟɬкоɜɛояɪышникɚɫɬɪɚнɚɯȻиоɮлɚɜоноиɞынɚɪɭжɟнныɟɛояɪышникɟɜключɚюɬолиɝомɟɪныɟɜиɬɟкɫинкɜɟɪцɟɬинɌɚкжɟɛояɪышникɚɫоɞɟɪжɚɬɫяɜиɬɚминɫɚпониныɞɭɛильныɟɜɟщɟɫɬɜɚкɚɪɞиоɬоничɟɫкиɟизоɛɭɬилɚминмɟɬокɫиɮɟнилэɬилɚминɯолинɚцɟɬилɯолинпɪоизɜоɞныɟɝɭɚнинɚмиɝɞɚлинɬɪиɬɟɪпɟноɜыɟкиɫлоɬыɭɪɫолоɜɚякиɫлоɬɚ ȼ ɪɟзɭльɬɚɬɟпɪоɜɟɞɟнныɯɝɪɭппойɫɚмɚɪɫкиɯиɫɫлɟɞоɜɚнийплоɞоɜɛояɪышникɚɞоминиɪɭющийɮлɚɜоноиɞ ? ɜиɬɟкɫинцɜɟɬкоɜɛояɪышникɚ ? ЦȿЛЬЮɪɚɛоɬыяɜляɟɬɫяɚнɚлизɫиɫɬɟмɚɬизɚɪɟзɭльɬɚɬоɜиɫɫлɟɞоɜɚнийоɛлɚɫɬиɯимичɟɫкойɫɬɚнɞɚɪɬизɚцииɛояɪышникɚɮɚɪмɚкопɟяɯɫɬɪɚнМȺɌȿɊИȺЛЫМȿɌОȾЫИɫɫлɟɞоɜɚниɟпɪоɜоɞилоɫьиɫпользоɜɚниɟмȽоɫɭɞɚɪɫɬɜɟннойɮɚɪмɚкопɟи XI изɞɚнияȽоɫɭɞɚɪɫɬɜɟннойɮɚɪмɚкопɟиɊоɫɫийɫкойɎɟɞɟɪɚции XIII изɞɚнияȿɜɪопɟйɫкойɮɚɪмɚкопɟи 6 изɞɚнияɮɚɪмɚкопɟиɋоɟɞинɟнныɯШɬɚɬоɜ 32 изɞɚнияȽоɫɭɞɚɪɫɬɜɟннойɮɚɪмɚкопɟиɊɟɫпɭɛликиȻɟлɚɪɭɫьɊɟɫпɭɛликиКɚзɚɯɫɬɚнɬɚкжɟинɮоɪмɚционнопоиɫкоɜыɯɛиɛлиоɬɟчныɯɊȿЗɍЛЬɌȺɌЫОȻɋɍЖȾȿНИȿОпɪɟɞɟлɟниɟпоɞлинноɫɬиɛояɪышникɚПлоɞы XI изɞɚнияплоɞоɜɪоɞɚȻояɪышникɪɚзɞɟлɟКɚчɟɫɬɜɟнныɟɪɟɚкцииɫыɜɚɟɬмɟɬоɞɬонкоɫлойнойɯɪомɚɬоɝɪɚɮииɌɋɏ), пɪɟɞɭɫмɚɬɪиɜɚющийɪɭжɟниɟɫɭɬɫɬɜииɝоɫɭɞɚɪɫɬɜɟнноɝоɫɬɚнɞɚɪɬноɝоȽɋОɯлоɪоɮоɪмɫпиɪɬ (8:2). эɬомɚнɚлизиɪɭɟмыɯщɟɫɬɜпɪоɜоɞяɬɭльɬɪɚɮиолɟɬоɜомɫɜɟɬɟɫɜɟɬɜолны 360 ȽɋОɞолжнɚпояɜиɬьɫяполоɫɚкоɪичнɟɜоɝоцɜɟɬɚзɚɬɟмплɚɫɬинкɭоɛɪɚɛɚɬыɜɚюɬ 5% ɫпиɪɬоɜымɪɚɫɬɜоɪомɚлюминиянɚɝɪɟɜɚюɬпоɫлɟчɟɝопɪиоɛɪɟɬɚɟɬжɟлɬоɮлɭоɪɟɫцɟнциюɫɜɟɬɟɜолны 5% ȿɜɪопɟйɫкɚяɮɚɪмɚкопɟя 8 изɞɚниямɚкопɟиɊɟɫпɭɛликиȻɟлɚɪɭɫьɊɟɫпɭɛликиКɚзɚɯɫɬɚнкɚчɟɫɬɜɟмɟɬоɞɚкɚчɟɫɬɜɟнноɝоɚнɚлизɚплоɞоɜɛояɪышникɚопиɫыɜɚюɬɬонкоɫлойнɭюɯɪомɚɬоɝɪɚплɚɫɬинкɟɫлоɟмɫиликɚɝɟля P (ɫиɫɬɟмɚɪɚɫɬɜоɪиɬɟлɟйкиɫлоɬɚɛɟзɜоɞнɚяɜоɞɚмɟɬилэɬилкɟɬон ? эɬилɚцɟɬɚɬ 10:10:30:50, иɫпользоɜɚнииɪɚɫɬɜоɪɚɫоɫɬоящɟɝоɯлоɪоɝɟноɜойкиɫлоɬыкоɮɟйнойкиɫлоɬыɪɭɬинɚɪɚɫɬɜоɪɟнныɯмɟɬɚнолɟпɪоɯожɞɟнияɮɪонɬɚɪɚɫɬɜоɪиɬɟляплɚɫɬинкɭɜыɫɭшиɜɚюɬопɪыɫкиɜɚюɬ 1% ɪɚɫɬɜоɪомɚминоэɬилоɜоɝоэɮиɪɚкиɫлоɬымɟɬɚнолɟзɚɬɟм 50 ɪɚɫɬɜоɪоммɚкɪоɝолɚ 400 мɟɬɚнолɟȾɚлɟɟплɚɫɬинкɭпɪоɫмɚɬɪиɜɚюɬɭльɬɪɚɮиолɟɬоPharmacy & Pharmacology V. 6 N 2, 2018DOI:10.19163/2307-9266-2018-6-2-104-120ɜомɫɜɟɬɟɜолны 365 ɪɟзɭльɬɚɬɟчɟɝоплɚɫɬинкɟɪɚɫɬɜоɪɚɞолжныɫлɟɞɭющиɟзоныɮлɭоɪɟɫцɟнцииɜɜɟɪɯɭɜɟличɟнияжɟлɬокоɪичнɟɜɚяɮлɭоɪɟɫциɪɭющɚязонɚɪɭɬинɫɜɟɬлоɝолɭɛɚяɮлɭоɪɟɫциɪɭющɚязонɚɯлоɪоɝɟноɜɚякиɫлоɬɚжɟлɬоɜɚɬокоɪичнɟɜɚяɮлɭоɪɟɫциɪɭющɚязонɚɜɟɪɯнɟйɬɪɟɬиɫɜɟɬлоɝолɭɛɚяɮлɭоɪɟɫциɪɭющɚязонɚкоɮɟйнɚякиɫлоɬɚиɫпыɬɭɟмоɝоɪɚɫɬɜоɪɚплɚɫɬинкɟоɛнɚɪɭжиɜɚюɬ 3 зоныɫɯоɞныɟɪɚɫположɟниюɮлɭоɪɟɫцɟнɪɚɫɬɜоɪомзоныɫооɬɜɟɬɫɬɜɭɯлоɪоɝɟноɜойкиɫлоɬɟкоɮɟйнойкиɫлоɬɟКɪомɟɬоɝооɬмɟчɚɟɬɫянɚличиɟ 3 кɪɚɫноɜɚɬыɯɮлɭоɪɟɫциɪɭющиɯзоноɞнɚкоɬоɪɚɫположɟниюɫооɬɜɟɬɫɬɜɭɟɬɪɭɬинɭɞɜɟоɫɬɚльныɟзоныɪɚɫположɟнызонынижɟɮлɭоɪɟɫциɪɭющɟйзоныɫɜɟɬлоɫинɟɝоцɜɟкоɬоɪɚянɚɯоɞиɬɫянижɟзоныкоɮɟйнойкиɫлоɬы 3 Нɚ нɚш ɜзɝляɞɜышɟпɟɪɟчиɫлɟнныɟɜɟщɟɫɬɜɚиɫпользɭɟмыɟкɚкɫɬɚнɞɚɪɬныɟɯлоɪоɝɟноɜɚякиɫлоɬɚкоɮɟйнɚякиɫлоɬɚɪɭɬиншиɪокоɜɫɬɪɟчɚюɬɫялɟкɚɪɫɬɜɟнныɯɫлɟɞоɜɚɬɟльнояɜляюɬɫяɛояɪышникɚПоэɬомɭпɪɟɞɫɬɚɜляɟɬɫячɬопоɞɯоɞоɬношɟнииɚнɚлизɚплоɞоɜɛояɪышникɚможноɫчиɬɚɬьцɟлɟɫооɛɪɚзнымЦɜɟɬкипɪɟɞɫɬɚɜлɟныȽоɫɭɞɚɪɫɬɜɟннойɮɚɪмɚкопɟɟ XI изɞɚния 8) ɮɚɪмɚкопɟɟɊɟɫпɭɛликиȻɟлɚɪɭɫь XI изɞɚниякɚчɟɫɬɜɟнноɝоɚнɚлизɚцɜɟɬкоɜɛояɪышникɚпɪɟɞлɚɝɚɟɬмɟɬоɞɌɋɏɫɬинкɚɯɋилɭɮолпɪиɫɭɬɫɬɜииɫɬɚнɞɚɪɬноɝоɯлоɪоɮоɪмɫпиɪɬ (8:2). эɬомпɪоɜоɞяɬɭльɬɪɚɮиолɟɬоɜомɫɜɟɬɟɜолны 360 ȽɋОɞолжнɚпояɜиɬьɫяполоɫɚкоɪичнɟɜоɝоцɜɟɬɚЗɚɬɟмплɚɫɬинкɭɬыɜɚюɬ 5% ɫпиɪɬоɜымɪɚɫɬɜоɪомɚлюминиянɚɝɪɟɜɚюɬпоɫлɟчɟɝопɪиоɛɪɟɬɚɟɬжɟлɬоɮлɭоɪɟɫцɟнциюɫɜɟɬɟɜолны 5% ȼ ɮɚɪмɚкопɟɟɊɟɫпɭɛликиȻɟлɚɪɭɫькɚчɟɫɬɜɟмɟɬоɞɚкɚчɟɫɬɜɟннойцɜɟɬкоɜɛояɪышникɚпɪɟɞɫɬɚɜлɟнмɟɬоɞɬонкоɫлойнойɯɪомɚɬоɝɪɚɮииɯлоɪоɮоɪммɟɬɚнол (80:20, пользоɜɚниɟмкɚчɟɫɬɜɟɫɬɚнɞɚɪɬноɝоПɪояɜлɟниɟпɪоɜоɞяɬɭльɬɪɚɮиолɟɬоɜомɫɜɟɬɟɜолны 365 ɞнɟɜномɫɜɟɬɟпɪɟɞɜɚɪиɬɟльнооɛɪɚɛоɬɚɜплɚɫɬинкɭɪɚɫɬɜоɪомɚлюминияпоɫлɟɞɭющимнɚɝɪɟɜɚниэɬомɭльɬɪɚɮиолɟɬоɜомɫɜɟɬɟоɬмɟчɚɟɬɫяжɟлɬоɮлɭоɪɟɫцɟнцияномɫɜɟɬɟяɪкожɟлɬɚяокɪɚɫкɚ 365 Мы ɫчиɬɚɟмчɬопоɞɯоɞиɫпользоɜɚниɟмȽɋОкоɬоɪыйяɜляɟɬɫяоɞнимɯɚɪɚкɬɟɪныɯɮлɚɜоноиɞоɜцɜɟɬкоɜɛояɪышникɚяɜляɟɬɫяоɛъɟкпозɜоляɟɬɚɞɟкɜɚɬноопɪɟɞɟляɬьпоɞлинноɫɬьɞɚнноɝоцɜɟɬкɚмиɮɚɪмɚкопɟɟкɚчɟɫɬɜɟнноɟопɪɟɞɟлɟниɟцɜɟɬкɚмиɛояɪышникɚпɪоɜоɞяɬиɫпользоɜɚниɟмɬонкоɫлойнойɯɪомɚɬоɝɪɚɮиикɚчɟɫɬɜɟɫɬɚнɞɚɪɬоɜпɪимɟняюɬɪɚɫɬɜоɪɪɭɬинɚɯлоɪоɝɟноɜойкиɫлоɬыɜиɬɟкɫинɚɋиɫɬɟмɚɬɜоɪиɬɟлɟйɜключɚɟɬэɬилɚцɟɬɚɬ ? ɜоɞɭ ? лɟɞянɭюɭкɫɭɫнɭюкиɫлоɬɭ ? киɫлоɬɭ (10 : 2,6 : Пɪояɜлɟниɟпɪоɜоɞяɬɪɚɫɬɜоɪомɚминоэɬилɞиɮɟнилɛоɪɚɬɚмɟɬɚнолɟ (1%), зɚɬɟмоɛɪɚɛоɬкойɪɚɫɬɜоɪомполиэɬилɟнɝликоля 4000 ɬɚнолɟзɚɬɟмпɪоɫмɚɬɪиɜɚюɬɫɜɟɬɟ 4000 КɪомɟɬоɝоɮɚɪмɚкопɟɟпɪɟɞɭɫмоɬɪɟнкɚчɟɫɬɜɟнныйɚнɚлизцɜɟɬкɚмиɛояɪышникɚмɟɬоɞомɜыɫокоэɮɮɟкɬиɜнойжиɞкоɫɬноймɚɬоɝɪɚɮииȼЭЖɏɊɚɫɬɜоɪɫоɫɬоиɬɪɭɬинɚɯлоɪоɝɟноɜойкиɫлоɬыɪɚɫɬɜоɪɟнныɯмɟɬɚнолɟɊɚɫɬɜоɪɫоɫɬоиɬɫмɟɫиɬɟɬɪɚɝиɞɪоɮɭɪɚнɚмɟɬɚнолɚɚцɟɬониɬɪилɚɊɚɫɬɜоɪɫоɫɬоиɬ 0,5% ɪɚɫɬɜоɮоɫɮоɪнойкиɫлоɬыɜоɞɟȾɟɬɟкɬиɪоɜɚниɟɜоɞяɬɜолны 336 колонкɟɪɚзмɟɪом ? 10 коɬоɪɚяɫоɞɟɪжиɬнɚполни L1 ɪɚзмɟɪом 5 Ɍɟмпɟɪɚɬɭɪɚколонкипоɞɞɟɪжиɜɚɟɬɫя 25?оɬɞɟльноɫɬимɚɬоɝɪɚɮɜɜоɞяɬоɛъɟмы (5 иɫпыɬɭɟмоɝоɪɚɫɬɜоɪɚɪɚɫɬɜоɪɚзɚɬɟмизмɟɪяюɬɭɞɟɪжиɜɚнияоɫноɜныɯпикоɜɪɚɫɬɜоɪɚɭɞɟɪжиɜɚнияпɪɟɞɫɬɚɜлɟноɬɚɛлицɟɌɚɛлицɚȼɪɟмяɭɞɟɪжиɜɚнияпикоɜɪɚɫɬɜоɪɚȼɟщɟɫɬɜоȼɪɟмяɭɞɟɪжиɜɚнияɏлоɪоɝɟноɜɚякиɫлоɬɚȽипɟɪозиɞȼиɬɟкɫиниɫпыɬɭɟмоɝоɪɚɫɬɜоɪɚɭɞɟɪжиɜɚнияоɫноɜныɯпикоɜɫоɫɬоиɬɭɞɟɪжиɜɚнияɯлоɪоɝɟноɜойкиɫлоɬыɜиɬɟкɫинɚɪɭɬинɚɫооɬɜɟɬɫɬɜɭющиɯɬɚкоɜомɭɪɚɫɬɜоɪɚɬɚкжɟɭɞɟɪжиɜɚнияɬɟкɫинɜиɬɟкɫинɚизоɜиɬɟкɫинɚɜиɬɟкɫинпɪɟɞɫɬɚɜлɟнныɯɬɚɛлицɟɎɚɪмɚцияɮɚɪмɚколоɝияОɛзоɪыɌɚɛлицɚȼɪɟмяɭɞɟɪжиɜɚнияпикоɜиɫпыɬɭɟмоɝоɪɚɫɬɜоɪɚȼɟщɟɫɬɜоȼɪɟмяɭɞɟɪжиɜɚнияȺцɟɬилɜиɬɟкɫинȼиɬɟкɫинИзоɜиɬɟкɫин 0.73ȼиɬɟкɫинцɜɟɬкɚмииɫпользоɜɚɬьɫмɟɫьɫɬɚнɞɚɪɬоɜоɞнɚкоɜɫɟɫɬɚнɞɚɪɬныɟɜɟщɟɫɬɜɚɯлоɪоɝɟноɜɚякиɫлоɬɚɜиɬɟкɫинопиɫɚнныɟɮɚɪмɚкопɟɟопɪɟɞɟлɟнияпоɞлинноɫɬицɜɟɬкɚмиɛояɪышникɚяɜляюɬɫяɊɚзɞɟлПоɞлинноɫɬьɛояɪышникɚȻɟлоɪɭɫɫкойɮɚɪмɚкопɟɟɬɚкжɟнɭжɞɚɟɬɫяɭɫоɜɟɪшɟнɫɬɜоɜɚнииɬɚккɚкɬолькокɚчɟɫɬɜɟнныɯɪɟɚкцийнɟɞоɫɬɚɬочноопɪɟɞɟлɟнияпоɞлинноɫɬиКоличɟɫɬɜɟнноɟопɪɟɞɟлɟниɟɮлɚɜоноиɞоɜɛояɪышникɚОɞнимɜɚжнɟйшиɯпɚɪɚмɟɬɪоɜмɟɬоɞикиличɟɫɬɜɟнноɝоопɪɟɞɟлɟниялɟкɚɪɫɬɜɟнномɬɟльномяɜляɟɬɫяэкɫɬɪɚкцияколичɟɫɬɜɟнноɝоопɪɟɞɟлɟнияɛояɪышникɚɮɚɪмɚкопɟяɯиɫпользɭюɬɜɚɪиɚнɬыэкɫɬɪɚкцииɌɚкэкɫɬɪɚкцииплоɞоɜɛояɪышникɚ XI изɞɚнияпɪɟɞлɚнɚɝɪɟɜɚниɟ 95% ɫпиɪɬомɬɟчɟниɟ 1 чɚɫɚȿɜɪопɟйɫкɚяɮɚɪмɚкопɟяɮɚɪмɚкопɟиɊɟɫпɭɛликиȻɟлɚɪɭɫьɊɟɫпɭɛликиКɚзɚɯɫɬɚнпɪɟɞлɚɝɚюɬэкɫɬɪɚкцию 70% ɫпиɪɬомнɚɝɪɟɜɚнииɬɟчɟниɟЦɜɟɬкиɮɚɪмɚкопɟɟɊɟɫпɭɛликиȻɟлɚɪɭɫьэкɫɬɪɚɝиɪɭюɬ 96% ɫпиɪɬомнɚɝɪɟɜɚнииɬɟчɟниɟоɞноɝочɚɫɚ XI изɞɚния 95% ɫпиɪɬомнɚɝɪɟɜɚнииɬɟчɟниɟоɞноɝочɚɫɚ 95% Экɫɬɪɚкциюцɜɟɬкɚмиɮɚɪмɚкопɟɟпɪоɜоɞяɬмɟɬɚноломɬɟчɟниɟ 5 ɪопɟйɫкойȻɟлоɪɭɫɫкойɮɚɪмɚкопɟям 60% ɫпиɪɬомɬɟчɟниɟ 60% Лиɫɬья ɫоɝлɚɫноȻɟлоɪɭɫɫкойɮɚɪмɚкопɟɟэкɫɬɪɚɝиɪɭюɬ 70% ɫпиɪɬомнɚɝɪɟɜɚнииɬɟчɟниɟчɚɫɚ 70% КɚкэкɫɬɪɚкцииэкɫɬɪɚɝɟнɬоɞниɯɬɟɯɪɚзняɬɫячɬоɫɜиɞɟɬɟльɫɬɜɭɟɬнɟоɛɯоɞимоɫɬипɪоɜɟɞɟнияɞополиɫɫлɟɞоɜɚнийпоɞɛоɪɭопɬимɚльноɝоэкɫɬɪɚɝɟнɬɚэкɫɬɪɚкцииɪɚзɪɚɛоɬкɟмɟɬоɞикиколичɟɫɬɜɟнноɝоопɪɟɞɟлɟнияɫɭммыɮлɚɜоноиɞоɜɜɚжнымяɜляɟɬɫянɚɭчнооɛоɫноɜɚнныйэкɫɬɪɚɝɟнɬɚɭчɟɬомоɫоɛɟнноɫɬɟйɮиɬоɯимичɟɫкоɝоɫоɫɬɚɜɚПлоɞыɫооɬɜɟɬɫɬɜии XI изɞɚнияɪɚзɞɟлКоличɟɫɬɜɟнноɟопɪɟɞɟлɟниɟɜключɚɟɬɯɪомɚɫпɟкɬɪоɮоɬомɟɬɪичɟɫкиймɟɬоɞɫɭммыɮлɚɜоноиɞоɜпɟɪɟɫчɟɬɟɫоɞɟɪжɚниɟкоɬоɪыɯплоɞɚɯɞолжно 0,06%, ɜолны 0,06%, По нɚшɟмɭ мнɟнию, ɞɚннɚя мɟɬоɞикɚɞоɜольноɝɪомозɞкɚзɚɬɪɭɞниɬɟльнɚɬочкиɬɚцииɪɟзɭльɬɚɬоɜɚнɚлизɚɬɚккɚкɯɪомɚɬоɝɪɚммɟиɫпыɬɭɟмоɝоɪɚɫɬɜоɪɚопɪɟɞɟляюɬɜɟщɟɫɬɜɚоɬɫɭɬɫɬɜɭющиɟɪɚɫɬɜоɪɟȿɜɪопɟйɫкойɮɚɪмɚкопɟɟɮɚɪмɚкопɟɟɊɟɫпɭɛликиȻɟлɚɪɭɫьɪɚзɞɟлɟКɚчɟɫɬɜɟнноɟопɪɟɞɟлɟцɜɟɬкɚмиɛояɪышникɚпɪɟɞɭɫмоɬɪɟнмɟɬоɞɬонкоɫлойнойɯɪомɚɬоɝɪɚɮиииɫпользоɜɚɪɚɫɬɜоɪɚɫоɫɬоящɟɝоɯлоɪоɝɟноɜойкиɫлоɬыɪɚɫɬɜоɪɟнныɯмɟɬɚнолɟкɚчɟɫɬɜɟпоɞɜижнойиɫпользɭюɬɛɟзɜоɞнɚякиɫлоɬɚ ? ɜоɞɚ ? кɟɬонэɬилɚцɟɬɚɬ (10 : 10 : 30 : 50). Пɪояɜляюɬɪɚɫɬɜоɪɚɫоɫɬоящɟɝо 10 ɪɚɫɬɜоɪɚɚминоэɬилоɜоɝоэɮиɪɚкиɫлоɬымɟɬɚнолɟзɚɬɟмɪɚɫпыляюɬ 50 ɪɚɫɬɜоɪполиэɬилɟнɝликолямɟɬɚнолɟпоɫлɟчɟɝопɪояɜляюɬɫɜɟɬɟ 50 КɚкɫɭщɟɫɬɜɭюɬнɟкоɬоɪыɟɪɚзноɝлɚкɚɫɚɬɟльноɚнɚлизɚцɜɟɬкɚмиɛояɪышникɚкоɬоɪыɟɜыɬɟкɚюɬиɫпользоɜɚнияпоɞɯоɞоɜɫɬɚнɞɚɪɬизɚцииɋлɟɞоɜɚɬɟльнооɫɬɚɟɬɫяɜопɪоɫкɚкоймɟɬоɞɫчиɬɚɬьɚɞɟкɜɚɬнымиɫɯоɞяоɫоɛɟнноɫɬɟйɮлɚɜоноиɞноɝоɫоɫɬɚɜɚиɫɫлɟɞɭɟмоɝокɚклɟкɚɪɫɬɜɟнноɝоопиɫɚныɮɚɪмɚкопɟɟɊɟɫпɭɛликиȻɟлɚɪɭɫьопɪɟɞɟлɟнияпоɞлинноɫɬиɮɚɪмɚкопɟɟпɪɟɞɫɬɚɜлɟныɪɟɚкцииɯлоɪиɞомзɟлɟноɜɚɬожɟлɬоɟокɪɚшиɜɚниɟнɚɝɪɟɜɚнииɪɚɫɬɜоɪомжɟлɟзɚ (III) ɫɭльɮɚɬомɫɭɬɫɬɜиикиɫлоɬыɯлоɪиɫɬоɜоɞоɪоɞнойɛɭɬɚнолɟкɪɚɫноɟокɪɚшиɜɚниɟнɚɝɪɟɜɚнии (III) Нɚ нɚш ɜзɝляɞопɪɟɞɟлɟнияпоɞлинноɫɬиɛояɪышникɚцɟлɟɫооɛɪɚзноɬоɞɬонкоɫлойнойɯɪомɚɬоɝɪɚɮиииɫпользоɜɚниɟмɫɬɚнɞɚɪɬныɯПоɞɜоɞяиɬоɝɞɚнноɝоɪɚзɞɟлɚпɪɟɞɫɬɚɜляɟɬɫячɬоɚнɚлизпоɞлинноɫɬиɜɫɟɯяɪышникɚнɟоɛɯоɞимопɪоɜоɞиɬьɞиɚɝноɫɬичɟзнɚчимымɜɟщɟɫɬɜɚмɌɚккɚчɟɫɬɜɟнныйɚнɚлизцɜɟɬкоɜиɫпользоɜɚниɟмȽɋОяɜляɟɬɫяоɛъɟкɬиɜным XI изɞɚнияɮɚɪмɚкопɟяɊɟɫпɭɛликиȻɟлɚɪɭɫьиɫпользоɜɚниɟчɟɬыɪɟɯɫɬɚнɞɚɪɬоɜɯлоɪоɝɟноɜɚякиɫлоɬɚкоɮɟйнɚякиɫлоɬɚɪɭɬинопɪɟɞɟлɟнияпоɞлинноɫɬиплоɞоɜɛояɪышникɚɫоɜɫɟмцɟлɟɫооɛɪɚзноɬɚккɚкɜɟщɟɫɬɜɚяɜляюɬɫяоɛɫɭжɞɚɟмоɝочɚɫɬоɜɫɬɪɟчɚюɬɫяɞɪɭɝиɯɜзɝляɞпоɛɟɝоɜPharmacy & Pharmacology V. 6 N 2, 2018DOI:10.19163/2307-9266-2018-6-2-104-120КоличɟɫɬɜɟнноɟопɪɟɞɟлɟниɟплоɞоɜпɟйɫкойɮɚɪмɚкопɟɟɮɚɪмɚкопɟяɯɊɟɫпɭɛликиȻɟлɚɪɭɫьɊɟɫпɭɛликиКɚзɚɯɫɬɚнпɪɟɞполɚɝɚɟɬɫпɟкɬɪоɮоɬомɟɬɪичɟɫкоɟопɪɟɞɟлɟниɟɫоɞɟɪжɚнияпɟɪɟɫчɟɬɟɬоɪоɝоɞолжно 0,06% (ɮɚɪмɚкопɟиɊɟɫпɭɛликиȻɟлɚɪɭɫьɊɟɫпɭɛлиКɚзɚɯɫɬɚнɜолны 550 545 ɮɚɪмɚкопɟиɊɟɫпɭɛликиȻɟлɚɪɭɫьɊɟɫпɭɛликизɚɯɫɬɚнКɪомɟɬоɝоɮɚɪмɚкопɟɟɊɟɫпɭɛликиɪɭɫьопиɫɚнмɟɬоɞɯɪомɚɬоɫпɟкɬɪоɮоɬомɟɬɪичɟɫкоопɪɟɞɟлɟнияɫоɞɟɪжɚнияɮлɚɜоноиɞоɜпɟɪɟɫчɟɬɟкоɬоɪоɝоɫɭɯиɯплоɞɚɯɞолжноɜолны 545 КɚкпɪɟɞɫɬɚɜлɟнныɯноɪмɚɬиɜныɯɞокɭмɟнɬɚɯɪɟкомɟнɞɭюɬɫяпоɞɯоɞыколичɟɫɬɜɟнномɭопɪɟɞɟлɟниюɫоɞɟɪжɚнияɮлɚɜоноиɞоɜплоɞɚɯɛояɪышникɚКɪомɟɬоɝомɟɫɬоɬолькомɟɬоɞɟопɪɟɞɟлɟниямɚɬоɫпɟкɬɪоɮоɬомɟɬɪичɟɫкийɫпɟкɬɪоɮоɬомɟɬɪичɟɫкийпокɚзɚɬɟлякɚчɟɫɬɜɚɫɭммɚɮлɚɜоноиɞоɜпɟɪɟɫчɟɬɟɫɭммыколичɟɫɬɜɟнноɝоопɪɟɞɟлɟнияцɜɟɬкоɜɛояɪышникɚ XI пɪиɜоɞиɬɫяɯɪомɚɬоɬɪоɮоɬомɟɬɪичɟɫкоɟопɪɟɞɟлɟниɟɫоɞɟɪжɚнияцɜɟɬкɚɯ 0,5%), ɜолны 0,5%), ȼ ɮɚɪмɚкопɟɟɊɟɫпɭɛликиȻɟлɚɪɭɫьколичɟɫɬɜɟнɚнɚлизцɜɟɬкоɜɛояɪышникɚпɪоɜоɞяɬɯɪомɚɫпɟкɬɪоɮоɬомɟɬɪичɟɫкиммɟɬоɞомпомощьюкоɬоɪоɝоопɪɟɞɟляюɬɫоɞɟɪжɚниɟɟɝоɞолжно 0,5%, ɜолны 365 365 ɏɪомɚɬоɫпɟкɬɪоɮоɬомɟɬɪичɟɫкоɟопɪɟɞɟлɟниɟɜзɝляɞɝɪомозɞкоɬɪɭɞноиɫполнɟниинɟɞоɫɬɚɬкɚɬочкиɬочноɫɬимɟɬоɞɚ 365 2.3. Лиɫɬья ɫ цɜɟɬкɚмиКоличɟɫɬɜɟнноɟопɪɟɞɟлɟниɟцɜɟɬкɚмиɛояɪышникɚɮɚɪмɚкопɟɟɜключɚɟɬмɟɬоɞомɜыɫокоэɮɮɟкɬиɜнойжиɞкоɫɬнойɯɪомɚɬоɝɪɚɮииɝликозилиɪоɜɚнныɯɮлɚɜоноɜпɟɪɟɫчɟɬɟɜиɬɟкɫинɫоɞɟɪжɚниɟкоɬоɪыɯɞолжно 0,6% ɝликозилиɪоɜɚнныɯɮлɚɜопɟɪɟɫчɟɬɟɫоɞɟɪжɚниɟкоɬоɪыɯɞолжно 0,45%. Ⱦɟɬɟкɬиɪоɜɚниɟопɪɟɞɟлɟнииɝликозилиɪоɜɚнныɯɮлɚɜоноɜпɪоɜоɜолны 336 колонкɟɪɚзмɟɪом 4 x 10 ɫкоɪоɫɬьюпоɬокɚоколо 1,0 минɭɬɭопɪɟɞɟлɟнииɝликозилиɪоɜɚнныɯɮлɚɜоноɜɬɟɪминоɞнɚкоɪɟчьзɞɟɫьɮлɚɜонолɚɯиɫпользɭюɬɜолныколонкɟɪɚзмɟɪом 4,6 ? 25 ɫкоɪоɫɬьюпоɬокɚминɭɬɭ ? 25 КоличɟɫɬɜɟнноɟопɪɟɞɟлɟниɟɜɟщɟɫɬɜцɜɟɬкɚмиȿɜɪопɟйɫкойɮɚɪмɚкопɟɟɮɚɪмɚкопɟɟɊɟɫпɭɛликиȻɟлɚɪɭɫьɜключɚɟɬɫпɟкɬɪоɮоɬомɟɬɪичɟɫкоɟопɪɟɞɟлɟниɟɫоɞɟɪжɚнияɫɭммыɮлɚɜоноиɞоɜпɟɪɟɫчɟɬɟкоɬоɪоɝоɞолжно 1,5%, ɜолныȿɜɪопɟйɫкɚяɮɚɪмɚкопɟя 410 ɮɚɪмɚкоɊɟɫпɭɛликиȻɟлɚɪɭɫь 410 По ɜɫɟйɜиɞимоɫɬиэɬомнɟоɛɯоɞимоɞополниɬɟльноɟиɫɫлɟɞоɜɚниɟɫооɬɜɟɬɫɬɜиɟɚнɚлиɬичɟɫкойɜолныɯɚɪɚкɬɟɪнойɬɟɯɜɟщɟɫɬɜкоɬоɪыɟɫоɞɟɪжɚɬɫяколичɟɫɬɜɟнноɝоопɪɟɞɟлɟнияɞɟйɫɬɜɭющиɯɜɟщɟɫɬɜɛояɪышникɚɮɚɪмɚкопɟɟɊɟɫпɭɛликиȻɟлɚɪɭɫьопиɫɚноɫпɟкɬɪоɮоɬомɟɬɪичɟɫкоɟопɪɟɞɟлɟниɟɫоɞɟɪжɚнияɫɭммыɮлɚɜоноиɞоɜɪɟɫчɟɬɟɪɭɬин 0,25%) ɜолныɫпɟкɬɪоɮоɬомɟɬɪичɟɫкоɟопɪɟɞɟлɟниɟɫɭммыпɟɪɟɫчɟɬɟ 5,0%) ɜолны 550 550 Нɚ нɚш ɜзɝляɞɜыɜоɞыоɬноɫиɬɟльнооɛъɟкɬиɜноɫɬимɟɬоɞикиɬолькопоɫлɟɭɝлɭɛлɟнноɝоизɭчɟнияɯимичɟɫкоɝоɫоɫɬɚɜɚɞɚнноɝоМɟɬоɞикиɚнɚлизɚɛояɪышникɚпɪɟɞложɟнныɟоɬɞɟльнымиɚɜɬоɪɚмиПлоɞынɟкоɬоɪыɯиɫɬочникɚɯопиɫɚнɚмɟɬоɞикɚколичɟɫɬɜɟнноɝоопɪɟɞɟлɟнияплоɞɚɯɛояɪышникɚиɫпользоɜɚниɟммоɞиɮициɪоɜɚнноɝомɟɬоɞɚПоɪɬɟɪɚɯоɞɟмɟɬоɞикиполɭчɚюɬизɜлɟчɟниɟплоɞоɜɛояɪышникɚпомощью 70% эɬилоɜоɝоɫпиɪɬɚизɜлɟчɟниюɞоɛɚɜляюɬɪɚɫɬɜоɪɛɭɬɚнолɚжɟлɟзоɫоɞɟɪжɚщийɪɟɚкɬиɜкиɫлоɬноɝоɚнɬоцизɚɬɟмизмɟɪяюɬопɬичɟɫкɭюплоɬноɫɬьɬɜоɪɚɫпɟкɬɪоɮоɬомɟɬɪɟɜолны 550 550 ɋɚмɚɪɫкимипɪɟɞложɟнɚмɟɬоɞиɚнɚлизɚɫоɞɟɪжɚнияɫɭммыɮлɚɜоноиɞоɜплоɞоɜɛояɪышникɚпɪɟɞɜɚɪиɬɟльнымполɭчɟниɟмизɜлɟоɫноɜɟ 70% эɬилоɜоɝоɫпиɪɬɚпɟɪɟɫчɟɬɟиɫпользоɜɚниɟмɞиɮɮɟɪɟнциɚльнойɫпɟкɬɪоɮоɬомɟɬɪииɜолны 70% 3.2. ЦɜɟɬкиȾля цɜɟɬкоɜɛояɪышникɚпɪɟɞложɟнɚмɟɬоɞикɚколичɟɫɬɜɟнноɝоопɪɟɞɟлɟнияɫɭммыɮлɚɜоноипɟɪɟɫчɟɬɟмɟɬоɞомɞиɮɮɟɪɟнциɚльнойɫпɟкɬɪоɮоɬомɟɬɪииɜолны 412 пɪɟɞɜɚɪиɬɟльнымполɭчɟниɟмизɜлɟчɟнияоɫноэɬилоɜоɝоɫпиɪɬɚ 412 3.3. Лиɫɬья ɫ цɜɟɬкɚмиɊɚзɪɚɛоɬɚнɚмɟɬоɞикɚопɪɟɞɟлɟнияпоɞлинноцɜɟɬкɚмиɛояɪышникɚмɟɬоɞомɬонкоɫлойнойɯɪомɚɬоɝɪɚɮиипоɞɜижнойцɟɬɚɬɭкɫɭɫнɚякиɫлоɬɚɜоɞɚ (5 : 1 : 1) пɪиɫɭɬɫɬɜииɪɚɫɬɜоɪоɜɪɭɬинɜиɬɟкɫинɯлоɪоɝɟноɜɚякиɫлоɬɚ [44]. КɪомɟɬоɝопɪɟɞложɟнɚмɟɬоɞикɚкɚчɟɫɬɜɟнноɝоколичɟɫɬɜɟнноɝоопɪɟɞɟɜиɬɟкɫинɚɪɭɬинɚкɜɟɪцɟɬинɚɎɚɪмɚцияɮɚɪмɚколоɝияОɛзоɪыцɜɟɬкɚмиɛояɪышникɚмɟɬоɞомȼЭЖɏɫпɟкɬɪоɮоɬомɟɬɪичɟɫкимɞɟɬɟкɬиɪоɜɚниɟмпоɫлɟпɪɟɞɜɚɪиɬɟльнойэкɫɬɪɚкциипомощью 70% ɜоɝоɫпиɪɬɚ 70% Иноɫɬɪɚннымиɬɚкжɟɪɚзɪɚɛоɬɚмɟɬоɞикɚколичɟɫɬɜɟнноɝоопɪɟɞɟлɟнияцɜɟɬкɚмиɛояɪышникɚмɟɬоɞомɫɜɟɪɯэɮɮɟкɬиɜнойжиɞкоɫɬнойɯɪомɚɬоɝɪɚɮииɮлɭомɟɬɪичɟɫкимɞɟɬɟкɬиɪоɜɚниɟмпɪɟɞɜɚɪиɬɟльполɭчɟниɟмɜоɞноɚцɟɬоноɜоɝоизɜлɟчɟнияɛояɪышникɚ 70% 3.4. Лиɫɬьяɋɚмɚɪɫкимипɪɟɞложɟнɚмɟɬоɞикɚличɟɫɬɜɟнноɝоопɪɟɞɟлɟнияɛояɪышникɚкɪоɜɚɜокɪɚɫноɝомɟɬоɞомɞиɮɮɟɪɟнциɚльнойɬɪоɮоɬомɟɬɪии 412 пɟɪɟɫчɟɬɟпɪɟɞɜɚɪиɬɟльнойэкɫɬɪɚкциɟй 70% ɫпиɪɬом 70% Опиɫɚнɚмɟɬоɞикɚколичɟɫɬɜɟнноɝоопɪɟɞɟлɟнияɜиɬɟкɫинɚɜиɬɟкɫинɚизоɜиɬɟкɫинɚɪɭɬинɚɛояɪышникɚмɟɬоɞомжиɞкоɫɬнойɯɪомɚɬоɝɪɚɮииɭльɬɪɚɮиолɟɬоɜымɬɟкɬиɪоɜɚниɟм 70% Ɍɚкжɟɫɭщɟɫɬɜɭɟɬмɟɬоɞикɚколичɟɫɬɜɟнноɝоопɪɟɞɟлɟния 2"-ɝлюкозиɞɜиɬɟкɫинɚɜиɬɟкɫинɚɪɭɬинɚɛояɪышникɚмɟɬоɞомɮɚзоɜойɜыɫокоэɮɮɟкɬиɜнойжиɞкоɫɬнойɯɪомɚɬоɝɪɚɮииɭльɬɪɚɮиолɟɬоɜымɞɟɬɟкɬиɪоɜɚниɟм 2"-Ƚɪɭппɚкиɬɚйɫкиɯколичɟɫɬɜɟнноɞɟɫяɬькомпонɟнɬоɜɜиɬɟкɫинɜиɬɟкɫинɝлюкозиɞɜиɬɟкɫинизокɜɟɪциɬɪинɯлоɪоɝɟноɜɭюкиɫлоɬɭэɭкомоɜɭюкиɫлоɬɭэпикɚɬɟɯин B2 C1 ɛояɪышникɚпɟɪиɫɬонɚɞɪɟзɚнноɝомɟɬоɞомɜыɫокоэɮɮɟкɬиɜнойжиɞкоɫɬноймɚɬоɝɪɚɮии C1 ЗȺКЛЮЧȿНИȿɌɚкимоɛɪɚзомпɪоɜɟɞɟнныйɚнɚлизɫиɫɬɟмɚɬизɚцияɪɟзɭльɬɚɬоɜиɫɫлɟɞоɜɚнийоɛлɚɫɬиɯимичɟɫкойɫɬɚнɞɚɪɬизɚцииɛояɪышникɚɮɚɪмɚкопɟяɯɫɬɪɚнпокɚзɚчɬомɟɬоɞикɚɯɚнɚлизɚɪоɞɚȻоя L.), ɜключɟнныɯоɬɟчɟɫɬɜɟнныɟзɚɪɭɛɟжныɟɮɚɪмɚкопɟииɫпользɭюɬɫямɟɬоɞичɟɫкиɟмɟɬоɞолоɝичɟɫкиɟпоɞɯоɞыɫɬɚнɞɚɪɬизɚцииплоɞоɜцɜɟɬкоɜКɪомɟɬоɝоɪɭжɟночɬооɞноɝонɚимɟноɜɚнияɚнɚлизиɪɭɟɬɫяиɫпользоɜɚниɟммɟɬоɞикэɬомɜзɝляɞиɫпользоɜɚниɟмɟɬоɞикɚɯэкɫɬɪɚɝɟнɬоɜɜɫɟɝɞɚоɛоɫноɜɚноɬочкиɮизикоɯимичɟɫкиɯɫпɟкɬɪɚльныɯɯɚɪɚкɬɟɚнɚлизиɪɭɟмыɯɜɟщɟɫɬɜɌɚкжɟпокɚзɚчɬомɟɬоɞикɚɯкɚчɟɫɬɜɟнноɝоколичɟɫɬɜɟнноɝоɚнɚлизɚɞɟйɫɬɜɭющиɯɜɟщɟɫɬɜɮлɚɜоноиɞыɜɫɟɝɞɚɜɟɞɟɬɫяоɪиɟнɬɚцияɫɬичɟɫкизнɚчимыɟɫɬɚнɞɚɪɬныɟɜɟщɟɫɬɜɚэɬойɫɜязинɟоɛɯоɞимоɛолɟɟɝлɭɛокоɟизɭчɟɯимичɟɫкоɝоɫоɫɬɚɜɚɛояɪышникɚɜыяɜлɟнияɞиɚɝноɫɬичɟɫкизнɚчимыɯɜɟщɟɫɬɜпоɞопɬимɚльныɯэкɫɬɪɚɝɟнɬоɜэкɫɬɪɚкчɬопозɜолиɬɪɚзɪɚɛоɬɚɬьнɚɭчнооɛоɫноɜɚнныɟпоɞɯоɞыɫɬɚнɞɚɪɬизɚцииɭниɮициɪоɜɚɬьмɟɬоɞиɚнɚлизɚпɪɟпɚɪɚɬоɜɪоɞɚɛояɪыш Currently, herbal medicines are prevention of various diseases [1, 2]. This may be due ciently high ef ciency, a wide range of therapeutic effects, a complex effect on the human body with their rational use. They are and also relatively cheap in They are and also relatively cheap in Currently, cardiovascular diseases remain the most Thus, according to the World Health Organization, treatment of this pathology acquire special urgency [4, gency [4, The reparations based on hawthorn have been used in folk medicine for a long time. The rst mention of the positive effect of hawthorn on the heart refers to the rst century of our era [8]. The use of hawthorn for treatment The use of hawthorn for treatment The authors describe the studies on the reduction of the cholesterol level and triglycerides in the blood of animals while using hawthorn raw materials [10, 11]. 1]. As for hawthorn raw materials, some authors also notify the presence of antibacterial activity against a number of microorganisms, in particular against Escherichia coli, Staphylococcus aureus, Pseudomonas eus, Pseudomonas In addition, some sources describe the antioxidant effect of extracts from hawthorn raw materials [16, 17, rmed by numerous clinical studies [19]. Thus, in 2003 a meta-analysis of randomized da Bunge) for treatment of patients with chronic t compared with placebo [20]. A group of Chinese based on hawthorn in the treatment of dyslipidemia. As Pharmacy & Pharmacology V. 6 N 2, 2018DOI:10.19163/2307-9266-2018-6-2-104-120a comparative study of the effects of aerobic exercise on intracellular adhesion molecules of Type 1 and E-selectin in patients with stable angina. As a result, as additional therapy effectively fectively It is also interesting that there was a study published in 2016, in the course of which it was concluded that hawthorn leaf extract (Crataegus azarolus L.) stimulates antiproliferative activity, cell cycle arrest and apoptosis in human colon cancer cells HT-29 and HCT-116 [23]. owers and are used to obtain cardiotonic medicinal drugs [24, 25]. Abroad, medicines on the basis owers have got widely spread owers have got widely spread On the territory of our country there are about 40 species of wild-growing hawthorns [29, 30]. Of the 12 species of hawthorn included into the current State Pharmacopoeia of the USSR, XI-th edition (GF USSR XI), 9 grow on the territory of the Russian Federation, and the fruits and ? owers are the pharmacopoeial species of hawthorn raw materials in Russia [24, 25]. At the At the The United States Pharmacopeia of the 32-nd edition describes hawthorn raw materials, representing leaves with ? owers collected from the species also also The European Pharmacopoeia (the 8-th edition) refers to the medicinal hawthorn raw materials the fruits of such species as Crataegus monogyna Jacq (Lindm.), C. laevigata (Poir.) owers of or C. laevigata (Poir.) DC. (synonyms for and other Waldst., C. nigra Waldst. and C. azarolus L The Belarusian Pharmacopoeia includes articles from the European Pharmacopoeia on fruits, leaves with ? owers, as well as some speci c articles on hawthorn owers and leaves. and (synonym of owers of 14 species of hawthorn, (Poir) DC., C. korolkowii L. Henry; C. altaica (Loud.) and others are considered to be included into [28]. The Pharmacopoeia of the Republic Crataegus laevigata (Poir.) DC. (synonym for (synonym for According to the literature data, hawthorn leaves, ? owers and fruits are known to contain a lot of avonoids, which seem to be primarily responsible owers in European countries. Bio avonoids vitexin, quercetin and hyperoside. The hawthorn raw adenine, guanine, caffeine, amygdalin), triterpenic acids feine, amygdalin), triterpenic acids As a result of the research conducted by a group of Samara scientists, the dominant ? avonoid vitexin was owers [40]. of the work is to analyze and systematize eld of chemical standardization of hawthorn raw materials in pharmacopoeias of different MATERIALS AND METHODS. The study was and RESULTS AND DISCUSSIONmethyl alcohol system (8: 2). Hereby, the detection of the analytes is carried out in the ultraviolet light (UV light) at the wavelength of 360 nm. At the spot level of the brown color should appear, then the plate is treated with uorescence in the UV light (hyperoside) at the wavelength of 360 nm [24]. The European Pharmacopoeia (6-th edition), chromatography on a plate with a layer of silica gel P (solvent system: acidic anhydrous water-methyl ethyl V / V / V / Vreference solution consisting of chlorogenic acid, caffeic ɎɚɪмɚцияɮɚɪмɚколоɝияОɛзоɪыFurther, the plate is viewed in ultraviolet light at the wavelength of 365 nm. As a result of these uorescence zones (bottom-up as Rf increases) should be visible on the plate in the case of the reference solution: a yellow-brown uorescent zone (routine), a light blue uorescent zone uorescent zone (hyperoside); in the upper third of the plate a light uorescent zone (caffeic acid) should be visible. In the case of the test solution, 3 zones are found on the plate. They are similar to a reference solution in uorescence, these zones correspond to chlorogenic acid, hyperoside and coffee acid. Besides, uorescent zones, one of which corresponds to rutin according to its location, and the other two zones are located above the hyperoside zone uorescent light blue zone of which is below the caffeic acid zone [26, 28, 34].used as standard samples (chlorogenic acid, caffeic acid, c for hawthorn fruits. owers the State Pharmacopoeia of the USSR (XI-th edition) suggests the thin layer chromatography (TLC) method on ?Siloufol? plates in the presence of a standard hyperoside sample in the system of chloroform-methyl alcohol (8: 2). Hereby the detection is carried out in ultraviolet light at the wavelength of 360 nm. At the spot level of the standard hyperoside sample a dark brown strip should appear. The plate is then treated with a 5% alcohol solution of aluminum chloride and heated. uorescence in UV light (hyperoside) at the wavelength of 360 nm In the Pharmacopeia of the Republic of Belarus, as a method of qualitative assessment of hawthorn ? owers, a hyperoside as a standard sample. The manifestation of the uorescence (hyperoside) (hyperoside) We consider the approach with the use of a standard avonoids of hawthorn owers, objective, as it makes it owersIn the US Pharmacopeia, a qualitative determination owers is carried out using thin layer chromatography. As standards, a solution of rutin, chlorogenic acid, hyperoside and vitexin is used. The sol-tate ? water ? glacial acetic acid ? formic acid (10 : 2.6 : 1.1 : 1.1). The manifestation of the plate is carried out with a solution of 2-aminoethyldiphenylborate in methanol (1%), then by treatment with a solution of polyethylene glycol 4000 in methanol (5%) and then viewed in UV light [27]. owers by high-performance liquid chromatography (HPLC). The reference solution consists of rutin, chlorogenic acid, hyperoside and vitexin dissolved in methanol. Solution A consists of a mixture of tetrahydrofuran, methanol and acetonitrile (92.4 : 4.2 : 3.4). Solution B consists of a 0.5% solution of phosphoric acid in water. The de-tection is carried out at the wavelength of 336 nm on ller particles. The column temperature is maintained at 25? C. Separately, equal volumes (5 l) of the test solution matograph, then the retention time of the main peaks is measured. For the reference solution, the retention time is shown in Table 1.Table 1 ? Retention time of the main peaks for the reference solutionSubstanceRetention time, minutesChlorogenic acid0.26Hyperoside1.4Vitexin1.0Rutin1.16-O-rhamnoside, as shown in Table 2 [27].Pharmacy & Pharmacology V. 6 N 2, 2018DOI:10.19163/2307-9266-2018-6-2-104-120Table 2 ? Retention time of the main peaks of the test solutionSubstanceRetention time, minutes-O-rhamnoside1.53Vitexin1.0Vitexin-2-O-rhamnoside0.67 owers, are speci c parts of the cient to identify the authenticity of raw materials. cation of avonoids in hawthorn raw Extraction is one of the most important parameter in the quantitative determination in medicinal plants raw materials.hawthorn raw materials in different Pharmacopoeias, various extraction options are used. Thus, for the of the USSR, XI-th edition, offers heating with 95% alcohol for 1 hour, and the European Pharmacopoeia, the Republic of Kazakhstan, offer 70% ethyl alcohol owers are extracted with 96% ethanol while heating for 1 hour, and according to the State , and according to the State According to the US Pharmacopeia, extraction of leaves with ? owers is carried out with methanol for 5 owers is carried out with methanol for 5 According to the Belarusian Pharmacopoeia, leaves are extracted with 70% ethyl alcohol while heating for 1 hour [28].As far as we can see, the extraction time and extractant for the same types of raw materials vary greatly, which of the optimal extractant and extraction conditions. When avonoids, it is important to scienti cally select the cation? avonoids (in terms of hyperoside). Their quantity in fruits should be at least Their quantity in fruits should be at least Quanti? cation of fruits in the European cult from the point of view of interpreting the test solution determines substances absent in the refer- owers, a thin lay-dissolved in methanol. The following system is used as ethyl ketone ? ethyl acetate (10: 10: 30: 50). The mani-polyethylene glycol in methanol. After that the substance is displayed in UV light at 365 nm [26, 28]. owers, which stem from the use of different approaches to the standardization of raw materials. Consequently, the prob- avonoid Belarus. To determine the authenticity, in the Pharmaco-, in the Pharmaco-In our opinion, to determine the authenticity of haw-thorn leaves, it is advisable to add a thin layer chroma-tography method using standard samples.Summing up the results of this section, it seems to us that the analysis of the authenticity of all types of haw-thorn raw materials should be carried out diagnostically on signi? cant substances. owers with coffee acid, hyperoside and rutin) to determine the c to the discussed owers) it makes sense to use a mixture of standards, ɎɚɪмɚцияɮɚɪмɚколоɝияОɛзоɪы avonoids in terms avonoids in terms 34].As far as we can see, in the submitted normative documents various approaches to quanti? cation of avonoids in hawthorn fruits are recommended. Besides, there is a difference not only avonoids in owers cation of hawthorn owers [24]. owers is carried out owers is carried out Chromato-spectrophotometric determination, in our opinion, is cumbersome, dif? cult to perform and is not cult to perform and is not 2.3. Leaves with ? owers cation of hawthorn avones in terms of vitexin (the quantity should avones in liquid chromatography is used. The detection for the avons is carried out ow rate of about 1.0 ml per minute. In the avons (the term is avonols), the detection is carried out on a 4.6 ow rate of 1.5 ml per minute [27]. cation of target substances in leaves with owers according to the European Pharmacopoeia and avonoids in terms of hyperoside. In raw avonoids in terms of hyperoside. In raw Apparently, in this case an further investigation is cation of active substances in hawthorn leaves, a- a-In our opinion, the conclusions regarding the objec-tivity of this methodology can be made only after a deep study of the chemical composition of this type of raw materials.3. Methods for analyzing the raw material of hawthorn, proposed by individual authors ed Porter?s method. According to this method, extraction of the extract. After that the optical density of the solution After that the optical density of the solution Samara scientists proposed a technique for analyz-ing the contents of the sum of hawthorn fruits ? avonoids alcohol in terms of hyperoside using differential spectro-ferential spectro-3.2. FlowersFor hawthorn ? owers, a method was proposed for avonoids in terms of hypero-side by differential spectrophotometry at the wavelength ferential spectrophotometry at the wavelength 3.3. Leaves with ? owersA method for determining the authenticity of leaves owers was developed by thin layer chro-owers was developed by thin layer chro-dition, methods for qualitative and quantitative determi-nation of vitexin, rutin, hyperoside and quercetin in raw leaves with hawthorn ? owers was proposed by high per--Foreign scientists have also developed a procedure for quanti? cation of procyanidins in leaves with haw-Pharmacy & Pharmacology V. 6 N 2, 2018DOI:10.19163/2307-9266-2018-6-2-104-120 eld of chemical L.), included into domes- owers and leaves are used. ed from the point of view the substances being analyzed. We have also shown that avonoids, procyanidins), the orienta- cant standard substances is cant substances diagnostically, cally owers by the method of ultra-ef cient liquid chro- uorometric detection with preliminary preparation of water-acetone extraction from hawthorn -acetone extraction from hawthorn 3.4. LeavesSamara scientists have proposed a method for quan-ti? cation of hawthorn blood-red leaves by differential ferential A procedure for quanti cation of 2?-O-rhamno-cation of 2?-O-rhamno-There is also methods for quanti? cation of of A group of Chinese scientists has quanti ed ten com- Bge.) by meth- Bge.) by meth-CONCLUSION. Thus, our analysis and system-ȻиɛлиоɝɪɚɮичɟɫкийMartins Ekor. The growing use of herbal medicines: issues relating to adverse reactions and challenges in moni-toring safety // Frontiers in Pharmacology. 2013. No 4. P. 177. URL: https://www.ncbi.nlm.nih.gov/pmc/articles/ɞɚɬɚ: 24.01.2018). DOI: 10.3389/fphar.2013.00177Pal S.K., Shukla Y. Herbal medicine: current status and the future // Asian Paci c Journal of Cancer Preven-tion. 2003. No 4(4). P. 281-288. URL: https://www.ncbi.nlm.nih.gov/pubmed/14728584 (ɞɚɬɚɋɚмɛɭкоɜɚОɜчинникоɜȽɚнɚпольɫкийЯɬмɚноɜПɟɪɫпɟкɬиɜыиɫпользоɜɚнияɮиɬопɪɟпɚɪɚɬоɜɮɚɪмɚколоɝии // ОɛзоɪыклиничɟɫкойɮɚɪмɚколоɝиилɟкɚɪɫɬɜɟннойɬɟɪɚпииWorld Health Organization. Cardiovascular diseases (CVDs) URL: http://www.who.int/mediacentre/factsheets/ɞɚɬɚȻɚɫыɪоɜɚɊɚɫпɪоɫɬɪɚнɟнноɫɬьоɫноɜныɯɮɚкɬоɪоɜɪиɫкɚɫɟɪɞɟчноɫоɫɭɞиɫɬыɯзɚɛолɟɜɚнийкомɛинɚцийɝоɪоɞɚОɪɟнɛɭɪɝɚȺɫпиɪɚнɬɫкийɜɟɫɬникПоɜолжьяПяɬиɝоɪɫкɚяȻояɪышник (Crataegus): ɜозможноɫɬимɟɞицинɫкоɝоɎɚɪмɚɬɟкɚRastogi S., Pandey M.M., Rawat A.K. Traditional herbs: a remedy for cardiovascular disorders // Phytomedi-cine. 2016. No 23(11). P. 1082?1089. URL: https://www.ncbi.nlm.nih.gov/pubmed/26656228 (ɞɚɬɚZorniak M., Szydlo B., Krzeminski T.F. Crataegus special extract WS 1442: up-to-date review of experimental and clinical experiences // Journal of physiology and pharmacology. 2017. No 68 (4). P. 521?526. URL: https://www.ncbi.nlm.nih.gov/pubmed/29151068 (ɞɚɬɚJieWang, Xingjiang Xiong, Bo Feng. Effect of Crataegus Usage in Cardiovascular Disease Prevention: An Evi-dence-Based Approach // Evidence-Based Complementary and Alternative Medicine. 2013. Available at: https://www.hindawi.com/journals/ecam/2013/149363/ (ɞɚɬɚ: 24.01.2018). DOI: 10.1155/2013/149363Liu X.Y., Zhou L., Liang R.Y. Study on lipid regulation mechanism of total avonoids from folium Crataegi by 3T3-L1 cells // Chin. Arch. Tradit. Chin. Med. 2009. No. 27. P. 1066?1068. Yang R.M., Chen H.M., Gao N.N., Song X., Li J.L., Cai D.Y. Mechanism of early atherosclerosis in guinea pig: abnormal metabolism of LDL-C // Acta Lab. Anim. Sci. Sin. 2011. Vol. 23. P. 237?241.Yang X.P. Medicinal value of Crataegus pinnati da // Jilin Med. J. 1998. Vol. 19. P. 41.Yuan Y., Zhao J., Gao H.J., Wa ng J.H. Experimental study on effect of hawthorn on compounding hypertension and hyperlipoidemia rats // J. Xinjiang Med. Univ. 2013. Vol. 35. P. 52?27.ɎɚɪмɚцияɮɚɪмɚколоɝияОɛзоɪыLi C.Q., Wu W., Tong Y. Study on germicidal ef cacy of extract of hawthorn fruit pit and its in uencing factors // Chin. J. Disinfect. 2007. Vol. 24. P. 50?52.Lin L., Chen Y.J., Li L., Cao Y., Sun Q.X. Experimental observation on germicidal ef cacy of hawthorn liquid and uencing factors // Chin. J. Disinfect. 2000. Vol. 17. P. 85?88.Li L., Lv H., Pang H. Anti-aging effect of total avone of hawthorn leaf // Lishizhen Med. Mater. Med. Res. 2007. Vol. 9. P. 2143?2144.Ji Y.S., Li H., Yang S.J. Protective effect and its molecular mechanism of FMCL on PC 12 cells apoptosis induced // Chin. Pharmacol. Bull. 2006. Vol. 22. P. 760?762.Chen Z.Y., Yan M.X., He B.H. The Change and the immpact of IFHL on oxidative stress in the formation of NASH in rats // J. Med. Res. 2007. Vol. 36. P. 33?36.Wang C.L., Lu B.Z., Hou G.L. Chemical constituent, pharmacological effects and clinical application of Crataegus da // Strait Pharm. J. 2010. Vol. 3. P. 75?78.ized trials // American Journal of Medicine. 2003. No. 114(8). P. 665?674. URL: https://www.ncbi.nlm.nih.gov/ɞɚɬɚHu M., Zeng W., Tomlinson B. Evaluation of a crataegus-based multiherb formula for dyslipidemia: a random-ized, double-blind, placebo-controlled clinical trial // Evidence-Based Complementary and Alternative Medi-cine. 2014. URL: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4009229/ (ɞɚɬɚDOI: 10.1155/2014/365742 G., Faramarzi M., Nematollahi A., Ra eian-kopaei M., Amiri M., Moattar F. Comparison of the effects of Crataegus oxyacantha extract, aerobic exercise and their combination on the serum levels of ICAM-No. 23. P. 54. URL: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4684934/ (ɞɚɬɚDOI: 10.1186/s40199-015-0137-2Mustapha N., Pinon A., Limami Y., Simon A., Ghedira K., Hennebelle T., Chekir-Ghedira L. Crataegus aza-rolus Leaves Induce Antiproliferative Activity, Cell Cycle Arrest, and Apoptosis in Human HT-29 and HCT-116 Colorectal Cancer Cells // Journal of Cellular Biochemistry. 2016. No 117(5). P. 1262?1272. URL: https://www.ɞɚɬɚȽоɫɭɞɚɪɫɬɜɟннɚяɮɚɪмɚкопɟя. 11-изɞɚниɟМɟɞицинɚКɭɪкинМоɪозоɜɚПɪɚɜɞиɜцɟɜɚИɫɫлɟɞоɜɚниɟɪɚзɪɚɛоɬкɟмɟɬоɞикиɫɬɚнɞɚɪɬизɚцииɛояɪышникɚкɪоɜɚɜокɪɚɫноɝоɪɚɫɬиɬɟльноɝоEuropean Pharmacopoeia. 8 ed. Strasbourg: Directorate for the Quality of Medicines & HealthCare of the Council 32 United States Pharmacopeia. URL: http://www.uspbpep.com/usp32/pub/data/v32270/usp32nf27s0_m36580.ȽоɫɭɞɚɪɫɬɜɟннɚяɮɚɪмɚкопɟяɊɟɫпɭɛликиȻɟлɚɪɭɫьизɞɚниɟɌом 2. МиниɫɬɟɪɫɬɜозɞɪɚɜооɯɪɚнɟнияɊɟɫпɭɛликиȻɟлɚɪɭɫьȺɬлɚɫɚɪɟɚлоɜɪɟɫɭɪɫоɜлɟкɚɪɫɬɜɟнныɯɋилɚɟɜɚȺɝɟɟɜɚКиɪюɯинМɚɬɜиɟнкоɛояɪышникɚɯ L.) ɊɟɫпɭɛликɟМоɪɞоɜияɎиɬоɪɚзнооɛɪɚзиɟȼоɫɬочнойȽоɫɭɞɚɪɫɬɜɟннɚяɎɚɪмɚкопɟяɊоɫɫийɫкойɎɟɞɟɪɚцииизɞɚниɟȽоɫɭɞɚɪɫɬɜɟннɚяɎɚɪмɚкопɟяɊоɫɫийɫкойɎɟɞɟɪɚцииизɞɚниɟȽоɫɭɞɚɪɫɬɜɟннɚяɎɚɪмɚкопɟяɊоɫɫийɫкойɎɟɞɟɪɚцииизɞɚниɟȽоɫɭɞɚɪɫɬɜɟннɚяɮɚɪмɚкопɟяɊɟɫпɭɛликиКɚзɚɯɫɬɚнизɞɚниɟɌом 2. МиниɫɬɟɪɫɬɜозɞɪɚɜооɯɪɚнɟнияɊɟɫпɭɛликиКɚзɚɯɫɬɚнȺɫɬɚнɚКɭɪкинКɭɪкинɚПɪɚɜɞиɜцɟɜɚМоɪозоɜɚИзɭчɟниɟɯимичɟɫкоɝоɫоɫɬɚɜɚпɪɟпɚɪɚɬоɜоɫноɜɟɛояɪышникɚ // Мɚɬɟɪиɚлы IX мɟжɞɭнɚɪоɞноɝоɫимпозиɭмɚɎɟнольныɟɫоɟɞинɟнияɮɭнɞɚмɟнɬɚльныɟɚɫпɟкɬыМоɫкɜɚDinesh Kumar, Vikrant Arya, Zul qar Ali Bhat, Nisar Ahmad Khan, Deo Nandan Prasad. The genus Crataegus: cognosy. 2012. No. 22(5). P. 1187?1200. URL: http://www.scielo.br/pdf/rbfar/v22n5/aop05712.pdf (ɞɚɬɚJiaqi Wu, Wei Peng, Rongxin Qin, Hong Zhou. Crataegus pinnati da: Chemical Constituents, Pharmacology, and Potential Applications // Molecules. 2014. No. 19(2). P. 1685?1712. URL: http://www.mdpi.com/1420-ɞɚɬɚSeyed Fazel Nabavi, Solomon Habtemariam, Touqeer Ahmed, Antoni Sureda, Maria Daglia, Eduardo Sobar-istry to Medical Applications // Nutrients. 2015. No. 7. P. 7708?7728. URL: https://www.ncbi.nlm.nih.gov/ɞɚɬɚPharmacy & Pharmacology V. 6 N 2, 2018DOI:10.19163/2307-9266-2018-6-2-104-120Wu S.J., Li Q.J., Xiao X.F., Li M., Yang X.R., Lv T. The research of chemical constituent and pharmacological effects of Crataegus pinnati da // Drug Eval. Res. 2010. Vol. 4. P. 316?319.Kurkina A.V., Pravdivtseva O.E., Kurkin V.A., Dubishchev A.V. Pharmacological activity of avonoid-containing plants. Internationaler medizinischer Kongress // Hannover. 2006, pp. 37?38.ɏишоɜɚȻɭзɭкКоличɟɫɬɜɟнноɟопɪɟɞɟлɟниɟплоɞоɜɛояɪышникɚ // ɮɚɪмɚцɟɜɬичɟɫкийжɭɪнɚлКɭɪкинɚОпɪɟɞɟлɟниɟɫоɞɟɪжɚнияɫɭммыɮлɚɜоноиɞоɜплоɞɚɯɛояɪышникɚ // ɏимикоɮɚɪмɚцɟɜɬичɟɫкийжɭɪнɚлКɭɪкинɚпоɞɯоɞыɫɬɚнɞɚɪɬизɚциицɜɟɬкоɜɛояɪышникɚ // ɪɚɫɬиɬɟльноɝоɋɚɝɚɪɚɞзɟȻɚɛɚɟɜɚКɚлɟникоɜɚɍɫɬɚноɜлɟниɟпоɞлинноɫɬипɟɪɫпɟкɬиɜноɝолɟкɚɪɫɬɜɟнноɝо ? цɜɟɬкоɜɛояɪышникɚ // ȼопɪоɫыɛиолоɝичɟɫкоймɟɞицинɫкойɮɚɪмɚцɟɜɬичɟɫкойɋɚɝɚɪɚɞзɟȻɚɛɚɟɜɚКɚлɟникоɜɚОпɪɟɞɟлɟниɟɮлɚɜоноиɞоɜцɜɟɬкɚɯɛояɪышникɚмɟɬоɞомȼЭЖɏɫпɟкɬɪоɮоɬомɟɬɪичɟɫкимɞɟɬɟкɬиɪоɜɚниɟм // ɏимикоɮɚɪмɚцɟɜɬичɟɫкийнɚлHellenbrand N., Sendker J., Lechtenberg M., Petereit F., Hensel A. Isolation and quanti cation of oligomeric owers of Hawthorn (Crataegus spp.). Fitoterapia. 2015. No. 104. P. 14?22. URL: https://www.ncbi.nlm.nih.gov/pubmed/25917901 (ɞɚɬɚ tote.2015.04.010КɭɪкинМоɪозоɜɚПɪɚɜɞиɜцɟɜɚИɫɫлɟɞоɜɚниɟɪɚзɪɚɛоɬкɟɫɬɚнɞɚɪɬизɚцииɛояɪышникɚкɪоɜɚɜокɪɚɫноɝоɪɚɫɬиɬɟльноɝоMudge E.M., Liu Y., Lund J.A., Brown P.N. Single-laboratory validation for the determination of avonoids in nished products by LC-UV // Planta Med. 2016. No. 82(17). P. 1487?1492. URL: https://www.ncbi.nlm.nih.gov/pubmed/27776376 (ɞɚɬɚCheng S., Qiu F., Huang J., He J. Simultaneous determination of vitexin-2?-O-glucoside, vitexin-2?-O-rham- da Bge.) leaves by RP-HPLC with ultraviolet photodiode array detection // Journal of Separation Science. 2007. No. 30(5). P. 717?721. Zhe Gao, Ya-Nan Jia, Tian-Yuan Cui, Zhe Han, Ai-Xia Qin, Xiao-Hu Kang, Yu-Lei Pan, Tong Cui. Quanti cation da Bge. var. major N.E. Br.) by HPLC // Asian Journal of Chemistry. 2013. Vol. 25. No. 18. P. 10344?10348. ReferencesMartins Ekor. The growing use of herbal medicines: issues relating to adverse reactions and challenges in moni-toring safety. Frontiers in Pharmacology [Internet]. 2013;4:177 [cited 2018 Jan 24]. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3887317/ DOI: 10.3389/fphar.2013.00177 Pal SK, Shukla Y. Herbal medicine: current status and the future. Asian Paci c Journal of Cancer Preven-tion [Internet]. 2003 Aug-Dec;4(4):281-8 [cited 2018 Jan 24]. Available from: https://www.ncbi.nlm.nih.gov/Sambukova TV, Ovchinnikov BV, Ganapolskii VP, Yatmanov AN, Shabanov PD. Perspektivy ispol?zovaniya to-preparatov v sovremennoj farmakologii [Prospects for phytopreparations (Botanicals) use in modern pharmacology]. Reviews on Clinical Pharmacology and Drug Therapy. 2017;15(2):56-63. DOI: 10.17816/RCF15256-63. Russian.World Health Organization. Cardiovascular diseases (CVDs). [Internet]. [cited 2018 Jan 24]. Available from: http://www.who.int/mediacentre/factsheets/fs317/en/Basyrova IR, Libis RA. Rasprostranennost? osnovnyh faktorov riska serdechno-sosudistyh zabolevanij i ih kom-binacij u zhitelej goroda Orenburga [The prevalence of major cardiovascular risk factors and their combinations in residents of Orenburg city]. Aspirantskiy Vestnik Povolzhiya. 2017;1-2:48-53. Russian.Samylina IA, Sorokina AA, Pyatigorskaya NV. Boyaryshnik (Crataegus): vozmozhnosti medicinskogo prime-. Boyaryshnik (Crataegus): vozmozhnosti medicinskogo prime-()7. Rastogi S, Pandey MM, Rawat AK. Traditional herbs: a remedy for cardiovascular disorders. Phytomedicine. [Internet]. 2016 Oct 15;23(11):1082-9 [cited 2018 Jan 24]. Available from: https://www.ncbi.nlm.nih.gov/Zorniak M, Szydlo B, Krzeminski TF. Crataegus special extract WS 1442: up-to-date review of experimental and clinical experiences. Journal of physiology and pharmacology. [Internet]. 2017 Aug;68(4):521-6 [cited 2018 Jan 24]. Available from: https://www.ncbi.nlm.nih.gov/pubmed/29151068 JieWang, Xingjiang Xiong, Bo Feng. Effect of Crataegus Usage in Cardiovascular Disease Prevention: An Evi-dence-Based Approach. Evidence-Based Complementary and Alternative Medicine. [Internet]. 2013 [cited 2018 Jan 24]. Available from: https://www.hindawi.com/journals/ecam/2013/149363/. DOI: 10.1155/2013/149363Liu XY, Zhou L, Liang RY. Study on lipid regulation mechanism of total avonoids from folium Crataegi by 3T3-L1 cells. Chin. Arch. Tradit. Chin. Med. 2009;27:1066?8. ɎɚɪмɚцияɮɚɪмɚколоɝияОɛзоɪыYang RM, Chen HM, Gao NN, Song X, Li JL, Cai DY. Mechanism of early atherosclerosis in guinea pig: abnor-mal metabolism of LDL-C. Acta Lab. Anim. Sci. Sin. 2011;23:237?41.Yang XP. Medicinal value of Crataegus pinnati da. Jilin Med. J. 1998;19:41.Yuan Y, Zhao J, Gao HJ, Wang JH. Experimental study on effect of hawthorn on compounding hypertension and hyperlipoidemia rats. J. Xinjiang Med. Univ. 2013;35:52?27.Li CQ, Wu W, Tong Y. Study on germicidal ef cacy of extract of hawthorn fruit pit and its in uencing factors. Lin L, Chen YJ, Li L, Cao Y, Sun QX. Experimental observation on germicidal ef cacy of hawthorn liquid and uencing factors. Chin. J. Disinfect. 2000;17:85?8.Li L, Lv H, Pang H. Anti-aging effect of total avone of hawthorn leaf. Lishizhen Med. Mater. Med. Res. Ji YS, Li H, Yang SJ. Protective effect and its molecular mechanism of FMCL on PC 12 cells apoptosis induced Chen ZY, Yan MX, He BH. The Change and the immpact of IFHL on oxidative stress in the formation of NASH Wang CL, Lu BZ, Hou GL. Chemical constituent, pharmacological effects and clinical application of Crataegus da. Strait Pharm. J. 2010;3:75?8.trials. American Journal of Medicine. [Internet]. 2003 Jun 1;114(8):665-74 [cited 2018 Jan 24]. Available from: https://www.ncbi.nlm.nih.gov/pubmed/12798455 Hu M, Zeng W, Tomlinson B. Evaluation of a crataegus-based multiherb formula for dyslipidemia: a randomized, double-blind, placebo-controlled clinical trial. Evidence-Based Complementary and Alternative Medicine. [Inter-net]. 2014 [cited 2018 Jan 24]. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4009229/. DOI: 10.1155/2014/365742 G, Faramarzi M, Nematollahi A, Ra eian-kopaei M, Amiri M, Moattar F. Comparison of the effects of Crataegus oxyacantha extract, aerobic exercise and their combination on the serum levels of ICAM-1 fects of Crataegus oxyacantha extract, aerobic exercise and their combination on the serum levels of ICAM-1 2015;23:54 [cited 2018 Jan 24]. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4684934/. DOI: 10.1186/s40199-015-0137-2Mustapha N, Pinon A, Limami Y, Simon A, Ghedira K, Hennebelle T, Chekir-Ghedira L. Crataegus azarolus Leaves Induce Antiproliferative Activity, Cell Cycle Arrest, and Apoptosis in Human HT-29 and HCT-116 Col-orectal Cancer Cells. Journal of Cellular Biochemistry. [Internet]. 2016 May;117(5):1262-72. [cited 2018 Jan 24]. Available from: https://www.ncbi.nlm.nih.gov/pubmed/26495895. DOI: 10.1002/jcb.25416Gosudarstvennaya farmakopeya SSSR [State Pharmacopoeia of the USSR]. 11th edition. Is. 2. Mockva: Medici-Kurkin VA, Morozova TV, Pravdivtseva OE. Issledovanie po razrabotke metodiki standartizacii list?ev boyarysh-, Pravdivtseva OE. Issledovanie po razrabotke metodiki standartizacii list?ev boyarysh-sanguinea Pall.]. Chemistry of plant raw materials. 2017;3:169-79. Russian.26. European Pharmacopoeia. 8 ed. Strasbourg: Directorate for the Quality of Medicines & HealthCare of the Council 32 United States Pharmacopeia. URL: http://www.uspbpep.com/usp32/pub/data/v32270/usp32nf27s0_m36580.Gosudarstvennaya farmakopeya Respubliki Belarus? [State Pharmacopoeia of the Republic of Belarus]. 1st edi-tion. Vol. 2. Ministerstvo zdravoohraneniya Respubliki Belarus?: Minsk; 2007. 471 p. Russian.ol. 2. Ministerstvo zdravoohraneniya Respubliki Belarus?: Minsk; 2007. 471 p. Russian.USSR]. Mockva: GUGK; 1980:242-3. Russian.30. Silaeva TB, Ageeva AM, Kiryuhin IV, Matvienko II. O boyaryshnikah (Crataegus L.) v Respublike Mordoviya , Matvienko II. O boyaryshnikah (Crataegus L.) v Respublike Mordoviya ()Russian.31. Gosudarstvennaya Farmakopeya Rossijskoj Federacii [State Pharmacopoeia of the Russian Federation]. 13th edition. Vol. 1. Mockva; 2015. 1470 p. Russian.ol. 1. Mockva; 2015. 1470 p. Russian.edition. Vol. 2. Mockva; 2015. 1004 p. Russian.ol. 2. Mockva; 2015. 1004 p. Russian.edition. Vol. 3. Mockva; 2015. 1294 p. Russian.ol. 3. Mockva; 2015. 1294 p. Russian.edition. Vol. 2. Ministerstvo zdravoohraneniya Respubliki Kazahstan: Astana; 2009. 803 p. Russian.Kurkin VA, Kurkina AV, Pravdivceva OE, Morozova TV. Izuchenie himicheskogo sostava preparatov na os-nove syr?ya boyaryshnika [The study of the chemical composition of preparations based on the raw material of Pharmacy & Pharmacology V. 6 N 2, 2018DOI:10.19163/2307-9266-2018-6-2-104-120Dinesh Kumar, Vikrant Arya, Zul qar Ali Bhat, Nisar Ahmad Khan, Deo Nandan Prasad. The genus Crataegus: cognosy. [Internet]. 2012;22(5):1187-200 [cited 2018 Jan 24]. Available from: http://www.scielo.br/pdf/rbfar/Jiaqi Wu, Wei Peng, Rongxin Qin, Hong Zhou. Crataegus pinnati da: Chemical Constituents, Pharmacology, and Potential Applications. Molecules. [Internet]. 2014;19(2):1685-712 [cited 2018 Jan 24]. Available from: http://www.mdpi.com/1420-3049/19/2/1685. DOI: 10.3390/molecules19021685Seyed Fazel Nabavi, Solomon Habtemariam, Touqeer Ahmed, Antoni Sureda, Maria Daglia, Eduardo Sobar-try to Medical Applications. Nutrients. [Internet]. 2015 Sep 11;7(9):7708-28 [cited 2018 Jan 24]. Available from: https://www.ncbi.nlm.nih.gov/pubmed/26378574. DOI: 10.3390/nu7095361Wu SJ, Li QJ, Xiao XF, Li M, Yang XR, Lv T. The research of chemical constituent and pharmacological effects da. Drug Eval. Res. 2010;4:316?9.Kurkina AV, Pravdivtseva OE, Kurkin VA, Dubishchev AV. Pharmacological activity of avonoid-containing plants. Internationaler medizinischer Kongress. Hannover. 2006:37-38.. 2006:37-38.termination of procyanidins in hawthorn fruits]. Pharmaceutical Chemistry Journal. 2006;40(2):20-1. Russian.42. Kurkina AV. Opredelenie soderzhaniya summy avonoidov v plodah boyaryshnika [Determination of total avo-Kurkina AV. Novye podhody k standartizacii cvetkov boyaryshnika [The new approaches to the standardization owers]. Chemistry of plant raw materials. 2013;2:171-6. DOI: 10.14258/jcprm.1302171. Russian.Sagaradze VA, Babaeva EYu, Kalenikova EI. Ustanovlenie podlinnosti perspektivnogo vida lekarstvennogo syr?ya ? cvetkov s list?yami boyaryshnika [Establishment of the authenticity of the perspective species of medici- owers with hawthorn leaves]. Problems of biological, medical and pharmaceutical chemistry. Sagaradze VA, Babaeva EYu, Kalenikova EI. Opredelenie avonoidov v cvetkah s list?yami boyaryshnika met-odom VEZHKH so spektrofotometricheskim detektirovaniem [Determination of avonoids in owers with haw-Hellenbrand N, Sendker J, Lechtenberg M, Petereit F, Hensel A. Isolation and quanti cation of oligomeric owers of Hawthorn (Crataegus spp.). Fitoterapia. [Internet]. 2015 Jul;104:14-22 [cited 2018 Jan 24]. Available from: https://www.ncbi.nlm.nih.gov/pubmed/25917901. DOI: tote.2015.04.010Kurkin VA, Morozova TV, Pravdivceva OE. Issledovanie po razrabotke standartizacii list?ev boyaryshnika krova-, Pravdivceva OE. Issledovanie po razrabotke standartizacii list?ev boyaryshnika krova-plant raw materials. 2017;3:169-73. Russian.48. Mudge EM, Liu Y, Lund JA, Brown PN. Single-laboratory validation for the determination of avonoids in haw- nished products by LC-UV // Planta Med. [Internet]. 2016 Nov;82(17):1487-1492 [cited 2018 Jan 24]. Available from: https://www.ncbi.nlm.nih.gov/pubmed/27776376Cheng S, Qiu F, Huang J, He J. Simultaneous determination of vitexin-2?-O-glucoside, vitexin-2?-O-rhamnoside, da Bge.) leaves by RP-HPLC with ultraviolet Zhe Gao, Ya-Nan Jia, Tian-Yuan Cui, Zhe Han, Ai-Xia Qin, Xiao-Hu Kang, Yu-Lei Pan, Tong Cui. Quanti cation da Bge. var. major N.E. Br.) by HPLC. Asian Journal of Chemistry. 2013;25(18):10344-8. КонɮликɬинɬɟɪɟɫоɜȺɜɬоɪызɚяɜляюɬоɬɫɭɬɫɬɜииконɮликɬɚинɬɟɪɟɫоɜМоɪозоɜɚɌɚɬьянɚ ? кɚɮɟɞɪыɮɚɪмɚкоɝнозииɛоɬɚникойоɫноɜɚмиɎȽȻОɍɋɚмȽМɍМинзɞɪɚɜɚɊоɫɫииОɛлɚɫɬьнɚɭчныɯинɬɟɪɟɫоɜɮɚɪмɚкоɝнозия. E-mail: tanyfrost@mail.ru ict of interest ict of interest.Morozova Tatyana Vladimirovna postgraduate Research interests: pharma-cognosy, phytochemistry. E-mail: tanyfrost@mail.ru.ɎɚɪмɚцияɮɚɪмɚколоɝияОɛзоɪыKurkin Vladimir Aleksandrovich? PhD (Pharma-, Professor, Federal State Budget Educational In-Research interests: pharmacognosy, phyto-, ? avonoids. E-mail: Kurkinvladimir@yandex.ru. Pravdivtseva Olga Evgenievna ? PhD (Pharmacy), docent, Federal State Budget Educational Institution of Higher Education ?Samara State Medical University?.Research interests pharmacognosy, phytochemistry, ? a-vonoids. E-mail: pravdivtheva@mail.ru. КɭɪкинȺлɟкɫɚнɞɪоɜич ? ɞокɬоɪмɚцɟɜɬичɟɫкиɯнɚɭкпɪоɮɟɫɫоɪɎȽȻОɍɋɚмȽМинзɞɪɚɜɚɊоɫɫииОɛлɚɫɬьнɚɭчныɯинɬɟɪɟɫоɜɮɚɪмɚкоɝнозияɮиɬоɯимияɮлɚɜоноиɞыПɪɚɜɞиɜцɟɜɚ ? ɞокɬоɪмɚцɟɜɬичɟɫкиɯнɚɭкɞоцɟнɬɎȽȻОɍɋɚмȽМɍМинзɞɪɚɜɚɊоɫɫииОɛлɚɫɬьнɚɭчныɯинɬɟɪɟɫоɜɮɚɪмɚкоɝнозияɮиɬоɯимияɮлɚɜоноиɞыПоɫɬɭпилɚɪɟɞɚкциюОɬпɪɚɜлɟнɚɞоɪɚɛоɬкɭПɪиняɬɚпɟчɚɬи×
Об авторах
Т. В. Морозова
Федеральное государственное бюджетное образовательное учреждение высшего образования «Самарский государственный медицинский университет» Министерства здравоохранения Российской Федерации
Email: tanyfrost@mail.ru
В. А. Куркин
Федеральное государственное бюджетное образовательное учреждение высшего образования «Самарский государственный медицинский университет» Министерства здравоохранения Российской Федерации
Email: Kurkinvladimir@yandex.ru
О. Е. Правдивцева
Федеральное государственное бюджетное образовательное учреждение высшего образования «Самарский государственный медицинский университет» Министерства здравоохранения Российской Федерации
Email: pravdivtheva@mail.ru
Список литературы
- Martins Ekor. The growing use of herbal medicines: issues relating to adverse reactions and challenges in monitoring safety // Frontiers in Pharmacology. 2013. No 4. P. 177. URL: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3887317/ (дата обращения: 24.01.2018). doi: 10.3389/fphar.2013.00177
- Pal S.K., Shukla Y. Herbal medicine: current status and the future // Asian Pacifi c Journal of Cancer Prevention. 2003. No 4(4). P. 281-288. URL: https://www.ncbi.nlm.nih.gov/pubmed/14728584 (дата обращения: 24.01.2018)
- Самбукова Т.В., Овчинников Б.В., Ганапольский В.П., Ятманов А.Н., Шабанов П.Д. Перспективы использования фитопрепаратов в современной фармакологии // Обзоры по клинической фармакологии и лекарственной терапии. 2017. Т. 15. № 2. С. 56–63. doi: 10.17816/RCF15256-63
- World Health Organization. Cardiovascular diseases (CVDs) URL: http://www.who.int/mediacentre/factsheets/fs317/en/ (дата обращения: 24.01.2018)
- Басырова И.Р., Либис Р.А. Распространенность основных факторов риска сердечно-сосудистых заболеваний и их комбинаций у жителей города Оренбурга // Аспирантский вестник Поволжья. 2017. № 1–2. С. 48–53.
- Самылина И.А., Сорокина А.А., Пятигорская Н.В. Боярышник (Crataegus): возможности медицинского применения // Фарматека. 2010. № 8. С. 83–85.
- Rastogi S., Pandey M.M., Rawat A.K. Traditional herbs: a remedy for cardiovascular disorders // Phytomedicine. 2016. No 23(11). P. 1082–1089. URL: https://www.ncbi.nlm.nih.gov/pubmed/26656228 (дата обращения: 24.01.2018). doi: 10.1016/j.phymed.2015.10.012
- Zorniak M., Szydlo B., Krzeminski T.F. Crataegus special extract WS 1442: up-to-date review of experimental and clinical experiences // Journal of physiology and pharmacology. 2017. No 68 (4). P. 521–526. URL: https:// www.ncbi.nlm.nih.gov/pubmed/29151068 (дата обращения: 24.01.2018)
- JieWang, Xingjiang Xiong, Bo Feng. Effect of Crataegus Usage in Cardiovascular Disease Prevention: An Evidence-Based Approach // Evidence-Based Complementary and Alternative Medicine. 2013. Available at: https:// www.hindawi.com/journals/ecam/2013/149363/ (дата обращения: 24.01.2018). doi: 10.1155/2013/149363
- Liu X.Y., Zhou L., Liang R.Y. Study on lipid regulation mechanism of total fl avonoids from folium Crataegi by 3T3-L1 cells // Chin. Arch. Tradit. Chin. Med. 2009. No. 27. P. 1066–1068.
- Yang R.M., Chen H.M., Gao N.N., Song X., Li J.L., Cai D.Y. Mechanism of early atherosclerosis in guinea pig: abnormal metabolism of LDL-C // Acta Lab. Anim. Sci. Sin. 2011. Vol. 23. P. 237–241.
- Yang X.P. Medicinal value of Crataegus pinnatifi da // Jilin Med. J. 1998. Vol. 19. P. 41.
- Yuan Y., Zhao J., Gao H.J., Wa ng J.H. Experimental study on effect of hawthorn on compounding hypertension and hyperlipoidemia rats // J. Xinjiang Med. Univ. 2013. Vol. 35. P. 52–27.
- Li C.Q., Wu W., Tong Y. Study on germicidal efficacy of extract of hawthorn fruit pit and its influencing factors // Chin. J. Disinfect. 2007. Vol. 24. P. 50–52.
- Lin L., Chen Y.J., Li L., Cao Y., Sun Q.X. Experimental observation on germicidal efficacy of hawthorn liquid and its influencing factors // Chin. J. Disinfect. 2000. Vol. 17. P. 85–88.
- Li L., Lv H., Pang H. Anti-aging effect of total flavone of hawthorn leaf // Lishizhen Med. Mater. Med. Res. 2007. Vol. 9. P. 2143–2144.
- Ji Y.S., Li H., Yang S.J. Protective effect and its molecular mechanism of FMCL on PC 12 cells apoptosis induced by H2O2 // Chin. Pharmacol. Bull. 2006. Vol. 22. P. 760–762.
- Chen Z.Y., Yan M.X., He B.H. The Change and the immpact of IFHL on oxidative stress in the formation of NASH in rats // J. Med. Res. 2007. Vol. 36. P. 33–36.
- Wang C.L., Lu B.Z., Hou G.L. Chemical constituent, pharmacological effects and clinical application of Crataegus pinnatifi da // Strait Pharm. J. 2010. Vol. 3. P. 75–78.
- Pittler M.H., Schmidt K., Ernst E. Hawthorn extract for treating chronic heart failure: meta-analysis of random-ized trials // American Journal of Medicine. 2003. No. 114(8). P. 665–674. URL: https://www.ncbi.nlm.nih.gov/pubmed/12798455 (дата обращения: 24.01.2018)
- Hu M., Zeng W., Tomlinson B. Evaluation of a crataegus-based multiherb formula for dyslipidemia: a random-ized, double-blind, placebo-controlled clinical trial // Evidence-Based Complementary and Alternative Medicine. 2014. URL: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4009229/ (дата обращения: 24.01.2018). doi: 10.1155/2014/365742
- Jalaly L., Sharifi G., Faramarzi M., Nematollahi A., Rafi eian-kopaei M., Amiri M., Moattar F. Comparison of the effects of Crataegus oxyacantha extract, aerobic exercise and their combination on the serum levels of ICAM-1 and E-Selectin in patients with stable angina pectoris // DARU Journal of Pharmaceutical Sciences. 2015. No. 23. P. 54. URL: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4684934/ (дата обращения: 24.01.2018). doi: 10.1186/s40199-015-0137-2
- Mustapha N., Pinon A., Limami Y., Simon A., Ghedira K., Hennebelle T., Chekir-Ghedira L. Crataegus azarolus Leaves Induce Antiproliferative Activity, Cell Cycle Arrest, and Apoptosis in Human HT-29 and HCT-116 Colorectal Cancer Cells // Journal of Cellular Biochemistry. 2016. No 117(5). P. 1262–1272. URL: https://www. ncbi.nlm.nih.gov/pubmed/26495895 (дата обращения: 24.01.2018). doi: 10.1002/jcb.25416
- Государственная фармакопея СССР. 11-е издание. Вып. 2. М.: Медицина, 1990. 400 с.
- Куркин В.А., Морозова Т.В., Правдивцева О.Е. Исследование по разработке методики стандартизации листьев боярышника кроваво-красного // Химия растительного сырья. 2017. № 3. С 169–173.
- European Pharmacopoeia. 8 ed. Strasbourg: Directorate for the Quality of Medicines & HealthCare of the Council of Europe, 2013.
- 32 United States Pharmacopeia. URL: http://www.uspbpep.com/usp32/pub/data/v32270/usp32nf27s0_m36580. html
- Государственная фармакопея Республики Беларусь. 1-е издание. Том 2. Министерство здравоохранения Республики Беларусь: Минск, 2007. 471 с.
- Атлас ареалов и ресурсов лекарственных растений СССР. М.: ГУГК, 1980. С. 242–243.
- Силаева Т.Б., Агеева А.М., Кирюхин И.В., Матвиенко И.И. О боярышниках (Crataegus L.) в Республике Мордовия // Фиторазнообразие Восточной Европы. 2007. №4. С. 216–218.
- Государственная Фармакопея Российской Федерации. XIII издание. Т. 1. М., 2015. 1470 с.
- Государственная Фармакопея Российской Федерации. XIII издание. Т. 2. М., 2015. 1004 с.
- Государственная Фармакопея Российской Федерации. XIII издание. Т. 3. М., 2015. 1294 с.
- Государственная фармакопея Республики Казахстан. 1-е издание. Том 2. Министерство здравоохранения Республики Казахстан: Астана, 2009. 803 с.
- Куркин В.А., Куркина А.В., Правдивцева О.Е., Морозова Т.В. Изучение химического состава препаратов на основе сырья боярышника // Материалы IX международного симпозиума «Фенольные соединения: фундаментальные и прикладные аспекты», Москва. 2015. С. 578–581.
- Dinesh Kumar, Vikrant Arya, Zulfi qar Ali Bhat, Nisar Ahmad Khan, Deo Nandan Prasad. The genus Crataegus: chemical and pharmacological perspectives // Revista Brasileira de Farmacognosia Brazilian Journal of Pharmacognosy. 2012. No. 22(5). P. 1187–1200. URL: http://www.scielo.br/pdf/rbfar/v22n5/aop05712.pdf (дата обра-щения: 24.01.2018).
- Jiaqi Wu, Wei Peng, Rongxin Qin, Hong Zhou. Crataegus pinnatifi da: Chemical Constituents, Pharmacology, and Potential Applications // Molecules. 2014. No. 19(2). P. 1685–1712. URL: http://www.mdpi.com/1420-3049/19/2/1685 (дата обращения: 24.01.2018). doi: 10.3390/molecules19021685
- Seyed Fazel Nabavi, Solomon Habtemariam, Touqeer Ahmed, Antoni Sureda, Maria Daglia, Eduardo Sobarzo-Sánchez, Seyed Mohammad Nabavi. Polyphenolic Composition of Crataegus monogyna Jacq.: From Chemistry to Medical Applications // Nutrients. 2015. No. 7. P. 7708–7728. URL: https://www.ncbi.nlm.nih.gov/pubmed/26378574 (дата обращения: 24.01.2018). doi: 10.3390/nu7095361
- Wu S.J., Li Q.J., Xiao X.F., Li M., Yang X.R., Lv T. The research of chemical constituent and pharmacological effects of Crataegus pinnatifi da // Drug Eval. Res. 2010. Vol. 4. P. 316–319.
- Kurkina A.V., Pravdivtseva O.E., Kurkin V.A., Dubishchev A.V. Pharmacological activity of fl avonoid-containing plants. Internationaler medizinischer Kongress // Hannover. 2006, pp. 37–38.
- Хишова О.М., Бузук Г.Н. Количественное определение процианидинов плодов боярышника // Хими-ко-фармацевтический журнал. 2006. Т. 40. № 2. С. 20–21.
- Куркина А.В. Определение содержания суммы флавоноидов в плодах боярышника // Химико-фармацевтический журнал. 2014. Т. 48. № 12. С. 27–30.
- Куркина А.В. Новые подходы к стандартизации цветков боярышника // Химия растительного сырья. 2013. № 2. С. 171–176. doi: 10.14258/jcprm.1302171
- Сагарадзе В.А., Бабаева Е.Ю., Каленикова Е.И. Установление подлинности перспективного вида лекарственного сырья – цветков с листьями боярышника // Вопросы биологической, медицинской и фармацевтической химии. 2017. № 2. С. 26–31.
- Сагарадзе В.А., Бабаева Е.Ю., Каленикова Е.И. Определение флавоноидов в цветках с листьями боярышника методом ВЭЖХ со спектрофотометрическим детектированием // Химико-фармацевтический журнал. 2017. № 4. С. 30–34.
- Hellenbrand N., Sendker J., Lechtenberg M., Petereit F., Hensel A. Isolation and quantification of oligomeric and polymeric procyanidins in leaves and fl owers of Hawthorn (Crataegus spp.). Fitoterapia. 2015. No. 104. P. 14–22. URL: https://www.ncbi.nlm.nih.gov/pubmed/25917901 (дата обращения: 24.01.2018). doi: 10.1016/j.fitote.2015.04.010
- Куркин В.А., Морозова Т.В., Правдивцева О.Е. Исследование по разработке стандартизации листьев боярышника кроваво-красного // Химия растительного сырья. 2017. № 3. С. 169–173.
- Mudge E.M., Liu Y., Lund J.A., Brown P.N. Single-laboratory validation for the determination of fl avonoids in hawthorn leaves and fi nished products by LC-UV // Planta Med. 2016. No. 82(17). P. 1487–1492. URL: https:// www.ncbi.nlm.nih.gov/pubmed/27776376 (дата обращения: 24.01.2018).
- Cheng S., Qiu F., Huang J., He J. Simultaneous determination of vitexin-2”-O-glucoside, vitexin-2”-O-rhamnoside, rutin, and hyperoside in the extract of hawthorn (Crataegus pinnatifi da Bge.) leaves by RP-HPLC with ultraviolet photodiode array detection // Journal of Separation Science. 2007. No. 30(5). P. 717–721.
- Zhe Gao, Ya-Nan Jia, Tian-Yuan Cui, Zhe Han, Ai-Xia Qin, Xiao-Hu Kang, Yu-Lei Pan, Tong Cui. Quantifi cation of ten polyphenols in the leaves of Chinese hawthorn (Crataegus pinnatifi da Bge. var. major N.E. Br.) by HPLC // Asian Journal of Chemistry. 2013. Vol. 25. No. 18. P. 10344–10348.
Дополнительные файлы
![](/img/style/loading.gif)